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Abstract
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DuchelUle Muscular Dystrophy (DMD), and the mild:':! allelic Becker muscular
,'

\'.

dystrophy (BMD), are X-linked recessive muscle wasting disorders characterised by
mutations in the dystrophin gene. DMD occurs at a frequency of approximately I in
3500 male newborns and life e1tpectanr,y is typically less than 30 years. Due to

progressive muscle wasting, affected boys are restricted to a wheelchair by the age of 12
years. The most common cause of death is pneumonia, compounded by cardiac
involvement.
Mutations that disrupt the dystrophin reading frame, or preve11t the synthesis of
either tenninus, preclude the synthesis of a fully functional dystrophin. The subsequent
Joss of membrane integrity results in a severe DMD phenotype, as these weakened but
still functional muscle fibres are subject to continuous cycles of damage and
regeneration. Conversely, BMD mutations are generally found to be in-frame deletions
where a shorter but semi-functional protein with intact amino and carbo1tyl tennini has
been synthesised. BMD has an incidence almost ten times less than DMD. While the
distribution of myopalhy parallels DMD, the onset and progression of BMD is variable
and generally less severe and some affected individuals are virtually asymptomatic.
From clinical studies on many patients with BMD, there is no doubt that some
dystrophin, even if of reduced quantity and/or quality, can be of significant biological
and functional advantage. Rare, naturally occurring dystrophin-positive, 'revertant'
fibres have been found in over 50% of DMD patients. These revertant fibres are thought
to result from the production of alternatively spliced dystrophin transcripts that bypass

partic1ilar e1tons in the defective mRN A transcript to maintain the re~.ding frame and
produce a shorter, semi-functional protein. The presence of these fibres has Jed to the
possibility of a new genetic therapy for uMD utilising small single-stranded fragments
of nucleic acid called antisense oligonucleotides (2'0MeAOs). These 2'0MeAOs can
be applied to the dystrophin gene to either restore the reading frame in the case of

frame~shifting deletions, by skipping one or more flanking e1toll!I, or to target the
disease-causing exons for removal from the final message. In this manner, the induced
transcript could be translated into a shorter, but presunnably semi-functional, dystrophin.
Thus, the DMD phenotype would be potentially converted to a milder BMD-Jike
phenotype.

iii

At the commencement of Ibis project, previous studies had targeted 2'QMeAO;
to either of the consensus acceptor or donor splice sites or to a less well defined exon
splicing enhancer sequence (ESE). However, none had compared these regions within
the same exon or across species. The principal aim of this study, therefore, was to
identify the target(s) within the dystrophin pre-mRNA most amenable to specific and
efficient 2'0MeAO-induced exon skipping, An additional aim was to then apply the
knowledge gained to mimic a natunilly occurring revertant transcript, by inducing the
removal of multiple exons.
Motifs involved in pre-mRNA splicing of mouse or human dystrophin eimns 19
to 25 and 46 were target,,,d by 2'0MeAOs complexed with one of several transfection

reagents, Cultured H-2K nol'tillll and mdx mouse, and nonnal and dystrophic human
myotubes were transfected with 2'0MeAOs, either individually or in combinations.
RT-PCR studies were widertaken to ascertain the extent of the 2'0MeAO-induced exon
skipping and t<l determine if there might b~ a preferred motif at which to direct future
2'0MeAOs. We repon vllf)'ing efficiency of 2'0MeAO-induced removal of each exon
of the dystrophin gene assessed by targeting a variety of splicing motifs. Furthermore,
no alterations in other 1egion11 of the final dystrophin transcript were detected as a
consequ:nce of these 2'0MeAO treatments.
The results presented in this thesis suggest that the sensitivity of acceptor, donor
or ESE splicing motifs to modulation by 2'0MeAOs is unique to the exon selected for
removal and Jess dependent on the targeted sites. Therefore, there does not appear to be
one specific splicing motif that can be universally targeted. Each mutation may have to
be treated individually, assessing the best motifs on an e,;.on to exon basis.
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Chapter 1 · Introduction
1,1 Duchenne and Becker muscular dystrophy
Dw::hennc muscular dystrophy (DMD), and the Jililder sllelic Becker muscular
dystrophy (BMD), arc X-linked recessive muscle wasting disorders caused by
mutations in the dystrophin gene (Hoffman, Brown & Kunkel, 1987; Koenig ct al.,
1989). DMD occurs at a frequency of approximately I in 3500 ,na.le newborns (Koenig
ct al., 1987) and life expectancy is typically less than30 years (Emery, 2002).

The main clinical feature of DMD, muscle weakness. becomes evident early in
childhood, htitially, affected boys have difficulty running and climbing stairs, and most
require a wheelchair by the age of 12 years. Mental impairment is also a common
clinical feature, with approximately 20% of affected boys having IQs under 70 (Emery,
2002). The most common cause of death is pneumonia, compounded by cardiac
involvement. Without assisted ventilation, few of those affected live beyond their third
decade (Emery, 2002).
BMD has an incidence slmost ten times less than DMD (Heald, Anderson,
Bushby & Shaw, 1994), with a broad spectrum of phenotypes, Although the distribution
of myopathy parallels DMD, the onset and progression of BMD is variable and
generally less severe (Emery, 2002), and some affected individuals are virtually
asymptomatic (England ct al., 1990),
Genomic deletions in the human dystropbin gene account for approximately
60% of the DMD mutations (Koenig ctsl., 1989), while the remaining cases arise from
genomic duplications and nonsense, splicing and missensc mutatiollll, Although geneUc
COUllllclling can reduce the incidence of DMD, an estimated one third of all reported
cases arise from de novo mutations in the dystrophin gene (Worton, 1992), emphasising
the urgent need for an effcciive treatment for this disorder.

1.2 The dystrophin gene end protein
The dystrophin gene, currently the largest known human gene, consists of 79
exons spanning approximately 2.4 megabases (Hoffman ct al., 1987; Roberts, Bobrow
& Bentley, 1992b) and undergoes extensive prc-mRNA processing to produce a number
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of isofonns (Feener, Koenig & Kunkel, 1989; Sadoulet-Puccio & Kunkel, 1996). The

major muscle specific ttanscript of 14kb (Anderson & Kunkel, 1992) represents only
0.02 to 0.12% of the mRNA in either human or mouse cardiac or skeletal muscle

(Chelly, Kaplllll, Maire, Gautron & Kahn, 1988). It has been estimated that this
transcript requires approidmately 16 hours for complete synthesis and is
co-transcrlptionally spliced, with the 5' end of thC transcript spliced before transcription
of the 3' end is complete (Tennyson, Klamut & Worton, 1995). Tennyson et al. (1995)
suggested that this mechanism may have developed in response to the need to restrict
the number of splice sites available by the end of transcription, as a means to maintain

splicing fidelity. This is of particular significance considering that the length of the
introns, accowiting for 99.4% of the sequence in total (Ahn & Kunkel, 1993), requires
the precise and orderly splicing of the 79 exons to take place across large physical
distances (Tennyson etal., 1995),

The tissue-specific expression of dystrophin isofomlS is based on transcriptional
control by seven to eight different promoters (Sadoule1-Puccio & Kunkel, 1996;
Culligan, Mackey, Finn, Maguire & Ohlendieck, 1998). Three full-length (427kDa)
dystrophin isoforms have been confmned, each controlled by a tissue-specific promoter.
The brain dystrophin isoform has been localised in neurons of the cerebral and
cerebellar cortices, while the Purkinje-cell isoforin is the predominate type found in the
cerebellum (Ahn & Kunkel, 1993; Gorecki et al., 1992). The muscle isofonn, expressed
in skeletal, smooth and cardiac muscle (Bies et al., 1992), has been found to be
localised to the muscle plasma membrane and I-tubules, tightly bound to the
glycoprotein complex (~ffman et al., 1987; Zubrzycka-Gaam et al., 1988). This
protein consists of

ro\lr' distinct structural domains - the N-tenninal (actin-binding)

domain, which connects dystrophin to the subsarcolemmal cytoskeleton, the central
rod, which gives the protein elasticity, the cysteine-rich domain, which anchors
dystrophin to the extracellular matrix, and the C-tcnninal domain, which binds to
dystrophin-associated proteins (Hoffman et al., 1987; Koenig, Monaco & Kunkei
1988).
It is thought that one of the primary roles of this isoform is in contributing to
muscle fibre stability through mechanical reinforcement and protection of the
sarcolemma from membrane stresses during llluscle contraction (Petrof, Shrager,
Stedman, Kelly & Sweeney, 1993; Vilquin et al., 1998; Zubrzycka-Gaam, Hutter,
Kaipati, Klamut & Bulman, 1991). Supporting this hypothesis is the fact that muscles
2
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·lacking dystrophin are SU!lceptiblc to mechanical injury and undergo repeated cycles of
necrosis and regeneration, leading to a gradual replacement of Jlll18Cle by fatty fibroU!I
tissue (Anderson & Kunkel, 1992; Halper et al., 2002). Dystrophin pcrfOJJIIS this critical
role despite amounting to only 0.002% of total muscle protein (Radojcvic, Lin &
Burgunder, 2000). The localisation of dystrophin to neural and vascular tissues also
suggests that there may be vasculogenic or neurogen!c components involved in the
pro8fC$!1iVe skeletal muscle pathology ohserved in DMD (Hoffman etal., 1988).

1.3

Dystrophin mutations and disease severity
The reading frame hypothesis proposed by Monaco, Bertelson, Liechti-Gallati,

Moser and Kunkel (1988) suggested that the different phenotypes expressed in DMD
and BMD depended on the break-point of the mutation and its effect on the translation
of downstream codons. For example, if the sum of the nucleotides within an deleted
region was not a multiple of three, the reading frame would not be maintained and the
resulting frame-shift would lead to the generation of a premature stop codon. These

frameshift mutations (typically resulting in DMD) lead to the premature termination of
protein synthesis during translation. Mutations which prevent the synthesis of the
carboxyl terminal of dystrophin have been shown to result in a severe phenotype (Prior
et al .. 1993; Roberts, Coffey, Bobrow & Bentley, 1992a), as both the actin binding and
carlmxyl termini are required to form functional dystropbin (Bulman, Murphy,
Zurzycka-Gaarn, Worton &Ray, 1991).
In contrast, BMD mutations are generally found to be in-frame deletions which

maintain the reading frame and termini, resulting in the production of a shorter but
semi-functional protein (Monaco et al., 1988; Koenig et al., 1989). II appears that
deletions of large portions of the central rod region can be associated with mild BMD
phenotypes (England et al., 1990), although there appears to be a threshold effect
whereby central in-frame deletions of more than 36 exons result in DMD phenotypes
(Faninetal., 1996).
Depending upon the position and nature of the mutation, BMD patients typically
have less severe symptoms with later onset and/or variable progression of muscle
degradation {Emeiy, 2002). From clinical studies on many patients with BMD, th~ is
no doubt that some dystrophin, even if of reduced quantity and quality, can be of
significant biological and functional advantage (Anderson & Kunkel, 1992). Examples
3
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include a patient with a deletion of cxons 3 to 9 who played competitive badminton and
went undiagnosed until his mid 60s (Heald et al., 1994). Another patient bad 46% of the
dystrophln coding sequence missing and still remained ambulant until 61 years of age
(England et al., 1990).
A study by Koenig et al. (19S9) reported that the reading frame hypothesis
predicted the correct clinical phenotype in approximately 92% of cases. AltematiYe
splicing eyenls which would overcome the effect of the original mutation by restoring
the reading frame (Chelly et al., 19SS), and very rare missense mutations where crucial
binding domains have been corrupted (Prior et al., 1993), could account for the
remaining 8% of patients not characterised by Monaco's hypothesis.

1.4 Revertant fibres
The discovery of rare, naturally-occurring dystrophin-positive fibers in DMD
patients has led to the possibility of a new genetic therapy for DMD. These revertant
fibres occur singly or in c\Wlters and may represent up to 1091, of the total muscle fibre
population (Shen'att, Vulliamy, Dubowitz, Sewry & Strong, 1993: Ucbino et al., 1995).

lmmunobistochemlcal staining has ideotified revertant fibres in the skeletal muscle of
up to SO'lb of DMD patients (Klein et al., 1992; Uchino et al., 1995), as well as the dog
(GRMD) and mouse (mdt) models of DMD (Hoffman, Morgan, Watkins & Partrtdge,
1990; Schatzberg et al., 199S; Shen'aU et al., 1993). The frequency of revertaot fibres
has b«n shown to incteMe with age and X-inadiation lreatment in mdx mice (Hoffman
et al, 1990).

The natural mechanism by which the original mutation is overcome, resulting in
restoration of the reading-frame, remains unclear. Mechanisms proposed to account for
the presence of dystrophin in these revertant fibres include secondary somatic genomic
mutations and alternative mRNA splicing (Hoffman et al., 1990; Klein et al., 1992; Lu
et al., 2000; Wilton, Dye, Blechynden & Laing, 1997). The low frequency and apparent
clonal development of revertant fibres seem to support seconda.-y somatic genetic
events rather than alternative splicing (Hoffman et al., 1990). It has been reported that
such an event, either by deletion or through a mutation affecting a splice site, can

remove exons from the dyslrophin gene such that the reading frame is restored (Klein et
al., 1992; Thanh, Man. Helliwell & Morris, 1995; Winnard, Mendell, Prior, Florence &

Burghcs, 1995). However, In siru hybridisation studies in mdt mice wiing a genomic
4
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probe spanning e1on 23 demonstrated that the majority of rcvertant fibrca bad not
undergone any gross genomic deletions to rc1110ve cxon 23, supporting sonw alternative
mRNA splicing mechanism (Lu et al, 2000). As there is evidence for both. it is possible
that these two main theories e1plalning the presence of rcvcrtant fibres are not mutually
exclusive (Dickson, Hill & Graham, 2002; Wilton, Dye & Laing, 1997).
Research using cxon-specific antibodies has suggested that revcrtant fibres skip

"
multiple
e1ons, up to 30 at one time, in order to restore the reading frame (Lu et al.,
2000). Although revertant transcripts appear to be translated into at lellllt partially
functional 'Becker-like' dystrophin proteins (Lu et al., 2000), there have been
conflicting reporti as to whether there is a relationship between the presence of
rcvenant fibres and the severity of the DMD phenotype, A study by Nicholson (1993)
reported a relationship between the abundance of dystrophin-positive fibn"..s and the age
at which independent ambulation Willi no longer possible, However, a later study failed
to find a correlation between the presence of revertant fibres and the clinical course of
the disease, citing inter• and intra-individual variability as the probable cause of thlll
discrepancy (Fanin et al., 1995). The authors suggested that the low levels of fibres
produced would be likely to limit their functional significance. Nevertheless, the very

e1istcnce of these fibres represents a rationale for a possible therapeutic approach lo
tcducc the clinical severity of DMD, provided that the frequency of revertants could be
raised to biologically significant levels (Sherratt et al., 1993; Wilton, Dye, Blecliyndcn
& Laing, 1997).

In addition, the natural occurrence of rcvertant fibres suggests that an approach
which increases the frequency or these fibres may avoid the possibility of triggering an
immune response, such as that reported to occur following the introduction of full
length dystrophin by gene transfer into dystrophic muscles (Ohtsuka, Udaka,
Yamashiro, Yagita & Okumura, 1998). Many of these individuals will not have been
e1poscd to dyBtrophin previously, except in the form of revcrtant fibrca', and may
perceive the introduced protein as a neoantigen (Ferrer, Wells & Wells, 2000).
However, targeted cxon skipping based on the exons commonly removed in revcrtant
fibre transcripts may rcsult in a less immunogenic product (Lu et al., 2000).

s
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1.S

Pre-mRNA splldng
Pre-mRNA splicing involves the _precise excision of introns from the primary

gene ttanscrlpt and the joining of ell.ons to fonn the mature RNA, This intricate process
is catalysed within the spliceosome, a large ribonuclcoprotein complex consisting of
five small nuclear ribonuclcoprotein particles (snRNP), UI, U2, U4, US and U6, as well
as approximately 80 - 100 non-mRNP proteins (Adams, Rudner & Rio, 1996; Kole &

sawn. 2001 ).
To ensure that intron cleavage and exon ligation is exact, the consensus spUce
sites are distinguished by the almost invariant dinucleotldes OU at tv.e 5' acceptOr site
1

and AG at the 3' donor site of lhe intron (Shapiro & Senapathy, 1987); In addition, the
3' splice site is associated with an upstream polypyrimidine tract and degenerate branch
point motif (Tanaka, Watakabe & Shimura, 1994). The components that initially

recognise the splice sites are the UlsnRNP, which pairs with the 5' splice site, and the
protein factor U2AF, which binds to the polypyrimidine tract wilhin the 3' splice site
sequence (Black, 1995). These factors trigger the formation of the spliccosome.
Cleavage at the S'splicc site, with ligation of the intron 5' end to an adenosinc residue at
the branch point, is followed by cleavage at the 3' splice site and ligation of the two
elOllS (Black, 1995). It is thought that lhe splicing of prc-mRNA transcripts generally
occurs in a 5' to 3' direction, although there is evidence to suggest that the splicing of

introns may also occur in anon-linear progression (Kessler.Jiang & Chasin, 1993).
Large genes, such as the dystrophin gene contain a high nwnbcr of exons and
very long introns, which presents a challenge to efficient and precise transcription and
splicing processes. In some regions, the 5' and 3' splice sites must be com:ctly paired
across large physical distances (200kb or more) while avoiding the inappropriate
exclusion of cxons (Berget, 1995; Black, 1995; Horowitz & Krainer, 1994).
Positive elements for prc-mRNA splicing include the strength of the 5' and 3'
splice sites (drttnnincd by how well they confonn to the consensus sequences) and the
branch point sequence (Chabot, 1996; Dominski & Kole. 1994). However, mRNA

contains many "cryptic" sequences which closely resemble the splice site consensus
sequences of true splice sites (Black, 1995). Th115, individual splice site strength alone

may not be sufficient to account for the high specificity observed in splice site selection,
indicating

~

presence of additional clements involved in exon recognition (Reed.

1996; Watak.abc, Tanaka & Shim11111, 1993).

'
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Several factors have been suggested lo affect the selection of splice sites and
subsequent spliceosomc assembly, including the spacing of each splicing element
(Berget, 1995; Reed, 1996), the length of the cxon (Dornin.W & Kole, 1994) and the

"

order of intron removal, through a change in secondary sln!cture or approximation of
protein binding sites (Kessler et al., 1993). These factors may help to explain why
ayptic splice sites are not wel\ rewgnised.
In addition, there is growing evidence that internal exon sequences can
efficiently stimulate inclusion of an cxon, presumably through recognition by the
splicing machinery. These exon splicing enhancers (ESEs) may act by co-operating
with, or compensating for, functionally weak.splice sites, allowing more efficient
recognition of the target exon (Dominski & Kole, 1996; Lam & Hertel, 2002). The
tenns ERS and ESE have been used interchangeably in the literature, but ESE is now
considered a general term for any sequence that promotes exon inclusion during
splicing (Xu, Teng & Cooper, 1993), whereas an ERS is defined as a purine-rich ESE
(Tanaka et al., 1994). It is important lo note, however, that not every purine-rich exon
sequence functions as an ERS. For example, it has been reported that purine-rich
sequences from three exons of the dystrophin gene (exons 43, 46 and 53) showed
varying degrees of splicing enhancer activity ranging froro very little (ex.on 46) to
powerful (exon 43), suggesting that each exon In the dystrophin transcript may be
subject to the influence of different splicing elements (Ito, Takesbima, Sakamoto,
Nakamura & Matsuo, 2001),
The mechanisms by which ESEs enhance exon inclusion remain unclear (Ito et

al., 2001). It bas been suggested that ESEs form an RNA secondary structure which
either directly influences cxon selection or improves the accessibility of splicing factors
lo the binding sites (Watakabe et al., 1993; van Dcutekom & van Ommen, 2003). In
addition, exonic splicing enhancers serve as binding sites for serine/arginine rich (SR)
proteins (Lam & Hertel, 2002; Liu, Zhang & Kreiner, 1998), which are thought lo
interact with the 5' splice site, the Ul snRNP, and the U2AF protein, providing a bridge
between the splice sites during splicing (Black, 1995), It is thought that the activity of
these bound SR proteins, sequence context and the distance between the ESE and the
intron, determines the strength of an ESE (Gmveley, Hertel & Maniatis, 1998), allhougb

the optimal distance may be protein specific and thus variable between exons (Liu,
Chew, Cartegni, Zllang & Krainer, 2000).
(.\
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In addition to sequences which enhance the inclusion of exons, less well
characterised sequences which inhibit splicing, known as exonic or intronic splicing
silencen, also exist (Blencowe, 2000; Fairbrother & Chasin, 2000). It is thought that
these sequences, which can be either purine or pyrimidine rich, bind a diverse array of
proteins and may have a role in suppressing the use of cryptic splice sites, thereby
favouring the selection of troc splice sites (Fairbrother & Chasin, 2000).

1,6

Animal models ofDMD
Animal models, including dystrophin-deficient dogs, mice and cats, play an

important role in DMD research by providing genetic and/or biochemical homologues
of their human counterparts (Cooper, 1993). Golden Retriever dogs with muscular
dystrophy (GRMD) exhibit a similar but more severe phenotype to that seen in DMD
(Howell el al., 1998; Valentine et al., 1992). This disorder arise!l from a point mutation
in the acceptor splice site of intron 6 of the GRMD dystrophin gene, resulting In the
exclusion of exon 7 from the mRNA (Sharp et al., 1992). Affected dogs have raised
serum creatine kinase levels, display progressive muscle atrophy with fatty infiltration

(although to a lesser degree than observed in DMD), develop cardiomyopathy, and have
a shortened life span, secondary to cardiac and respiratory failure (Nonaka, 1998;
Valentine et al., 1992).
The mdx mouse commonly serves as an animal model for DMD as it also
exhibits an absence of dystrophin in its muscle tissue (Sicinski et al., 1989). The
skeletal muscle of mdx mice demonstrates dystrophic changes such as muscle fibre
necrosis and regeneration, with the diaphragm most severely affected (Nonaka, 1998).

In the mdx mouse the absence of dystro1:1hin is caused by a nonscD!le mutation at
position 3185 in exon 23 of the dystrophin gene, leading to premature termination of
dystrophin synthesis (Sicinski et al., 1989). As a model for DMD, the mdx mouse is
convenient and economical, but it is limited in its clinical similarity to the human
disease. By comparison, the GRMD dog more accm:ately reflects the human DMD
phenotype, but is more difficult and expensive to maintain as a colony (Cooper, 1989).
In consideration of these different models, the mdx mouse appears most appropriate for

DMD laboratory experiments, whereas the GRMD dog may be an essential model for

preclinical studies before hwnan trials.

8 .
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1,7

Therapies for DMD
TilC objective of most therapeutic approaches to the trcaunent of DMD is to

raise the quantity of functional dystrophin in all dystrophic tissues to clinicaliy
significant levels,
Many gene replar.ement or modification strategies are being tested; however
there are numerous technical problems that must be overcome before any of these
therapies can be used safely and effectively, as briefly considered below.
1,7,1 Cell-mediated treatment
One approach to the treatment of genetic disorders involving muscle is myoblast
transplantation, where mononucleated precursor cells isolated from normal donor
tiss\lC!I are propagated in cell culture before injection into diseased muscle (Coovert &
Burghes, 1994; Smythe, Hodgetts & Grounds, 2000). However, transplanted myoblasts
have a tendency to remain localised near the injection site, rather than migrating lo
distant damaged sites (Blau & Springer, 1995). Additionally, implanted myoblasts were
shown to have poor survival rates, typically less than 1% (Mendell et al., 1995), with
the majority of donor cells failing to survive for more than one hour after injection
(Smythe et al,. 2000). This poor survival Is thought to be callSCd by immune rejection of
the implanted my ob lasts (HodgeUs, Spencer & Grounds, 2003).
In another cell-mediated approach, injection of genetically marked bone marrow

into damaged muscles of immunodeficient mice revealed that the bone marrow cells are
able to undergo myogenic differentiation and contribute to regeneration of the damaged
muscle fibres (Ferrari et al., 1998). In another study, it was reported that intravenous
injection of either haematopoetic stem cells or muscle-derived stem cells into irradiated

nuJx mice resulted in dystrophin expression in up to 10% of the muscle fibres within an
individual mouse. Of the dystrophin·positive fibres, 10 - 30% contained donor nuclei
(Gussoni et al., 1999). More recently, stem cells derived from blood vessels
(mesoangioblasts) have been demonstrated to reconstitute dystrophin expression
following intravenous injection in dystrophic mice (SlUIIPaolesi et al~ 2003). This
approach may be a promising development in the treatment of DMD, particularly as
systemic dclivecy appears possible, at least within the mouse.

9
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1.7.1 Gene replacement
Gene replacement aims 10 introduce normal or semi-functional genes into cells
which lack the product of that gene (KIUpali & Acsadi, 1993). In treating DMD, the
main aim has been to supply dystrophin minigenes, consisting of partial or full-length
dystrophin cDNAs driven by a suitable promoter, to muscle cells (Acsadi et al., 1991;
Ragot et al., 1993). Further development of novel plasmid and viral vectors has allowed
greater delivery of cDNAs to skeletal myocytes (reviewed by Fletcher, Wilton &
Howell, 2000; Manmall & Leideo, 1998).
Unfortunately, even if gene replacement therapies were developed successfully
in skeletal muscle, the absence of the two other major full length dystrophin products
found in the brain and heart would still remain a problem (Karpati & Acsadi, 1993). For
this reason, and to avoid multiple injections into the muscle to achieve transgene
delivery, a systemic delivery system would be advantageous (Hartigan-O'Connor &
Chamberlain, 2000). Furthermore, ii is poS11ible that not all of the symptoms of DMD
can be alleviated by replacement of only the full length dystrophin isoform (CUiiigan et
al., 1998).

1.7.2.1 Non-viral yectors
Non-viral delivery systems, such as cationic liposomcs, DNA protein complexes
and direct injection of naked plasmid have the advantages of being non-infectious and
potentially less immunotoxic when med in vivo (reviewed by Fletcher et al., 2000). By
comparison with virus-based systems, non-viral vectors are easier to manufacture, allow
the delivery of larger inserts and may be particularly suitable for the delivery of
oligonucleotidcs to mammalian cells (reviewed by Romano, Michel, Pacilio &
Giordano, 2000). Unfortunately, non-viral vectors have demonstrated low transfection
efficiencies (Marshall & Leiden, 1998) and lack target specificity (Romano et al.,
2000). Liposome-mcdiated delivery of plasmid DNA also increases host immune
responses compared to naked plasmid DNA (Romano et al., 2000).
The U!IC of plasmid RNA and DNA injected directly into mo\l!IC skeletal muscle
to modify gene expression was first demonstrated by Wolff and colleagues (Wolff et al,,
1990). Subsequent studies in dystrophic muscle used expression plasm.ids containing 12
kb humandystropbin cDNA or a 6.3 kb BMD-like cDNA. These were directly injected
10
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into mdx muscle and gave rise to approximately I% dystrophln-positive fibres (Acsadi

ct al., 1991). A similar trial In GRMD dogs yielded dystrophin expression of up to 2.5%
of fibres in skeletal muscles injected with plasmid containing a full length dystrophin
gene or II dystrophin minigenc (Howell ct al., 1998), The authors concluded that for
gene therapy to be useful as II treatment for DMD, more efficient expression will need
to be achieved.

More recent resca,,--cli has aimed to improve efficiency by using an Epstein-Barr
virus based plasmid 'minichromosome' injected into mdx muscle tissue (Tsukamoto et

al., 1999). Over a ten-wCC"k period, this resulted In II statistically significant increase in
the number of muscle fibres expressing dystrophin, compared with a conventional
Vector. In addition, the effects of direct intra-muscular injection of a plasmid expressing
full-length dystrophin have been assessed in DMD and BMD patients (Romero et al.,
2002).

Besides the standard DNA delivery methods discussed, several other Innovative
'physical' approaches to enhance gene transfer into muscle have been trialled with
varied success. These include muscle electroporation which hyper-permeabilises
the myocytes (Vilquin et al., 2001), hyperosmotic pressure (Duchler et al., 2001),
high velocity tissue bombardment ('gene-gun') (Zelenin et al., 1997) and
ultrasound-mediated microbubble destruction (Frenkel, Chen, Thai, Shabel &
Graybum, 2002). However, a less invasive method of delivery will need to be
developed for routine clinical use of plasmid vectors (van Deutekom & van Ommen,
2003).

1.7 .2.2 Viml vectors
Retroviral, lentiviral, adenoviral and adeno-associated viral vectors have been
employed to increase the efficiency and delivery of DNA transfer, but have been
hindered by immunotoxicity and other factors (reviewed by Coovert & Burghes, 1994;
Fletcher ct al., 2000; Morgan, 1994).
Retroviruses are single-stranded RNA viruses which can efficlently integrate
into the host genome, carrying gene products such as the dystrophin minigene, and
transduce the host cell by reverse-transcnbing their viral RNA (with insert) into DNA
(Morgan, 1994). However, as viral insertion is random, the cell genome may be

II
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disrupted, possibly leading to the Inactivation of tumour suppressor genes or even
induction of the expression of cellular oncogenes (Romano et al., 2000).
Additional limitations include a relatively small payload, as only an insert of
approximately g kb can be carried, and the fact that mosl retroviruses require the
presence of mitotically active host cells for transfer of the viral load and therefore do
not infect mature myofibrils (Coovert & Burghes, 1994; Morgan, 1994). Lentiviroses,
while able to transfect both dividing and non-dividing cells, have the disadvantage of
being }UV-I based, and so carry the potential danger of scrum conversion to HIV-I in
the patient(Romano et al., 2000).
Adcnoviruses are double-stranded DNA viruses which can be rendered
replication-defective (Ragot et al., 1993; Romano et al., 2000). These altered viral
particles enter the target cell through endocytosis and reside D5 autonomously
replicating episomal units in the nucleus, but are not integrated into the host genome
(Coovert & Burghes, 1994). The advantages of adenovirusC!I are that they can infect
non-dividing cells and be prepared in large quantities. Unfortunately, they also have an
insert-size limit of approximately 8 kb and, as they do not integrate into the host
genome, can only provide transient gene expression (Hauser, Amalfitano, KumarSingh, Hauschka & Chamberlain, 1997; Mountain, 2000). Furthermore, they may
trigger potent immune and inflanunatory responses (Mountain, 2000).

A funher development in adcnoviral vectors has sought to overcome these
limitatioll!I by removing all viral coding sequences, producing 'gutless' adcnoviruses.
This manipulation allowed the accommodation of up to 30 kb of foreign DNA
(Kochanek et al., 1996). In addition, the expression ofviral proteins is eliminated u all
protein coding sequences are removed. The authors proposed that this would reduce the
cellular immune response and allow longer-term expression of the transferred gene. A
more recent study has reported restoration of functional dystrophin production to mdx
muscle following single injections of gutted adenovira.1 vectors carrying full•length
dystrophin cassettes (DelloRusso et al., 2002). Only a slight immune response to the
injected material was observed.
Adeno-usociated viruses (AAV) are single-stranded DNA viruses which can
stably integrate into host DNA. One limitation is that they can carry only a small
gene load of approximately 4 kb (Romano et al., 2000). Injection of AAV carrying
micro-dystrophin gene constructs into dystropbic muscles of mdx mice have been

reported to reverse the bistopathoJogical features of this disease (Fabb, Wells, Serpentc
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& Dickson, 2002; Harper et al., 2002; Sakamoto et al., 2002). However, substantial
immune responses to AAV-delivered transgene products have been observed In
dysttophic mice, causing destruction of trans Weed myofibres (Yuasa cl aL, 2002). In
addition, it has been suggested that despite its apparent ability to prevent ongoing
muscle damage, this approach may not be able to fully restore muscle strength (Harper
et al., 2002; van Deutekom & van 01nmen. 2003).

Several llpProaches have been attempted in order to yield higher transduction
efficiencies with viral vectors. A study by vanDeutekom etal. (1998) demonstrated that
the use of cardiotoxin to generate a specific myofibre degeneration resulted in markedly
higher levels of retroviral, herpes simplex viral, and adenoviral transduction of mature
muscle compared to non-regenerating muscle. In addition, streptokinase treatment of
myofibres was shown to increase the permeability of the extnicellular matrix, resulting
in higher levels of herpes simplex viral transduction.
1,7.3 Utrophln upregulatlon

The utrophin gene, encoding 74 exons sj)8Dlling over 1Mb of genomic DNA, is
widely expressed in many fetal and adult tissues (Pearce et al., 1993) and may be a
developmental precursor of d}'lltrophin (Lin & Burgunder, 2000). Studies on utrophin
upregulation have been based on the hypothesis that utrophin, a protein which shares
over 80% homology with dystrophin (Love, Byth, Tinsley, Blake & Davies, 1993), may
offer protection against damage and necrosis in dystrophic muscle (Wilson, Cooper,
Dux, Dubowitz & Sewry, 1994). Utrophin is expressed at the membrane surface of
immature myotubes and becomes restricted to the neuromuscular junction in mature
muscle (Davies, 1997). Utrophin constitutes part of the complex of proteins and
glycoproteins which link the basal lamina to the cytoskeleton, providing muscle fibre
membrane stability (Radojevic et al., 2000). Utrophin has been detected as sarcolemma
staining of muscle cells obtained from DMD patients and mdx mice (Davies, 1997), and
appears to increase in response to muscle degeneration and regeneration, particularly in
DMD muscle (Pearce et al., 1993).
A truncated utrophin transgene, driven by the human skeletal a-actin promoter,
was used to generate high level utrophin expression in mdx skelellll muscle and
diaphragm, preventing development of dystrophic pathology (Tinsley ct al., 1996). In
addition, adenoviral delivery of mini•utrophin has been demonstrated to restore the
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dystropbin-glycoprotein complex and prevent the dystrophic phenotype in animal
models of DMD (Cerletti et al., 2003; Wakefield et al., 2000). A higher level of
function was achieved, as demonstrated by muscle strength, following the expression of
full-length utrophin mRNA in mdx mice (Gillis, 2002). In a different approach,
overexprcssion ofutrophin in mdx diaphragm muscle was stimulated by treatment with
nitric oxide donors (Chaubourt et al., 2002). Utrophin upregulation may avoid the
potential immune response associated with the delivery of dystrophin to previously
dystropbin-deficient tissues (Hartigan·O'Cowior & Chamberlain, 2000; van Deutckom
& van Ommen, 2003; Wakefield et al, 2000). In addition, no toxic effects were

observed following non-specific overexpression of full-length utrophin in a broad range
of tissues in the mdx mouse (Fisher et al., 2001). Thm this approach remains a
promising potential therapy for DMD once suitable compounds to upregulate this gene
can be identified.

1.7A Genetk therapies

t.7 .4.1 Short frai!Dent homologous m:ombination
,;.,,

The introduction of short fragments (400 - 800 bp) of wild type DNA to the

nuclei of mutant cells is thought to result in homologous replacement of the endogenous
allele with the wild type counteq,art, through utilisation of recombination gene
repair (Gonez et al., 2001).

In a study by Kapsa et al. (2001) a 603 bp wild-type PCR

product was applied to mdxmuscle cells, with IS - 20% exhibiting conversion of mdx to
wild-type transcripts. Despite the high level of gene repair reported, none of the
corrected cells were shown to express dystrophin. ln vivo, only 0.0005% to 0.1% of
treated muscle cells e~ibited gene repair, again with no expression of dystrophin. The
authors attributed the lack of dystrophin e:tpression to the observed dfop in cell
numbers after transfection, possibly due in part to the tmnsfection agents used (Kapsa et
al., 2001). However, it now apPellfS iikcly that the high levels of correction were an
artefact of the assay used for correction (A. Sl1Xena, unpublished observations).
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t.7.4.2 Chim;ric oJiaonucleotides
Chimeric oligonucleotides (COs), also known as chimeraplasts, consist of sclroomplcmcntary DNA and RNA nucleotides arranged in a doublc-baupin configuration
(Gampcr ct al., 2000), It is thought that COs with the appropriate sequence can anneal
to the target region containing a point mutation. The COs could then act as a template,
exploiting the cell's own mismatch repair mechanism, and induce the com:ction of the
mutation (Rando, Disatnik & Zhou, 2000). COs have been shown to correct
substitution, deletion and insertion mutations in yeast cells (Liu, Rice & Kmiec, 2001).
However, as COs correct only single base mismatches, this approach would not be
suitable for the 60% of patients with DMD who have large deletions in the dystrophin
gene (Rando et al., 2000).
In a study by Rando et al. (2000), single doses of chimeric RNA/DNA
oligooucleotides targeting the point mutation in exon 23 were injected into muscles of
mcb: mice. CO-mediated repair was low, with only 1% - 2% of the muscle fibres in the

total muscle staining positive for dystrophin. These fibres were located directly around
the needle track and injection site but they represented 10% - 20% of fibres staining
positive for CO uptake and subsequent gene correction. It has been suggested that the
muscle fibre correction rate must eicccd 10 • 20% before this method could become a
potential treatment for DMD (Fletcher et al., 2000). Rando and colleagues (2000)
suggested that the efficiency of the procedure could have been enhanced by performing
multiple injections, increasing the concentration of CO, use of a dclivcry vector or
possibly IV injection, In a later study, the Sllllle group demonstrated CO-mediated
gene repair in mdx muscle precursor cells, indicating that improved persistence of
CO-mediated effects may be possible (Bertoni & Rando, 2002). While this approach
remains inefficient, the potential for cumulative, more permanent gene correction
warrants further optimisation (van Deutekom & van Ommen, 2003).
1.7.4.3

Antisense oJigonucleotides
Of the genetic therapies, antisensc oligonucleotides (AOs) represent an attractive

approach to the regulation of specific gene expression. AOs are single-stranded
fragments of nucleic acid approximately 10 - 40 bases in length and arc composed of
nucleotide sequences complementary to the mRNA or pre-mRNA sense strand
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(Lavrovsky, Chen & Roy, 1997). The mechanism by which AOs exert lheir effect is

lhrough Watson-Crick base-pair hybridisation to the target sequence (Agrawal, 1996).
AOs were originally used to inhibit the replicaUon of the Rous !IIIICOlllll virus by
causing targeted downregulation of the viral mRNA in cell culture (Stephenson &

Zamccnik, 1978). Many subsequent studies have .investigated AOs as agents for specific
downregulation of gene expression in the treatment of viral infections, cancers and
inflammatory disorders (Agrawal, 1999; Lebcdeva & Stein, 2001; Mercatante, Bortner,
Cidlowski & Kole, 2001). This has resulted in the commencement of clinical trials and
the approval of the first oligonucleotide drug, Vilfavene™, for the treatment of an
acquired.disease, cytomegalovirus retinitis (Orr, 2001),
The first antisense agents used were wunodified oligodemtynucleotides (0DNs1
which were hampered by rapid degradation in the cellular environment caused by
nuclease-mediated hydra\isation of the phosphodiester (PO) bond (Seeberger &
Caruthers, 1998). Efforts to alleviate these effects by modifying the ODN backbone
resulted in the production of the first generation o\igonuclcotides. Of these, the AOs
studied most extensively are the phosphorothioatcs (PS), where one of the non-bridging
oxygen atoms of the FO moiety has been replaced by sulphur (Dias & Stein, 2002;
Seeberger & Caruthers, 1998). Compared to the natural PO b.ackbone, this modified
linkage greatly enhances resistance to nucleases (Allmann, Cucnoud & Von Matt, 1998;
Dias & Stein, 2002), although binding affinity is reduced (Guga, Koziolkiewic1.,
Okrisz.ek & Stek, 1998).
The mechanisms of action through which AOs modulate gene expression can be
divided into two main categories: in the first, duplexes formed by a PS AO and its
complementary RNA act as substrates for RNaseH, an ubiquitous enzyme that
specifically cleaves the RNA strand of the duplex (Altmann et al .. 1998), In the second
category, the AO can sterically interfere with pre-mRNA splicing or the translation of
protein (Dias & Stein, 2002). However, PS AOs have a disadvantage in biological
systems, as they tend toward non-specific protein binding, which may result in
significant non-anlisense side effects (Altmanll etal, 1998; Crooke & BCllllell, 1996).
Further attempts to ameliorate these side effects and enhance both binding
affinity and nuclease resistance led to the development of AOs with a wide variety of
riba;e'modifications, one of which includes the addition of a methyl group at the 2'-0
position (Seeberger & Caruthers, 1998). Modifications at this position of the sugar
molecule produces an oligonucleotide that resembles RNA more than DNA. This
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increases the stability of the AO and allows the 2'-0-methyl antisense oligonucleotidc

(2'0MeAO) to hybridise tn its complementary RNA target sequence without inciting
RNascH degradation of the resulting duplex (Lavrovsky et al., 1997).
1.7.4.3.1 Antisenseoligonucleotides as modulators of splicing
In addition to downregulating gene expression, 2'0MeAOs have been shown to
have potential in restoring the expression of genes inactivated by abeJrant splicing
mutations (Dominski & Kole, 1993; Sierakowska, Sambade, Agrawal & Kole, 1996),
The requirements of 2'0MeAOs for splicing modification differ from those which aim
to downregulate gene expression, in that the activation of RNascH should be avoided
(Sazani & Kole, 2003). In addition, the AOs must be able to effectively displace the
splicing factors required for the normal processing of the pre-mRNA within the cell
nucleus (Sazani & Kole, 2003). Possible pre-mRNA targets for 2'0McAO hybridisation
include the consensus splice sites, branch point sequence and internal exon sequences
(Dunckley, Manohoran, Vllliet, Epcron & Dickson, 1998; Mann et al., 2001; van
Deutekom & van Ommen, 2003).
Modification of pre-mRNA splicing by 2'0MeAOs was initially demonstrated
by Kole and colleagues in the l}-globin gene, mutations of which result in ~thalassemia
(Dominski & Kole, 1993). 2'0McAOs were targeted to cryptic splice sites activated
by intronic mutations, forcing the utilisation of the correct splice sites and restoring
fi-globin expression. Several other targets, including the CFTR gene and the Tau
gene (reviewed in Sazani & Kole, 2003) have been found to be amenable to
2'0MeAO-mediated modification. Additionally, 2'0MeAOs have been applied to
dystrophic cell lines carrying frame-shifting mutations (Aartsma-Rus et al., 2003;
Duncltley et al. 1998; Mann et al., 2001; Pramono et al. 1996; van Dcutekom et al.,
2001; Wilton et al. 1999).
1.7,4.3.2 Antisensc oligonuclcotides and DMD
In 1990, Matsuo and colleagues described a plltient with an intra-exon deletion
of S2bp in ex.on 19 of the dystrophin gene which resulted in an out-of-frame mutation
with a subsequent DMD phenotype (Matsuo et al., 1990). This mutation, despite the
retention of the consensus splice sites, prevented correct exon 19 defmition so Iha! the
17
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entire wm was ellcludcd during processing. leading these researchers to believe that the
deleted sequence or ellon 19 contained a cis-acting eleme'lt (i.e. an ESE) essential for
accurate splicing of the flanking introns (Matsuo et al .. 1991). Subsequently, a 31-mer

2'0MeAO complementary to the S' region of the deleted sequence in dystrophin Kobe
cxon 19 was demonstrated to Inhibit prc-mRNA splicing in a mini-gene in a dose- and
time-dependent manner. It was noted that splicing efficiency was proportional to the
number of polypurine stretches in exon 19, supporting the notion that these stretches are
important for exon recognition (Takeshima, Nishio, Sakamoto, Nakamura and Ma~uo.
1995). Additional studies by the same group induced highly efficient 1111d specific
skipping of dystrophin Kobe exon 19 in normal human lymphoblastoid cells by
directing a 31-mcr antisense oligodeollynucleotide to the ESE of ell'.on 19 (Pramono et
al., 1996).
It has been suggested that targeting the DMD gene transcript to remove an ellon
containing a disease-causing nonsense mutation, or removing one or more exons
flanking a deletion to restore the reading frame. should minimise the consequences of
the dystrophin mutation. In this manner, the DMD gene is processed to produce an
in-frame BMD-like mRNA with subsequent reading frame restoration (Matsuo, 1996;
Wilton et al., 1999). This principle was demonstrated in mdx mice, with consistent and
efficient 2'0MeAO-induced skipping of exon 23 by targeting the 5' sp!i;:.;; site of intron
23 (Wilton et al., 1999}. This re-directed processing of the pre-mRNA, such that the
nonsense mutation in exon 23 was removed. Skipping of exon 23 did not disrupt the
reading frame and near full length dystrophin was detected in 2'0MeAO-treated mdx
cells and muscle (Mann et al., 2001). However, it was observed that these 2'0MeAOs
also induced the sporadic removal of an adjacent exon, suggesting a potential lack of
specificity or that the splicing of ell'.ons 22 and 23 are intimately linked (Mann et al.,
2001; Wilton et al, 1999). A more rccenl study by the same group reported
improvements to the design of the 2'0MeAOs, resulting in increased efficiency of exon
skipping. 2'0MeAOs targeted to the S' splice site, extending further into intron 23,
induced greater levels of protein synthesis than previously reported (Mann, Honeyman,
McClorey, Fletcher & Wilton, 2002). It was demonstrated that refining the region
targeted by 2'0MeAOs could lead to detection o£2'0MeAO-induced mRNA transcripts
in cell culture al transfection doses as low as SnM.

In 2001, van Deutekom and colleagues applied 2'0MeAOs to a polypurinc-rich
sequence in dyslrophin exon 46 and induced the precise excision of that exon from
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dystrophin pre-mRNA in normal human cells. These AOs were then s=essfully
applied to myotubes derived from a DMD patient with an exon 45 deletion, to restore
the reading frame in that particular defective dystrophin transcript. The authors
proposed that the specific skipping of exon 46 after targeting the ESE indicated that
these motifs may be more efficient targets than the splice sites for precise exon skipping
(van Deutekom el al., 2001). Subsequent studies by this group demonstrated the broad
therapeutic potential of 2'0MeAOs. The individual skipping of an additional 11
dystrophin exons were induced by 2'0MeAOs in cultured normal human muscle cells
(Aartsma-Rus et al., 2002). The authors suggested that lhe targeted skipping of one
particular exon could be apPlied to a series of different mutations in order to restore the
reading frame. This approach was then demonstrated in cultured muscle cells from
DMD patients exhibiting a variety of mutations (Aartsma-Rus ct al., 2003). In each
case, thc skipping of the CJlOD required to restore !he reading frame was induced,
restoring dystrophin synthesis in over 75% of cells.
A limitation in these studies was the transient nature of dystrophin elprcssion,
which would necessitate periodic administration of lhe 2'0MeAO. An alternative
approach to 2'0MeAO delivery was to achieve a more permanent bypass of a mutation
in thc dystrophin gene (De Angclis et al .. 2002). Antiscnse sequences, targeting both thc
5' and 3' splice sites of exon 51, were cloned into small nuclear RNAs (snRNAs) and

delivered into human muscle cells by a recombinant virus. It is thought !hat these
rmRNPs would stably and efficiently produce the antisense sequences, leading to a more
permanent antisense effect and reducing the need for repeated delivery. As the human
cells were from a patient with an eJlon 48 to 50 deletion, the reading frame was
effectively restored, resulting in dystrophin synthesis as demonstrated by Western
blotting (De Angelis et al., 2002).
Although considerable advances in this field have been made, several
parameters, including choice of target sequence, antisense drug design and safe and
efficient delivery require further optimisation, wilh the ultimate aim of restoring
dystrophin synthesis to therapeutic levels in all affected tissues (van Dcutckom & van
Ommen, 2003).
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2.1 Cell lines
2.1.1 Mouse cells
Two conditionally inunortal mouse cell lines were used in this project, H-2K

nonnaJ and H-2K mdx. Both cell lines were derived from H-21'6-tsASS transgenic mice
carrying a thermolabile T antigen (Jat ct at 1991; Morgan et al., 1994). These mice
harbour a temperature sensitive (tsAS8) strain of the immortalising simian virus 40
(SV40) large tumour antigen (Tag) under the control of a mouse major

bistocompatability complex H-21:! class I promoter. This promoter is active in a broad
range or tissues and acts to control the expression of the transgene. H-2K cells remain in
a proliferative phase while exposed to high serum concentrations and lhe cytokine
interferon-gamma and incubalion at a constant 33°C. Increasing the cell culture
temperature to 37°C inactivates the tsAS8 Tag gene product, thus removing its
immortalising function. Furthermore. exposure to low scrum media stimulates terminal
cell diffmintiation (!at et al. 1991; Morgan et al., 1994).
2.1.2 Human cells

2.1.2.1 Primacyhwnan "Us
Quadriceps muscle biopsies were obtained after infomaed consent from patients
undergoing screening for susceptibility to general anaesthesia-Induced malignant
hypcrthennia. The procedure was pcrfomaed at Royal Perth Hospital, Western Australia
from where the biopsy remnants were transported In ice to the laboratory and
immediately subjected to enzymatic disassociation. All initial culturing of the primary
human myoblasts was perfomaed by Dr Sue Fletcher (Experimental Molecular
Medicine Group) according to the protocol of Rando and Blau (1994).
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2.1.2.2 Immortalised HDMD cells
The immortalised hwnan DMD {HDMD) cell line was generously provided by

Professor Jacques Tremblay (Universilt Laval, Quebec, Canada). These cells were
Initially obtained from a DMD patient with a deletion of dystrophin exons 46 to 51
inclusive. Immortalisation of the HDMD cells required subsequent tnmsfection with
two retroviruses. To delay senescence in these cells, they were fiflll transfected with
a retrovirus containing the SV40 large T antigen (Tag). After apProdmately
25 doublings, DMD-Tag, a clone of the transfonned cells, was then infected with
the human telomerase reverse transcription (hTERT) subunit retrovirus to
activate telomerase, allowing the DMD-Tag cells to escape crisis and fonn the
DMD-Tag-hTERT cell line (Seigneurin-Venin, Bernard & Tremblay, 2000).

2,2 Reagents and Suppliers
SuppUer

2'-0- methylated antisense oligonucleotidcs

Geneworks and CNND

40% acrylamide/Bis solution 19:1 (2.6% C)

Bio-Rad Laboratories

40% acrylamide/Bis solution 37.5:1 (26% C)

Bio-Rad Laboratortcs

Acetic acid, glacial (CH,COOH)

BDH Laboratory Supplies

Acrylamide/Bis solution (40%, 37.5:1)

BioRad

Agarose (molecular biology grade)

Scientifix

Agarose, low melting point (LMP)

Promega

Ammonium persulphate (APS)

Sigma

Amphotericin B

Sigma

Baxter sterile water

Baxter Healthcare

Big Dye Tenninator Sequencing Mix (Version 3.1)

AB!

Bovine fetal growth factor (BFGF)

·""''

Bromophenol B\ue/XyleneCyanol dye solution

Sigma
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Supplier
C. thtrm. Polymerase One-step RT-PCR system

Roch,

Calcium chloride

BDH

Chick embryo extract (CEE)

Invitrogen

Chloroform

Sigma

Collagenase (grade II)

Invitrogen

Dimethyl sulphoxide {DMSO)

Sigma

Di-potassium hydrogen phosphate

Sigma

Di-sodium hydrogen orthophosphate dihydrate

BDH

Di-sodium hydrogen phosphate

Sigma

dNTP,

Prom<g,

DOTAP

Biontex

Dulbecco's modified Eagle's Medium (DMEM)

Invitrog~n

Ethanol

Mmcl<

Ethidium bromide

Sigma

Ethyleucdiamine tetra acetic acid (EDTA)

Sigma

ExGen 500 (PEI)

MBI Fennentas

Fetal Calf Serum (FCS), heat inactivated

Invitrogen

Formamide

Sigma

Fungizone

Sigma

Glycerol

Sigma

Glycine

Sigma

HAMS'sFIO

Invitrogen

Horse Serum (HS), heat inactivated

Invitrogen

Hydrochloric acid

BDH Laboratory Supplies

Intelleron-gamma (IFN-1)

Roche Molecular Biochemicals

Isopropanol

Sigma

Lipofectamine 2000

Invitrogen
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Supplier

.(-:

Lipofcctin

lnvitrogcn

Matrigcl

Becton Dickinson

M"""'°l

Selby S<licntific

Mineral oil

Sigma

Molecular wclgh1 marker (IOObp ladder)

Geneworks

Opti-MEM (Reduced Scrum Media)

Invitrogcn

PCR prilllCfS (sequencing grade)

Gcneworks

Penicillin/ Stteptavidin solution

s;gm,

Poly-D-Lysinc, hydrobromidc

Sigma

Potassium chloride (KCI)

Sigma

Potassium dihydrogen phosphate (KH1POJ

Ajllll'. Chemicals

Q!Aquick PCR Purification Columos

Qiagcn

RNA-Bee (RNazol B)

Tcl-TCSI

,NTP,

Promog•

Sodium acetate, anhydrous (CHiCOONa)

BDH

Sodium bicarbonate (NaHC01)

s;gm,

Sodium chloride (NaCl)

Sigma

Sodium hydroxide (NaOH)

APS F'mechcmicals

Sodium phosphate (Na,PO,)

Sigma

Streptomycin

Sigma

SyBrGold

BioScicntific Pty Ltd.

TEMED (N,N,N' ,N'·tctramcthylcthylcnediaminc)

Sigma

Titan One Tube RT-PCR System

Roche Molecular Biochemicals

Trypanblue

Sigma

TI)'p!lin (lyophiliscd)

lnvitrogen

TI)'p!lin·EDTA solution (0.5% trypsin, 5.lmM EDTA) Jnvitrogcn
Till Plus DNA polymerase

FisherBiotech
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Ve:rscnc

Life Tcclumlogics

Xylene

Rowe Scientific
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3.1 Cell culture
J,1,1 Resurrection ol cells

Stocks of cells were stored frozen as lmL aliquots in liquid nitrogen until
required. Each stock vial contained -5 x 104 cells. Resurrection of a vial of cells was
performed as quickly as possible to limit lhe amount of time the cells are CJ:posed to
DMSO, the cryopreservation agent. When DMSO reaches temperalllreS aOOve 0°C, it
exerts a toxic effect on the cells. Under sterile conditioll!I in a liiminlll' flow biological
cabinet, the vial of cells was rapidly thawed by the dropwise addition of pre-warmed
10% HS, DMEM or 10% HS HAM's FlO according to lhe cell type (Table 3.1). As lhe
cells thawed they were removed from the vial and placed into 9mL of the warm medium

and then pelleted by centrifugation al -3 000 x g for S minutes in a MSE Minor
centrifuge. The supernatant was then removed and discarded and the pellet resuspended
in IOmL of the relevant proliferative medium (Table 3.1) containing antibacterial
2

and fungicidal agents. The final cell suspension was then transfemd into a 7Scm flask
pre-coated with IOOµgfmL Matrigel solution. Incubation conditions for proliferation
were dependant on the particullll' cell type, Both the primacy human and HDMD cell
lines were proliferated at 37°C and 5% CO2 / 95% air atmosphere in a Sanyo MCO 17A
model incubator. Proliferation of the H2K cell lines required the addition of 20)11. (20
units/mL) interferon gamma (IFNy) to the !OmL cell suspension and then incubation at
33°C and 10% CO2 air atmosphere in a Sanyo MCO 17A model incubator. All cultures
were checked daily and lhe media changed every second day.
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Table 3.1 CUllllre medlwn for lllOllM ud h11m111 cells.

c.o.,,. I

I '""""""' I
"""'
'"'"'
.,,
'"'"'

.
--

DU'l'ereatlalloa

1--1

DMEM

DMEM

,OHS

'"'"'

DMEM

112K Donna! and.

HAM'oFJO

...

10%HS

·-

Primal)' and DMD

20%FCS

...

0.5%CEE

,

OFN-y
•,''.'
HAM\1'.iO ,

,

20%FCS·,
!'1~·HS
,1;:,,

O~?,CEE
'J

""'
,..,

DMEM

...

...

..

HAM'1FIO

'"'"'

p/,Jf

BFGF(HDMD

~Its only)
1'r):

DMEM- Dulbccco's Modified Eagle's Medlum (In•ibugen)

HAM& FIO - (ln>lbugen)

FCS - Pei.I Calf Sorum (lnvltrogcn)
CEB- Chick Embryo Emact (lnvibugai)
HS - Ho..e Serum (lnvibugen)

IFN-y- lntaferon-gamma (Roche Moleculor Dioc:bem.icaJ,)
BFOF - Dovinc fetal growth foctcr (Roc:ltc Molecular Blocbemioal•)
pl,Jf - antib&cterial agents Penici!ltn and Sttq,tav!din inCQmbinalion (Sigma)
- fungicidal agen~ FWlgwloe(Sigma)

3.1.2 Seeding cells onto plates and dishes
When the proliferating cells reached - 70% confluency in the flllsk (typically 3-4
days), they were deemed ready for splitting and seeding into plates or dishes. This
process was identical in all respects regardless of the cell type. All medium was warmed
to -37°C prior to use to protect the celis from any temperature differential.
Firstly, the proliferation medium was removed and the cells were washed twice
with sterile PBS to remove the serum proteins and antiproteases which inhibit the
trypsin. Then 4mL of ltypsin ,was added to the flask and a gentle 2-3 minutes of
agitation applied to augment detachment of the cells, which was verified
microscopically, from the matrigel basement. The reaction wu halted by the addition of
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6 mL of 10% HS DMEM at which time the 1OmL cell suspension was transferred to a
15mL Falcon tube and pelleted by centrifugation at -3 000 x g for 5 minutes in a MSE
Minor centrifuge. The supernatant was removed and discarded and the pellet thoroughly
resuspended by pipetting in lmL of 5% HS DMEM (differentiation) media containing
antibacterial and fungicidal agents (Table 3.1 ).
From the cell suspension, 1OµL was removed and mixed with trypan blue. The
size of the cell pellet determined the volume of trypan blue used. Typically, 40-70µL
would be sufficient to afford a satisfactory dilution and ensure an accurate
representation of the total cell number. Ten microlitres of the trypan blue-cell mixture
was then applied to a Neubauer haemocytometer and a cell count determined
microscopically. Dead or injured cells, which take up the blue dye, were deemed not
viable and therefore not included in the final total. The count was obtained by averaging
the number of cells observed in four squares of the counting chamber. The
concentration of cells/mL was derived using the formula:

Fl:

Number of viable cells in four squares

x

dilution factor

x

1 x 10

4

cells/ mL

4

The multiplication constant lx I 04 is derived from the volume of each square, 0.1 mm deep and 1 x I mm
in area, equating to O.lmm3 (10 4 mL).

All vessels were seeded at a final cell density of 2 x 104 cells/l .88mm2 which
equates to the growth area of a single well in a 24 well plate. The number of cells/mL
obtained from Fl was then divided by the total number of cells required to seed the
vessel chosen as seen in F2, an example for a 24 well plate:

F2:

cells/ mL

mL of cells removed and added to 12mL medium

24 wells x 2 x I 04 cells / well

The 12mL of differentiation medium (Table 3.1) is calculated by the number of wells (24) multiplied by
500µL, the standard growth volume for a single well.

Prior to seeding, 50µg/mL poly-D-lysine was applied to the growth area of the
plate and allowed to remain at room temperature for 1 hour before its removal and
replacement with 1OOµg/mL Matrigel solution. This coating was incubated for -1 hour
at 37°C and the surplus removed immediately prior to seeding the trypsinised cells.
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Typically, all remaining immortalised cells were returned to the flask for further
proliferation and cultures were disc:arded after 3-4 passages lo ensure the low level of
non-myogenic cell types was kept to a minimum. Primary human cells that remained
after the first trypsinisation were generally only passaged a second time before they
were discarded.

3.1.3 Cryopreservingcells

To maintain cell stoclcs, low passage cultures were proliferated in a flask lo
-70% confluency and then trypsinised as described in Section 3.1.2. After

centrifugation, the medium was removed and the cells were diluted to a concentration of

-SO x 101 cclls/mL in cold 10% HS DMEM or 10% HS HAM's FIO (Table 3.1). The
agent DMSO was then added to a final concentration of 10% and the cell solution
mixed thoroughly. Finally, lmL of cell solution was quickly added to each sterile screw
cap cryogenic tube. The tubes were placed into a pre-chilled (·20°C) controlled cooling
chamber which was adjusted to -80°C for -24 hours, after which tbne they were placed
into liquid nitrogen for long tcnn storage.

3.2 Transfection of cells
3,2,1 Transf'ectlon reagent comparison - nuclear fluoreseence study

Transfci.:tion reagents are used to augment the transportation of the 2'0MeAOs
into the cell nucleus, as this is where post-transcripliomtl processing occurs. Because
several different cell lines were lo be used in the transfection studies, it was necessary to
determine the most suitable ttansfection reagent for each cell line.
Initially, a transfection reagent was tested in each cell line using
M23D(+l2-08)·F1TC, a S' fluorescein isothiocyanate (FITC)-labelled 2'0MeAO.
M23D(+l2-08)-FITC wu based on a previously reported 2'0MeAO (without FITC)
which was shown to induce skipping of exon 23 in the dystrophin gene in cultured
C2Cl2 and primacy mouse mdx myoblasts (Wilton el al., 1999). The addition of the
fluorescein tag provided the opportunity lo assess the ability of the transfection reagent
to carry the 2'0MeAO into the cell cytoplasm and facilitate its nuclear uptake.
Additionally, comparisons could be made to previously reported studies utilising
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fluorescently labelled 2'0McAOs in both moullC and human muscle cells (Dunckley ct
al., 1998; van Dcutekom ct al., 2001).
Each transfected well received lµg (-266nM) of M23D(+12-08)-FITC
complexed wilh one of the three transfection reagents assessed In this study, according
to lhc protocols described below, Toe optimal ratios of carrier to M23D(+12-0B}FITC

were determined by titrating lhc volume of transfection reagent against the standard
lµg of M23D(+l2-0B)-FITC. Nuclear fluorescence was evalua1ed at three or 24 ho\lf!l
post-transfection. The three hour time point was chosen, as this was when all
transfecting complexes would typically be removed from lhc cells and replaced by
differentiative medium. This would provi!k information about the efficiency of the
reagent to complex with the M23D(+12-0B}FITC and then infiltrate the cell membrane
within the three hour transfection period. The 24 hour time point was assessed as total
RNA would be extracted from the cells in order to assay for any mRNA modification 24
hours following lrall!lfection. It was at this point that further localisation and persistence
inside the nucleus of M23D(+12-0B)-mC could be evaluated.
3.2.1.1 Cell fuation
Cell fixation at both time points was identical. Three hours post-transfection, lhc
medium in wells to be viewed 24 hours post-transfection was replaced with the relevant
differentiative medium. In contrast, the short term wells were rinsed twice with PBS
which was then removed before the addition of ice cold methanol. This was removed 60
seconds later and the cells allowed to air dry for 60 seconds before SOOµL of PBS was
added. Cells were visualised with an Olympus IX70 inverted microscope equipped with
a U-RFL-T fluorescent burner. M23D(+12-0B)-FITC was excited with a WB cube and
!he digital images were captured by an Olympus DPII camera. The images were
processed using the Adobe Photoslwp 6.0 (for Macintosh) software.
Based on the results from each transfection, the optimal carrier and hence ratio
of carrier to 2'0MeAO was cslablished and adhered to throughout the project. For H-2K
mouse cells and primary human cells, Lipofectin provided the maximum transfection
with the minimal degree of cell loss. ExGen SOD however, was trialled late in the project
as a potential 2'0MeAO carrier in10 the primary human cells to (Cproduce conditions
(Cported by van Deutckomct al. (2001). This transfection agent was subsequently found
to be less effective. Lipofectarninc 2000 was found to be the best 2'0MeAO-delivcry
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agent for the transformed human DMD ceU line. The protocol for transfection with each
reagent, detailed below, is designed for duplicate well transfection in a 24 well plate.

3.2.2.1 Llpofcctin
The optimal ratio was determined to be 2:1 (w:w) of Lipofectin to 2'0MeAO,

within the rwige suggested by the manufacturer. Transfoction was perf~rmed 72 hours
after seeding to allow the myoblasts sufficient time to differentiate and form
multinucleatc myotubes.
Lipofectin and 2'0MeAO were diluted as two separate solutions each in looµL
of Opti-MEM. Lipofectin WWI incubated at room temperature for 45 minutes before
being gently mb;ed with the 2'0MeAO and then incubated for a further 15 minutes at
room temperature to a][ow the complexes to form and equilibrate. The rmal lmL
volwne was made up by the addition of 800µL of Opti-MEM, The transfection !ll".dium
was then gently mixed to ensure homogenicity before SOOµL was added to each well.
The cells were incubated at 37°C and 5% C02 / 95% air atmosphere for three hours,
after which the transfection medium was replaced with 5% HS DMEM differentiative
medium.
3.2.2.2 E!Gcn 500
ExGen 500 is the registered name for PEI (polyethyleneimine) and it was
selected due to its reportedly low toxic effect and high efficiency of DNA delivery in
human cells. Differentiation of the primary human myoblasts appeared to be slower
than lhe mouse cells and so tr811!1fection of multinucleate myotubes was performed four
days and 12 da}'!I following s~ding in the exon 19 and exon 46 studies respectively.
According to the nuclear accumulation of fluorescence in the preliminary study, 3.5
equivalents was observed to be optimal and was comparable to other reports (Dunck.ley
et al., 1998; van Deutckom et al., 2001).

Transfection medium was prepared by diluting the 2'0MeAO in ISOmM NaCl
to a final volume of IOOµL. PEI was then added to the mixture and immediately
vortcml for 5 seconds, briefly centrifuged to gather the solution, and incubated at room
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temperature for 15 minutes. The final lmL volume was made up by the addition of
~ of Opti·MEM,

which was mixed by pipetting up and down before 500pL wn

added 10 each well. The cells were iocuba!Cd at 37°C and 5% C01 195% air atmosphere

for three hours after which lhc transfecdon medium was replaced wilh 5% HS DMEM
dlffcrcntiativc medium.
3.2.2.3 Ljpofcctaminc 2000
The optimal ratio was determined IO be 3:1 (w:w) of Lipofectamine 2000 to
2'0MeAO which is within lhe range of 1:1 10 S:1 suggested by the manufacturer.
Lipofectaminc 2000 caused significant cell death when delivered to the
mouse myotubes at ratios greater than 1:1 and with no greater nuclear uptake of the
FITC-2'0MeAO complex. No to!liC effect was observed in the case of the HDMD cells
at the 3:1 ratio. However, presumably due to the immortalising process, these cells

appear to be arrested in a mitotic state and most cells did not differentiate into mature
myotubcs. Therefore myoblast transfection was perfonned 72 hours post-trypsinisation.
Lipofcctamine 2000 and 2'0MeAO were dilu!Cd as two separate solutions each
in IOOµL ofOpli-MEM. Lipofectamine 2000 was incuba!Cd at room temperature for IS
minutes before being gently mixed with the 2'0MeAO and then incubated for a further

20 minutes at room temperature to allow the complexes to form and equilibrate. The
final lmL volume was made up by the addition of 800µL of Opti-MEM. The
traosfectioo medium was then gently mixed to ensure homogenicity before SOOµL was
added to both wells. The cells were incubated at 37°C and 5% C01 I 95% air
atmosphere for 3 hours, after which the trarulfection medium was replaced with 5% HS
DMEM differentiation medium.
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3.3 Antisense Oligonucleotides
3.3.1 Nomenclature

During the course of this project, a nomenclature system was proposed by our
laboratory as a means to identify the specific target to which a particular AO bearing
that name was directed (Mann et al., 2002). This nomenclature provides information
about the species in which the testing is undertaken, the exon at which the 2'0MeAO is
directed and the exact annealing position (and hence length) relative to the acceptor or
donor splice sites (Figure 3.1).
An addition to the published nomenclature is the prefix 'd' which was adopted

only in this project. This prefix served to distinguish between PCR-grade DNA
oligonucleotides (deoxy-AO) and the 2'-0-methylated RNA-like oligonucleotides with
a full phosphorothioate backbone (2'0MeAOs) that were both directed at the same
sequence.

3' (A) cceptor or
5' ( D) onor splice site
Species:
H
H = Homo sapiens
0
M = Mus musculus
C
C = Canis familiaris

A

~

~ l(±xx ±yy)

§
\

!--

coordinates:
x
first 5' base
y
final 3' base
+
exonic position
intronic position

exon number

Figure 3.1 Schematic representation of2'0MeAO nomenclature. Detailed is the systematic way in which

all 2'0MeAOs were classified in this project. Note also that regions between species that bear 100%
sequence homology are also acknowledged in the 2'0MeAO names' prefix ie. HM19A(+46+65) is
directed at a wholly exonic sequence within both human and mouse exon 19. Figure taken with
permission from Mann et al., 2002.

32

Chapter 3 - McU10d.1

In Ibis study, all 2'0MeAOs designed to re-direct dysttophin prc-mRNA splicing
in mouse or human cells incoJpOratcd the phosphorolbioate backbone and a mclhyl
group at the 2' hydroJ.yl position of lhe ribosc moiety. The modified chemislr)' of lbc
2'0MeAO affords greater resistance to nuclease degradation wilhin the cellular
enviro11ment (Altmann et al., 1998), as well

WI

preventing the recognition of the

2'0McAO:RNA duplex by RNAseH WI a target for deslrUction (Lavrovslr.y et al., 1997).
Initial eJ.periments in the study were based on lbc llmer 2'0MeAO reported by
Talr.eshima et al. (1995), which would be described as HM19A(+35+6S) under this
nomenclature system. HM19A(+3S+65) was directed at a putative exon splicing
enhancer (ESE) and was able to induce lhe specific and effective removal of exon 19
from lhe mature lranscript. Early 2'0MeAOs aimed to refine the 31 base region targeted
by HM19A(+35+65). Furthermore, as lhe acceptor and donor splice sites play a vital
role in lhe splicing process (and hence definition of exon boundaries), these exon 19
splice sites were also examined ai; potential targets for 2'0MeAO-induced exon
removal.
Targeting and comparing each of these three sites formed a significant portion of
the project, with the ultimate goal to determine lbc optimal target for2'0MeAO-induced
exon skipping. Consequently 2'0MeAO design was somewhat empirical in nature,
necessitating a trial and error approach to detem1ine the most effective motifs to which
2'0MeAOs should be directed.
Typically, directing 2'0MeAOs of varying lengths within the general confines of
the splice sites was sufficient to induce the removal of the targeted exons. However,
when this failed, a computational method, RESCUE-ESE (Relative Enhancer and
Silencer Classification by Unanimous Enrichment, http:1/genes.mit,edwburgelab/rescueese/) wai; employed to predict the likely positions of ESEs within the given sequences

(Fairbrother, Yeh, Sharp & Burge, 2002).
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3.3.3 Qualltyuuyror2'0MeAOs
The quality of all 2'0MeAOs used in this study was assessed by gel
electrophoresis to confirm a satisfactory standard of synthesis. All exon 19 directed
2'0MeAOs save one, Ml9D(+02-18), were synthesised by Oencwotb, Adelaide, South
Australia. The remaining 2'0MeAOs Including MISD(+-02-18) and those directed at
exons 20 to 25 and c:,.:on 46 were synthesised 'in-house' on an Expedite 8909 Nucleic
Acid Synthesiser (Applied Biosystems) using a lµmol thioate synthesis protocol.
The quality of eru:h 2'0MeAO WWI confmned by first diluting approximately
200ng of 2'0MeAO with 5µL of formamide loading buffer, heating lo 94°C for 2min
and !hen snap-chilling on ice. The 2'0MeAOs were then loaded onto a denaturing 20%
polyacrylamide (acryl:bis ratio 19:l) TBE gel containing 7M urea and e\cctrophorescd
for up to 2 hours al 300V. In addition to the trityl outputs during synthesis, !his assay
satisfactorily validated the integrity of each 2'0MeAO and further verified the high
standard of manufacture of the in-house synthesised 2'0MeAOs as compared to the
commercially available molecules. Consequently, all 2'0MeAOs were generally
deemed lo be of a sufficiently high slalldard to proceed to cell transfections.

"
"
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Table 3.2 Sequences of 2'0MeAOs used in this study. Upper and lower case characters represent
exonic and intronic nucleotides respectively (silencer sequences abbreviated as Pu and Py
(guggcaggguggu and cucucucu respectively) attached to M20D(+04-16) and the random 2'0MeAO are
excepted).

Name

Sequence (shown 5' to 3')

HM19A(+35+65)

GCCUGAGCUGAUCUGCUGGCAUCUUGCAGUU

HM19A(+35+54)

UCUGCUGGCAUCUUGCAGUU

HM19A(+46+65)

GCCUGAGCUGAUCUGCUGGC

HM19A(+49+65)

GCCUGAGCUGAUCUGCU

HM19A(+52+65)

GCCUGAGCUGAUCU

HM19A(+32+45)

AUCUUGCAGUUUUC

HM19A(+46+57)

UGAUCUGCUGGC

M19A(-20+05)

AUGGCcugcagcaugagagcaaagg

Ml9D(+05-20)

aaucaacuucauguaauuacCAUUU

M19D(+02-18)

ucaacuucauguaauuacCA

Hl 9A(-20+ 10)

GCUCUAUGGCcugcagcaugagagcaaaga

H19D(+ 10-15)

aacucguguaauuacCAUUCACCAU

Random

ccagaucggacgacgucaggacaaac

M23D(+ 12-8)-FITC

FITC-cggcuuacCUGAAAUUUU

M20D( +04-16)

aggaggaaaaccuuacCUUA

M20D(+04-16)-Pu

aggaggaaaaccuuacCUUA-guggcaggguggu

M20D(+04-16)-Py

aggaggaaaaccuuacCUUA-cucucucu

Pu-M20D(+04-16)

guggcaggguggu-aggaggaaaaccuuacCUUA

M20D(+08-12)

ggaaaaccuuacCUUACAAA

M20A(+23+47)

GUUCAGUUGUUCUGAAGCUUGUCUG

M20A(+140+164)

AGUAGUUGUCAUCUGUUCCAAUUGU

M21D( +04-16)

aaguguuuuuacuuacUUGU

M22D( +04-16)

ucaaauguccacagacCUGU

M22D(+08-12)

auguccacagacCUGUAAUU

M23D(+02-18)

ggccaaaccucggcuuacCU

M24D(+06-14)

gauacaaaucuuacUCUGCA

M24D(+08-12)

uacaaaucuuacUCUGCAUU

M24A(-10+15)

GGUUUUUAUGUGAUUcuggaauaaa

M24D(+l0-15)

agauacaaaucuuacUCUGCAUUGU

M24A( + 16+40)

CAACUUCAGCCAUCCAUUUCUGUAA

M24A(+78+102)

GAGCUGUUUUUUCAGGAUUUCAGCA

M25D(+06-14)

uaaacuagucauacCUGGCG

H46A(-07+13)

UUGUUCUUCUAGCcuggaga

H46A(+63+82)

GUUAUCUGCUUCCUCCAACC

H46A(+l 15+134)

GCUUUUCUUUUAGUUGCUGC

H46D(+02-18)

uugagaaaauaaaauuacCU
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3.4 Total RNA preparation
The ell.traction and purification of total RNA from all cell lines was performed
24 hours post transfoction. A cursory microscopic observation of the state of the cells
was pcrfonned prior to harvesting and a compariron made against the untreated control.
Though the subjective nature of the e11.amination does not lend itself to any publishable
data, an obvious trend of increased cell dealh with lhe highest 2'0McAO concentration
ICSted (correlating with the largest volume oftransfection fCllgenl) Wll.'I observed
RNA e11.traction was conducted wider sterile conditions in a laminar flow
biological cabinet. The diffenmtiative medium was first removed and to each well of a
24 well plate was added 250µL of RNA Bee, an acid phenol RNA e11.traction
fonnu]ation. A pipette tip was then used to disrupt and ensure thorough lysing of the
cells. Duplicate wells were pooled to yield a starting volume of 500µL which was
placed into a sterile 1.6mL microfuge tube.
To each tube was added IOOµL of chlorofonn. This was vorteled thoroughly
before incubation at 4"C for 5 minulCS and centrifugation at 14 000 11, g for 15 minutes
at 4°C in a Beckman-Coulter Microfuge 18 Cenlrlfuge. The resultant upper aqueous
layer containing the RNA (250. 280µL) was carefully removed to avoid distwbance of
the intcrphase, and placed into a fresh RNAse-free 1.6mL tube containing 300µL of
isopropanol. Each tube was vorteled thoroughly and incubated for 10 minulCS at room
temperature before pelleting the RNA by centrifugation at 14 000 11, g for 15 minutes at
4°C. The supernatant was then removed and discarded and the pellet thoroughly
resuspended in 50 µL of 300mM sodium acetate (pH 5.2) by vortexing, to facilitate
removal of carry-over phenol and salts. The samples then each received 12SµL of
absolute ethanol, were vorte11.ed and then incubated at -80°C for JO minutes to enhance
RNA precipitation before centrifugation at 14 000

11,

g for 15 minutes at 4"C. The

supernatant was removed and the pellet Wll.'I given a final Wll.'lh by resuspending in
2SOµL 7S% ethanol before centrifugation at 14 000 x g for IS minutes at 4°C. After
removing the supernatant, the RNA pellet was allowed to air dry at room temperature
before thorough resuspension in SOµL of RNAse-frec water and storage on ice for
immediate use or at -20°C or -HO"C for long term storage.
The quality and quantity of RNA slllllples was assessed by spectrophotometry on
a Beckman DU6SO spectrophotometer. A I in 20 dilution of RNA was prepared by
mill.ing SµL of RNA in 9SµL of water and readings were taken at 260nm and 280nm to

36

Chapter 3 - Methods

estimate the purity and final yield. If further validation was required, 5µL of RNA was
combined with glycerol loading buffer and electrophoresed through a 2% T AE agarose
gel at 90V for - 2 hours.

3.5 Analysis of dystrophin mRNA
3.5.1 Reverse transcription and PCR amplification
To determine if any modification to the splicing pattern had been induced by the
introduction of the antisense molecules, regions flanking the 2'0MeAO target site in
dystrophin mRNA were subjected to reverse transcription (RT) with subsequent
amplification of the cDNA strand by the polymerase chain reaction (PCR) method. Two
RT-PCR systems were used in this project, the Titan One-tube RT-PCR system (Roche)
and the C. therm. Polymerase One-step RT-PCR system (Roche). Each system contains
several enzymes that allow the initial cDNA synthesis from the total RNA strand and
then amplification of the region bounded by the sense and antisense cDNA strand
primers. The Titan One-tube RT-PCR system was performed in a total reaction volume
of 12.5µL and was used predominately throughout the project. The C. therm. system
was employed only when it was necessary to duplicate conditions reported by van
Deutekom et al. (2001) (see Chapter 6), and was performed in a total reaction volume of
20µL. The components of each reaction mix are described below in Tables 3.3 and 3.4,
with primer sequences listed in Table 3.5.

Table 3.3 Component composition in a 12.SµL Titan One-tube RT-PCR reaction.
Reaction
component

RNA

H20

Buffer*

varied

varied

-

dNTP

OTT

2.5

0.5

lx

200µM

Forward Reverse

Enzyme

primer

primer

mix

0.625

0.75

0.75

0.25

5mM

3ng/µL

3ng/µL

-

Reactant
volume (µL)
Reactant final

50ng/

concentration

reaction

* Supplied as a 5x preparation and diluted to yield a final concentration of l.5mM magnesium chloride.
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Table 3.4 Component composition in the 20µL C. therm. One-step RT-PCR reaction.
Reaction

H20

Buffer*

varied

4.0

0.8

1.0

-

lx

200µM

5mM

RNA

component

dNTP

DTT

Forward

Reverse

primer

primer

1.0

0.75

0.75

0.2

0.25

7%

3ng/µL

3ng/µL

20U

-

DMSO

RNAzin

Enzyme
mix

Reactant

varied
volume (µL)
Reactant final

50ng/

concentration

reaction

* Supplied as a 5x preparation and diluted to yield a final concentration of2.5mM magnesium chloride in
a single 20µL reaction.

Table 3.5 Forward and reverse primers used in RT-PCR reactions.

Name

Sequence (shown 5' to 3')

MlF

ATGCTTTGGTGGGAAGAAGTAG

2153

M13F

GCTTCAAGAAGATCTAGAACAGGAGC

1736

M17F

TGGAAACGGTAACTATGGTG

1600

H17F

CATGCTCAAGAGGAACTTCC

126

M20F

CAGAATTCTGCCAATTGCTGAG

2616

H42F

CACACTGTCCGTGAAGAAACGATGATG

212

M69F

GCACTTTAATTATGACATCTGCC

2187

MllR

GCTTTGTTTTTCCATGCTAGCTACCCT

DS Number*

M22R

CCTGATGCTACTCATTGTCTCC

JSR4l
2316

H25R

CTGAGTGTTAAGTTCTTTGAG

22

M26R

TTCTTCAGCTTGTGTCATCC

3658

M27R

AGTTCCTTTTTTAAGGCCTC

2494

H48R

CTGAACGTCAAATGGTCCTTC

3540

M79R

CTCTGCCCAAATCATCTGCC

2512

* Laboratory nomenclature; denotes D.NA Synthesis number given to each primer (Geneworks).
# This primer synthesised on site with an Expedite 8909 Nucleic Acid Synthesiser

The preparation for each RT-PCR reaction was essentially the same for each
system. All components were thawed on ice and vortexed briefly before addition to a
master mix. This contained sufficient reagent mixture for all RNA samples to be
assayed, a negative control for the reaction itself and an 'extra sample'. The master mix
was briefly vortexed and then aliquoted into 0.6mL thin walled tubes to await the
addition of the RNA template. As standard throughout this project, 50ng of total RNA
was added to each reaction mixture, except the reaction negative control which received
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water. However, repetition of lhe conditions reported by van Deutekom el al (2001)
(see Chapter 6) required the addition of RNA to the reaction in amounts ranging from
5ng to IOOOng. The cycling conditions for each reaction aJC outlined in Tables 3.6 and
3.7.

Table

J., CJdllll condttlou tor RT-PCR 1W111 tllt Tltlll <hie-lube RT-PCR IYl'ltm• Step 4 IO ilep

6cycledtluooJh 30tmei a&rlhc initial cDNA ,ttm;J denanu,uion.

Step 1

Reactant equilibration

2 minutes

2s 0 c

30minutes

48°C

,,,.,

Step2

Reverse transcription
Initial denaruration

2 minutes

94"C

Step4

Subsequent denaruration

30sec

94"C

Steps

Primer annealing

I minute

55°C

Step6

Strand elongation

2minutes

12°c

Table 3.1 C1d1D1 cundlC.W lbr RT,PCR ull• the C.:
ty1lem.

ill,,._

Pulymerase Onwlep RT-PCR

Step 4 IO step 6 cycled through 20 times ofter !be initial cDNA itl'and denatuntion.

Step I

Reactant equilibration

2minutes

25°C

Step2

Reverse transcription

30 minutes

62°C

Step3

Initial denaturation

2 minutes

94°C

Step4

Subsequent denaturation

45sec

94"C

Step.!!

Primer annealing

45 sec

60°C

Step6

Strand elongation

1 minute

n•c

Reactions were performed on eilher a MJ PTC 100 or MJ Research mini thermal
cycler, both equipped With a hot bonnet to provide more even temperature distribution,
and eliminate the need for a mineral oil overlay.
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3.5.2 Nested PCR amplification

When electrophoresed through a 2% agarose TAE gel as standard, RT-PCR
(primary amplification) products were extremely difficult to visualise and hence an
evaluation of the 2'0MeAO' s ability to modify splicing patterns was difficult. This was
not unexpected as dystrophin messenger RNA is reported to represent less than 0.01 %
of the mRNA in either human or mouse cardiac or skeletal muscle (Hoffman, Brown &
Kunkel, 1987). Consequently, a second round of PCR amplification was performed on
the primary template using a nested primer set. This ensured adequate representation of
the dystrophin mRNA species present and increased the specificity of the reaction. The
primer sequences are listed in Table 3.8 and components of the reaction mix are
described in Table 3.9.

Table 3.8 Forward and reverse primers used in the nested secondary PCR reactions.

Name

Sequence (shown 5' to 3')

MIF
Ml7F
Hl7F
Ml8F
M20F
M20F
M22F
H44F
H70F#
MIOR
HM21R
HM2IR
M23R
M24R
H25R
M26R
M27R
H47R
M79R

GTGGGAAGAAGTAGAGGACTG
TGGAAACGGTAACTATGGTG
GCAGATTACTGTGGATTCTG
GAAGCTGTATTACAGAGTTCTG
CAGAATTCTGCCAATTGCTGAG
CCCAGTCTACCACCCTATCAGAGC
AGTAGCATCAGGACGTGGATCC
GCGATTTGACAGATCTGTTG
CATCAGGAGAAGATGTTCGAGAC
ACATCATTWGAAATCTCTCCTTG
GGCCACAAAGTCTGCATCCAG
TTGTCTGTAGCTCTTTCTC
TGGGAGGAAAGTTTCTTCCAGT
GAAAACATCAACTTCAGCCATCC
GTCTCAAGTCTCGAAGCAAAC
CCTGCCTTTAAGGCTTCCTT
CTATTTACAGTCTCAGTAAGG
TTATCCACTGGAGATTTGTCTG
CCAAATCATCTGCCATGTGG

DSNumber*
2153
1600
123
936
2616
1803
2232
2495
852
2355
1889
2954
1643
2233
124
3657
2264
3540
405

* Laboratory nomenclature; denotes ;QNA fu'nthesis number given to each primer (Geneworks)
# Human sequence specific primer used to amplify mouse cDNA had 2 mismatches (underlined)
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Table 3.9 Component composition in a 50µL secondary nested PCR.
Reaction

cDNA

component

template

H20

lOx
Buffer

dNTP

MgCli

Forward Reverse
primer

Tth plus

primer polymerase

Reactant
1.0

37.4

5.0

1.0

4.0

0.75

0.75

0.1

-

Ix

200µM

2mM

3ng/µL

3ng/µL

0.55U

volume (µL)
Reactant final

50ng/

concentration

reaction

All reaction components were thawed on ice and vortexed briefly before
addition to the master mix. To each 49µL of reaction mix, lµL of primary amplification
product was added as template. The study by van Deutekom et al. (2001) also reported a
nested secondary PCR reaction, and while reaction components remained the same the
cycling conditions were different as described in Tables 3.10 and 3.11 respectively.

Table 3.10 Cycling conditions for the secondary nested PCR using Tth plus polymerase. Step 2 to
step 4 cycled through 25 times after the initial cDNA strand denaturation.

Step 1

Initial denaturation

2 minutes

94°c

Step2

Subsequent denaturation

30 sec

94°c

Step3

Primer annealing

1 min

55°c

Step 4

Strand elongation

2min

12°c

Table 3.11 Cycling conditions for the secondary nested PCR using Tth plus polymerase. Step 2 to
step 4 cycled through 32 times after the initial cDNA strand denaturation according to the protocol
outlined by van Deutekom et al. (200 I).

Step 1

Initial denaturation

2 minutes

94°c

Step2

Subsequent denaturation

45 sec

94°c

Step 3

Primer annealing

45 sec

60°C

Step 4

Strand elongation

2min

12°c

Typically, the last three steps cycled through 25 times after the initial cDNA
strand denaturation (Table 3.10). However, cycling conditions reported by van
Deutekom et al. (2001) were not the same and were adjusted accordingly (Table 3.11).
Reactions were performed on either a MJ PTC 100 or MJ Research mini thermal cycler.
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J.5.3 Agarese gel eJectrophoresla
Products from lhe second round of amplification were typically slorcd at -20"C
or run dircc!ly on to a gel. Typically, 2.SµL of secondary PCR product was combined
with glycerol loading buffer wid e\cctrophoresed through a 2% agarosc TAE gel at 90V
for - 2 hours, depending on the e1tpccted size of lhe amplified transcript fragment. All
agarose gels incorporated a IOObp ladder molecular weight marker as a size standard.
Initial e1tperiments investigating exon 19 skipping were tailored to generate 1280bp
unmodified (full length) amplicons after amplification across exons 13 to 21. Eitcision
of dystrophin e1ton 19

(88 bp) would produce a smaller product which was difficult

to discern from the full length product. The advantage of this assay was the minor size

variation between the full length and shonened products which ensured similar
amplification efficiencies for both. To increase !he separation between these species,
3% agarose TAE gels were originally used. The increased resolving power of this
system, however, also required a longer running time (- 3 hours). Consequently, nested
primers were designed to yield smaller products, that is, the relative size difference
between the full length and skipped products was increased so that less time was
required to elecuophnrese them through the gel while still maintaining a satisfactory
separation.
On completion of the elcctrnphoresis, the agarose gels were immersed in a
O.Sµg/mL solution of ethidium bromide for -JO minutes. The products were then
visualised on an ultraviolel transilluminator wid images recorded at a fixed resolution of
180dpi using a Kodak DC ID 2.0 digital gel documentation system.
J.5.4 Characterisation ol 2'0MeAO-lllduced products
3.S.4.1 Amp]icon Isolation
Initial identification of each amplicon was performed visually relative to the
IOObp 5ize marker 1111d compared with the transcript fragment length e1tpected to be
generated in the secondary nested PCR. However, to fully characterise the products of
in1erest, each amplicon was isolated and reamplified using the bandstab technique
(Wilton et al., 1997) or by complete band w:ision.
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3.S.4.1.1 Bandstab proccdUie
The bandslab procedure. was typically performed ditecily after observation of the

products of interest. Using the UV transilluminator to visualise the bands in !he gel,
specific amplicons were pierced wilh a pipette lip which was !hen placed directly into a
PCR tllbe containing a PCR reaction mixtUie as described by Wilton ct al. (1997). This
procedure was performed in duplicate to maximbe eventual product recovery and was
sometimes required when attempting to characterise products of low abundance. The
product under investigation removed by th~ tip was thus used as template for a further
35 cycles of amplification under identical conditions as described in Tables 3,9 and
3.10, except that the annealing tempcniture was reduced to SO"C. The presence of the

re-amplified product was confirmed by electrophomis through a 2% agarosc gel and
visualised on a UV transilluminator.
3.5.4.1.2 Gel slice excision procedure

On occasiollS, the bandstab technique was unable to isolate a single product
when lhe source contained several amplified transcript species that were smaller than
the amplicon of interest. When Ibis occuned, 4SµL of the duplicate bandstab mixtures
were elcctrophoresed through a 2% low melting point gel at 70V for -3 hours. After
staining in fresh ethidium bromide, the products, while being viewed on the UV
transilluminator, were completely excised wid1 a sterile scalpel with care taken to avoid
removing excess agarose.
3.S.4.2 Amplicon purification

Amplicons derived through either the bandstab or gel slice excision procedures
were purified using Qiaquick spin colunms according to lhe manufacturer's instructions.
The presence of the purified amplicon was confirmed by electrophoresis of a SµL
aliquot through a 2% agarose gel as described earlier. The remaining'material was then
stored al -20°C to await further analysis.
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3.5.4.3 Amplicon sequencing

Following verification of purity and abundance, the amplicons of interest were
placed into a sequencing reaction which incorporated the Big Dye Terminator chemistry
(version 3). The components comprising the sequencing reaction mix are described in
Table 3.12.

Table 3.12 Sequencing components and their proportions in a lOµL sequencing reaction. Template

volume determined amount of water to be added. Forward or reverse primers were added at 50ng per
reaction.
Reaction
component

Big Dye Big Dye
(V3)

buffer

3.0

1.0

Primer

cDNA

(F orR) template

H20

Reactant
volume (µL)

1.0

l-5µL

to IOµL

The sequencing reaction was always made up to a final volume of IOµL (with
water if required). Both size and abundance of the purified product (estimated by band
intensity on the gel), determined the amount to be added to the reaction as template.
Based on the expected identity of the amplicon and also as a measure of congruity, SOng
of forward and reverse primer, in separate reactions, were chosen for sequencing of
each template. Where possible, the primer selected for use in the sequencing reaction
would be internal to the relevant primers used in the nested PCR. Primer sequences are
listed in Table 3.13.
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Table 3.13 Forward and reverse primers used in the sequencing PCR reactions.

Name

Sequence (shown 5' to 3')

H17F
HM21R
M18F

HM21R
M19F
M22R

M19F
M23R
M20R
M26R

M21F
M26R

M21F
M26R

M24F
M26R

H44F
H47R

DSNumber*

GCAGATTACTGTGGATTCTG
TTGTCTGTAGCTCTTTCTC
GGATGTCGATATAACTGAACTTC
TTGTCTGTAGCTCTTTCTC
GCCATAGCACGAGAAAAAGCAG
CCTGATGCTACTCATTGTCTCC
CAGAATTCTGCCAATTGCTGAG
TGGGAGGAAAGTTTCTTCCAGT
CCCAGTCTACCACCCTATCAGAGC
CCTGCCTTTAAGGCTTCCTT
TCAGCTCTTCAGCCTCAAATTG
CCTGCCTTTAAGGCTTCCTT
TGAGGGCCAAAGAGAAAGAGC
CCTGCCTTTAAGGCTTCCTT
TGTTTTCCTGAAAGAGGAATGG
TTCTTCAGCTTGTGTCATCC
GCGATTTGACAGATCTGTTG
TTATCCACTGGAGATTTGTCTG

Exon(s) skipped

123
2954
935
2954
2261
2316
2616
1643
1803
3657
3737
3657

Human 19

783

Mouse 24

3657
2317

Mouse 25

Mouse 19
Mouse 20
Mouse 21
Mouse 22
Mouse 23

3658

2495
3540

Human46

* Laboratory nomenclature; denotes QNA fu'nthesis number given to each primer (Geneworks)

The 25 cycle sequencing PCR reaction detailed in Table 3.14 was performed on
a MJ Research mini thermal cycler equipped with a hot bonnet to bypass the need for an
oil overlay.

Table 3.14 Sequencing PCR reaction conditions. All sequencing reactions were performed on the

same MJ Research mini thermal cycler for 25 cycles.

Step 1

Template denaturation

30 sec

94°c

Step2

Primer annealing

30 sec

50°C

Step3

Strand elongation

4 min 15 sec

60°C

Following the sequencing PCR reaction, non-template reactants were removed
by ethanol precipitation. Template purification was performed at room temperature and
commenced with the addition of 10µ1 of 600mM sodium acetate (pH 5.2) and 50µ1
absolute ethanol. The mix was then vortexed briefly prior to incubation for 15 minutes
and centrifugation at 14 000 x g for 20 minutes in an Eppendorf 5415C centrifuge. The
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supernatant was removed and the pellet resuspended in 2SOµL or 70% ethanol before
centrifugation at 14000 x g for 5 minutes. Finally, the supernatant was removed and the
purified template allowed to air dJ)'. Products were fractionated on an ABI 377 DNA
Sequencer at lhe DNA sequencing facility, Centre for Ncuromuscullll' and Neurological
Disorders, by Ms. Lori Blcchyndcn.

3.6 RNA binding assay
An RNA binding assay is an in

vitro test of RNA fragment template amenability

to hybridisation with antiscnse orientated DNA oligonucleotides (deoxy-AOs) directed

at specific sequences. The assay was designed as a precursor to cell culture experiments
as a means to increase target assessment throughput and reduce cost by bypassing the
relatively lengthy cell culture process and expense of 2'0MeAO synthesis. When a
deoxy·AO was able to demonstrate a high affinity for its target, it was selected for
synthesis (in.house) as a standard 2'0MeAO and transfected into cells to assess its
effect on lhe natural splicing process.
3.6.l DNA lsolalion aadpurlflcatJoo

H2K mdx or primary hwnan cells were proliferated in a 7Scm2 flask as described
in Sectlon 3.1.l until they reached approllimatcly 100'1, conflucncy, after which the
cells were trypsinised as outlined in Section 3.1.2. After centrifugation, the supernatant
was removed and the pellet resuspended thoroughly in 200µL PBS before being
transferred to a sterile l.6mL microfuge tube. All following steps, including cell lysis,
RNA and protein removal and DNA precipitation were perfonned exactly as described
in the Gentra Systems genomic DNA purification kit protocol for DNA isolation and
purification from cultured cells. The purified genomic DNA was quantified and stored
at -20"C to await downstream application.
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3.6.2 Genomic DNA fragment synthesis incorporating a T7 promoter sequence

Purified mouse or human genomic DNA isolated from muscle cell cultures, was
used as template in T7-PCR. The subsequent amplicons with the T7 promotor sequence
incorporated became the template in an in vitro RNA transcription reaction. In an
attempt to ensure an adequate approximation of secondary structure formation in the
region under investigation, 300 - 400 bp of DNA sequence was selected as a template to
be transcribed into RNA. Each DNA fragment would, if possible, contain the entire
exon and >70 bases of intronic sequence both 5' and 3' of the exon. In situations where
the exon was large and this was not possible, two fragments of -350bp in length were
selected to be synthesised, each incorporating only one splice site. The fragment length
was determined by the position of the reverse primer and the forward primer which
contained a 31 base T7 polymerase promoter sequence at the 5' end (Table 3.17).
Reaction component composition and initial DNA fragment amplification conditions
are outlined in Tables 3.15 and 3.16 respectively. All primers sequences are listed in
Table 3.17.

Table 3.15 Component composition for a 2SµL PCR reaction. Included was the template DNA at a
final concentration of 4ng/µL and the -60bp forward primer (includes T7 promotor sequence) at 2x that
of the reverse primer which was only half the length.
Reaction

DNA

component

template

H20

lOx
Buffer

dNTP

MgCh

Forward Reverse
primer

Tth plus

primer polymerase

Reactant
varied

varied

2.5

0.5

2.0

1.0

0.5

0.5

4ng/µL

-

lx

200µM

2mM

3ng/µL

3ng/µL

0.55U

volume (µL)
Reactant final
concentration

Table 3.16 Cycling conditions for genomic DNA fragment amplification. Step 2 to step 4 cycled
through 40 times after the initial DNA strand denaturation.

Step 1

Initial denaturation

2 minutes

94°c

Step2

Subsequent denaturation

30 sec

94°c

Step3

Primer annealing

1 min

55°c

Step 4

Strand elongation

2min

12°c
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Table 3.17 Forward and reverse primers used in the amplification of the genomic DNA fragments.
Reverse primers are given in an antisense orientation in the 5' to 3' direction. The T7 polymerase
promotor sequence is listed separately and is denoted as "T7'' at the 5' position in each forward primer.
Primers are based on exonic sequence unless prefixed with "Int" which indicates an intronic origin.
Name

Sequence (shown 5' to 3')

T7

GATCCTAATACGACTCACTATAGGGAACAGA

Int19T7F

T7GGTCATTGGTTTCCAGAGCATG

20T7F

T7GGGTGTTAATGCTGAAAGTATCAG

Int20R

CCAGAGTTTGCTTTGGCCCTCTTGC

3728

Int20T7F

T7CAGTATATGCAAAGTTTCAAAGTTAC

3729

Int21R

GATAGAGGGTTTAGCCTTGGG

Int21T7F

T7GCTGACAAATTAGAAAAATATGACAG

Int22R

CTTTACTTTTTCATTATTACCTTAAG

Int23T7F

T7GCTACAATGAGACCTCCCTCAAAC

Int24R

CCAAGAATGTGCTCAGGTACTGG

Int24T7F

T7CATGTCGAATGTCATGATAAATGTATG

Int25R

GTGTTTTGACAATATTTTCATAAAC

Int45T7F

T7GGTTAACATCTTTTAAATTGC

46T7F

T7AAGAACAAAAGAATATCTTGTC

Int46R

GCAAGGAACTATGAATAACCT

Exon Targeted

DS Number*

NIA

NIA

20

3735

21

3781
22
24

3730
3731
3786
3787

25

3775
3776
3472

46

3474
3473

• Laboratory nomenclature; denotes QNA Synthesis number given to each primer (Geneworks).

Initially, the genomic DNA was amplified between the two primers in a 25µL
PCR reaction for 40 cycles and the fragment electrophoresed through a 2% agarose gel
as described earlier. Once synthesis of the correct size product was confirmed by
visualisation on an UV transilluminator, two 50µL DNA amplification reactions were
performed to increase the final yield of the product. After gel analysis of the second set
of amplification products, the duplicate reactions were combined and purified on
Qiaquick spin columns according to the manufacturer's instructions. The presence of
the purified fragment was confirmed by electrophoresis through a 2% agarose gel.
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3.6.3 In vitro RNA transcription

To produce an RNA fragment, the purified genomic DNA amplicons were used
as template in an in vitro RNA transcription reaction using the Riboprobe® in vitro
Transcription System (Promega) (Table 3.18). After addition of the DNA template, the
reaction mixture was incubated at 37°C for 1 hour. A further 15 min incubation at 37°C
with lµL DNase I ensured the removal of the DNA template before the synthetic RNA
was extracted and purified as described in Section 3.4. The purified RNA was
quantified, diluted to 50ng/µL and stored at -20°C.

Table 3.18 Component composition in a 20µL in vitro RNA transcription reaction.
Reaction
component

DNA
template

Transcription
H20

buffer*

rNTP

DTT

RNAzin

T7RNA
polymerase

Reactant

varied

varied

4.0

4.0

2.0

1.0

1.0

-

lx

200µM

lOmM

40U

20U

volume (µL)
Reactant final

-300ng/

concentration

reaction

* Supplied as a 5x preparation and diluted to yield a final concentration of l .2mM magnesium chloride in
a single 20µL reaction.

3.6.4 Target hybridisation and bandshift detection

To estimate deoxy-AO affinity to the target sequence, varied amounts of each
deoxy-AO (sequence information given in Table 3.19) were added to a hybridisation
reaction containing a constant 50ng of the synthetic RNA, 2µL of 2x hybridisation
buffer and water to a final volume of 4µL. The reactants were incubated for 30 minutes
at 37°C before being combined with glycerol loading buffer and electrophoresed
through an 8% polyacrylamide TBE gel at 200V for approximately 3 hours under
non-denaturing conditions. The gel was then placed into a SYBR gold stain followed by
visualisation of the reactants on a UV transilluminator. As the secondary structure of the
RNA fragment could be altered when a deoxy-AO annealed, the complexed and
uncomplexed RNA were often discerned as separate bands. The complexed band was
separated from the unbound RNA band, thus inducing a 'bandshift'.
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The degree of bandshift induced was given a rating between O and 4, where a 0
rating indicated no bandshift (equivalent to the RNA alone control) and a rating of 4
corresponded to 100% bandshift. A deoxy-AO was required to score a rating of at least
2 (equivalent to approximately 50% bandshift) when present at 5ng per reaction to be
considered suitable for synthesis as a 2'0MeAO for further evaluation in cell culture.

RBA Rating
0

2

3

4

Figure 3.2 Non-denaturing polyacrylamide gel demonstrating the varied degrees ofbandshift induced by
deoxy-AOs. Five nanograms of deoxy-AO was added to 50ng of RNA fragment.

Table 3.19 Sequences of deoxy-AOs used in this study. Upper and lower case characters represent
exonic and intronic nucleotides respectively.
Name

Sequence (shown 5' to 3')

dM20A(-18+02)

CTctacaaagaaaaccaaaa

DS
3849

dM20A(-16+04)

CCCTctacaaagaaaaccaa

3850

dM20A(-14+06)

CACCCTctacaaagaaaacc

3851

dM20A(-12+08)

AACACCCTctacaaagaaaa

3852

dM20A(-15+10)

TTAACACCCTctacaaagaaaacca

3875

dM20A(-10+ 15)

CAGCATTAACACCCTctacaaagaa

3876

dM20D(+02-18)

gaaggaggaaaaccttacCT

3720

dM20D(+04-16)

aggaggaaaaccttacCTTA

3721

dM20D(+06-14)

gaggaaaaccttacCTTACA

3722

dM20D(+08-12)

ggaaaaccttacCTTACAAA

3723

dM20D(+10-15)

ggaggaaaacattacCTTACAAA TT

3854

dM20D( + 10-20)

tggaaggaggaaaacattacCTTACAAA TT

3853

dM2 lD(+02-18)

aaaagtgtttttacttac TT

3784

dM21D(+04-16)

aagtgtttttacttac TTG T

3782

* Laboratory nomenclature; denotes QNA Synthesis number given to each primer (Geneworks).
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Table 3.19 continued.
Name

Sequence (shown 5' to 3')

DS

dM21D(+06-14)

gtgtttttacttacTTGTCT

3783

dM21D(+08-14)

gtttttacttacTTGTCTGT

3785

dM22D(+o2-18)

attcaaatgtccacagacCT

3724

dM22D(+04-16)

tcaaatgtccacagacCTGT

3725

dM22D(+06-14)

aaatgtccacagacCTGCAA

3726

dM22D(+08-14)

atgtccacagacCTGTAATT

3727

dM24A(-16+04)

CCCTctacaaagaaaaccaa

3850

dM24A(-14+06)

CACCCTctacaaagaaaacc

3851

dM24A(-12+08)

AACACCCTctacaaagaaaa

3852

dM24A(-15+10)

TTATGTGATTctggaataaaaaagc

3877

dM24A(-10+15)

GGTTTTTATGTGATTctggaataaa

3878

dM24D(+02-18)

atcagatacaaatcttacTC

3788

dM24D(+04-16)

cagatacaaatcttacTCTG

3789

dM24D(+06-14)

gatacaaatcttacTCTGCA

3790

dM24D(+08-12)

tacaaatcttacTCTGCATT

3774

dM24D(+10-20)

tcatcagatacaaatcttacTCTGCATTGT

3859

dM24D(+15-10)

caaatcttacTCTGCATTGTTTGAG

3860

dM25D(+02-18)

gaattaaactagtcatacCT

3777

dM25D(+04-16)

attaaactagtcatacCTGG

3778

dM25D(+06-14)

taaactagtcatacCTGGCG

3779

dM25D(+08-12)

aactagtcatacCTGGCGGC

3780

dH46A(-13+07)

TTCTAGCctggagaaagaag

3598

dH46A(-11 +09)

tctttctccagGCTAGAAGA

3599

dH46A(-09+ 11)

tttctccagGCTAGAAGAAC

3600

dH46A(-07+13)

tctccagGCTAGAAGAAC

3646

dH46A(+28+47)

AGAATTTCAAAGAGATTTAA

3611

dH46A(+63+82)

GGTTGGAGGAAGCAGATAAC

3445

dH46A(+83+ 103)

ATTGCTAGTATCCCACTTGAA

3612

dH46A(+l 15+134

GCAGCAACTAAAAGAAAAGC

3446

dH46A(+l l 1+125

AAGAGCAGCAACTAA

3613

dH46D( +04-16)

CAAGgtaattttattttctc

3601

dH46D(+06-14)

GTCAAGgtaattttattttc

3602

dH46D(+08-12)

AAGTCAAGgtaattttattt

3603

dH46D(+08-l4)

AAGTCAAGgtaattttattttc

3647

* Laboratory nomenclature; denotes DNA Synthesis number given to each primer (Geneworks).
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Chapter 4 - Targeting exon 19: l'OMeAOs directed at exon
splicing enhancers
In 1991, Matsuo and colleagues reported

11

52bp deletion in e:,;on 19 of the

dystrophin gene. It was concluded that this deletion was responsible for the abnormal
processing of the DMD Kobe allele (missing exon 19) found in the 16 year old patient
with DMD (Matsuo et al., 1990) as the resultant mature transcript was out-of-frame.
This was despite the fact that the CO!l5Cll.'iUS acceptor and donor splice sites of exon 19
were untouched. In 199S, Tal:eshima et al. investigated the role of lhe deleted sequence
in e:,;on 19. Using a minigcnc transcription product, which included the wild-type exon
19 in a HeLa cell nuclear e:,;tract, they demonstrated that the region missing in the DMD
Kobe allele was necessary for exon 19 definition. By directing a 2'0MeAO at a 31 base

!\

region within the 'deleted' sequence, the authors were able to inhibit inlron 18 splicing

\

and thereby prevent exon 19 inclusion in the mature RNA. A follow-up study by
Pmnono ct al. (1996) was undertaken in human lymphoblastoid .cells using a DNA
version of the 2'0McAO used in the Takeshima et al. (1995) study. This antisell.'le
ODN, directed at the ESE (ERS) of exon 19, was able to alter the dystrophin pre-mRNA
· -, splicing in these cells such that c:,;on 19 was excluded.
The focus of this section of the project was to further define the cxonic motif
targeted by the 31mer in the previous studies (Tal:eshima et al., 1995: Pramono ct al.,
1996). To achieve this aim, 2'0MeAOs were systematically designed to various
portions of the 31bp region of cxon 19 to identify crucial motifs involved in definidon
of the exon. Three transfectioo reagents were evaluated to determine which would
deliver the 2'0MeAO to the cell nucleus most effectively in H-2K normal and mr/x
mouse muscle cells, and in primary human ond HDMD muscle cells.

/

.
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4,1 Transrectlon reagenl optimisation
To detennine !he most effective vehicle for 2'0MeAO delivery in H-2K mouse,
normal primary human and human DMD cells, the ua.nsfcct!on reagents Lipofectin,
Lipofectamine 2000 and ExGen SOO were evaluated. These reagents were assessed at
two time points, 3 hours and 24 hours post-uansfection, for their ability to deliver a
fl1mrescem]y-]abclled 2'0MeAO, M23D(+l2-08)-FITC (Table 3.2) to the cell nucleus.
All transfcctions were performed with a standard 300nM (-lµg) final 2'0MeAO
concentration in serum-free Opti-MEM media and according to the manufacturer's
instructions. M23D(+l2-08)-FITC was designed to target the donor splice site of exon
23 in the dystrophin gene (Mllilll ct al., 2001). The same F1TC-Jabclled 2'0MeAO was
used in this study to ensure reproducibility and to determine the best reagent for
trnnsfection of human cells. Based on the assumption that the nuclear uptake of
M23D(+l2-08J-FITC is not sequence dependent, its utility was still relevant in this
project. As locnlisa\ion of the fluorescent tag to the nucleus, the site of pre-mRNA
transcription, is the finol outcome measure, coupling FITC to M23D(+l2-08) simply
gives the fluorescent tag 'directions' specific to the dystrophin gene.
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4.1.1 Tnndecdon or H·2Km0Ull! muscle cells with Ml3D(+12-08)-ITTC
Three ratios of Lipofectin:2'0MeAO, 1:1, 2:1, and 5:1 (weight:weight) were
evaluated in mouse cells. After three hours, cytoplasmic fluorescence in both H-2K
normal and mdx cell lines appeared to be weak and diffuse throughout the cell at each
ratio tested with no preferential nuclear accumulation observed. After 24 hours,
however, nuclear fluorescence was observed in approximately 100% of cells when the
2'0MeAO was complexed with lipofectin at a ratio of2:I (Figure 4.1), with a minimal
increase in both fluorescence and cell death at a ratio of 5: I. Transfection at a I: I ratio
resulted in less uptake compared to the optimal 2:1 ratio (results not shown). No
fluorescence was detected in the untreated cells or those cells that received Lipofectin
alone at a sham 300nM concentration (2µg/SOOµL). When 300nM of the uncomplexed
M23D(+12·08)·F1TC was delivered to the cells, only a weak and diffuse ceUular
fluorescence was observed in both cell lines lifter three hours. This signal, however, was
no longer detectable after 24 hours and was not observed in the nucleus.
Based on these results and previous sua:css with this reagent (Mann et al., 2001;
Mann et al., 2002), all H-2K cells used in this project were transfected at a ratio of 2:1
of lipofectin:2'0MeAO because of cell death, high efficiency and low volume of usage
per transfection.

lipofoctamine 2000 and ExGen 500 were also assessed and each displayed
differing abilities to deliver M23D(+l2-08)-F1TC to the nuclei of the mouse myoblasts.
Three ratios of lipofoclllmine 2000:2'0MeAO, 1:2, 1:1 and 2:1 were tested. The lower
ratios were chosen as previous experience in our laboratory with this reagent had
indicated that higher doses were associated with punctate cyloplasmic structures
(nuorescent aggregates) and greater cell damage. At both time points transfection
efficiency was high. with-100% of cells demonstrating some degree of fluorescence,
although very little accumulolion of the 2'0McAO was observed specifically in the
nucleus. However, the intensity of the signal throughout the cell appeared to be slightly
higher than comparable ratios oflipofectin and 2'0MeAO {results not shown). The 1:1
ratio of Lipofectamine 2000:2'0MeAO was considered to be optimal for this reagenl.
However, considering the degree of cell death and the apparent lack of localis.ntion to
the nucleus. Lipofectamine 2000 was not used to transfect mouse cells in this project
The third reagent assessed, ExGen 500, was tested late into the project as a
potential replacement for lipofectin. Three equivalents ofExGcn 500 to 2'0MeAO, 2,
S4
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3.5 and 5 were evaluated. A diffuse cellular fluorescence was detected after three hours
which then became predominantly localised to the nucleus 24 hours post-transfection.
While the highest ratio was associated with only a minor toxic reaction, small
fluorescent aggregates were observed across the well (Figure 4.2), possibly indicating a
maximal uptake of the complex. Due to the reduced toxicity and aggregates, the ratio of
3.5eq of ExGen 500 to lµg 2'0MeAO was deemed optimal for transfecting the H-2K
cells. These observations were consistent with those reported previously (Dunckley et
al., 1998; van Deutekom et al., 2001).

Figure 4.1

Phase contrast and fluorescent photographs taken 24 hours after H-2K mdx mouse

myotubes were transfected with M23D(+ 12-08)-FITC. Typically, cells were allowed to differentiate for
72-96 hours before transfection (A). Strong nuclear fluorescence (B) could be detected 24 hours
post-transfection when Lipofectin was complexed with M23D(+l2-08)-FITC at the optimal ratio of2:l.
(40x magnification).

4.1.2 Transfection of human muscle cells with M23D(+12-08)-FITC

The results observed from the fluorescent studies using Lipofectin and
Lipofectarnine 2000 in the primary human cells were similar to those obtained in the
mouse cells. However, in primary human cells transfected with Lipofectin, the nuclear
localisation was not as distinct after 24 hours compared to the mouse cells.
Lipofectarnine 2000 was again found to be associated with increased cell death, and
despite comparable transfection efficiency, was excluded due to its more toxic nature.
Therefore all experiments involving 2'0MeAO-induced exon 19 skipping (section
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4.3.2.1) in primary human cells were performed with Lipofectin at a 2:1 ratio of
Lipofectin:2'0MeAO, the reagent (and ratio) deemed most effective for inducing exon
23 skipping in the same primary human cell line (pers. comm. C. Mann). When the
opportunity to reproduce the previously reported 2'0MeAO-induced skipping of exon
46 in human cells arose, ExGen 500 was, however, selected as the transfection reagent
based on the protocol outlined by the authors (van Deutekom et al., 2001).
As observed in the mouse cell transfection experiments, ExGen 500 was able to
efficiently deliver M23D(+ 12-08)-FITC to the cell nucleus after 24 hours. Interestingly,
the fluorescent aggregates but not cell death were observed to increase with an increase
in the amount of ExGen 500. Again, the ratio of 3.5eq to lµg of M23D(+ 12-08)-FITC
was considered to be the point at which the signal intensity was strongest with minimal
fluorescent aggregate accumulation (Figure 4.2), consistent with the findings of van
Deutekom et al. (2001 ).

Figure 4.2

Phase contrast and fluorescent photographs taken 24 hours after primary human myotubes

were transfected with M23D(+ 12-08)-FITC. Typically, cells were allowed to differentiate for 96 hours
before transfection (A). When M23D(+l2-08)-FITC was delivered to the cell uncomplexed with ExGen
500, a weak and diffuse cellular fluorescence was observed 3 hours later but not after 24 hours (not
shown). However, strong nuclear fluorescence (B) could be detected 24 hours post transfection when 3.5
eq of ExGen 500 was complexed with -1 µg of M23D(+ 12-08)-FITC. Note the low level of fluorescent
aggregates outside the cells (lOx magnification).
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Fluorescent studies in the immortalised HDMD cells were less pronounced than
those obtained in the three cell lines previously tested. Furthermore, distinct nuclear
localisation ofM23D(+12-08)-FITC was very rarely observed, regardless of the carrier.
Therefore, as no reagent appeared to have a toxic effect on the cells, higher ratios of
carrier to 2'0MeAO were tested. The greatest difference was seen with Lipofectamine
2000. While a 5:1 ratio (weight:weight) of carrier to 2'0MeAO resulted in 20-30% cell
death after 24 hours, a 3: 1 ratio resulted in minimal or no cell death and an increase in
the uptake of the fluorescent molecule. Also, as was seen with the ExGen 500
transfections in the primary human cells, the increase in both ExGen 500 and
Lipofectamine 2000 was associated with an increase in fluorescent aggregates (Figure
4.3)

Figure 4.3

Phase contrast and fluorescent photographs taken 24 hours after HDMD myotubes were

transfected with M23D(+ 12-08)-FITC. Typically, cells were allowed to differentiate for 72 hours before
transfection (A). Diffuse cytoplasmic fluorescence (B) could be detected 24 hours post-transfection when
Lipofectamine 2000 was complexed with M23D(+ 12-08)-FITC at a ratio of 3: 1 (weight:weight). Further
increasing the ratio of the carrier to the 2'0MeAO did not increase signal intensity, only fluorescent
aggregates and cell death (lOx magnification).

4.2 Quality assay of 2'0MeAOs directed at the exon 19 ESEs
At the onset of this study, the first and second generation 2'0MeAOs were
synthesised by Geneworks. However, our group acquired access to an Expedite 8909
Nucleic Acid Synthesiser (Applied Biosystems) and commenced synthesising all
subsequent 2'0MeAOs in-house. For comparison and to ensure the continued quality of
all succeeding 2'0MeAOs, 200ng of each 2'0MeAO from Geneworks and 200ng of
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each 2'0MeAO synthesised in-house were resuspended with formamide loading buffer
and electrophoresed through a denaturing polyacrylamide gel (Figure 4.4). In addition
to the monitoring of the trityl signal at the end of each coupling during synthesis, this
assay satisfactorily validated the integrity of each 2'0MeAO used to induce exon 19
skipping.
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Each 2'0MeAO targeting the exon 19 ESE in this study was run on a denaturing

polyacrylamide gel to assess the standard of synthesis. As apparent yields varied, 2'0MeAO
concentrations were adjusted and re-evaluated by spectrophotometry prior to cell transfection

4.3

Induction of exon 19 skipping across species using 2'0MeAOs

directed at the ESE
4.3.1 Exon 19 skipping in mouse muscle cells

Our initial experiments to induce dystrophin exon 19 skipping were
undertaken using the conditionally immortalised normal H-2K mouse muscle cell line
which can be induced to fuse and express normal dystrophin (Morgan et al. , 1994).
However, the dystrophin mRNA would be out-of-frame when exon 19 is removed, as
an amber stop codon 43 bases into exon 20 is created (Figure 4.5) and, as a
consequence, no dystrophin can be produced. Therefore, detection of the exon 19
deleted message was anticipated to be more difficult relative to the normal message, due
to a high turnover arising from nonsense mediated decay mechanisms (Maquat, 1995).
Based on the results of these early investigations, it was hypothesised that the H-2K
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mdx cell line may represent a better model with which to assess 2'0MeAO-induced

exon skipping in the dystrophin gene, as this dystrophin mRNA carries a nonsense
mutation in exon 23 and should be metabolised at a similar rate to the 2'0MeAO
induced, out-of-frame transcripts missing exon 19.
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Schematic representation of normal and 2'0MeAO-induced splicing patterns. Normal

splicing (indicated by broken lines above the exons) removes the introns (single horizontal lines) and
retains each exon to produce a mature RNA (not drawn to scale). The 2'0MeAO-induced splicing
(2'0MeAOs indicated by small bold horizontal lines, modified splicing indicated by broken lines
below the exons) prevents recognition of the targeted exon. The transcript missing the entire exon 19 is
out-of-frame and a termination signal (arrow) occurs at the 15th codon into exon 20 (Errington, Mann,
Fletcher & Wilton, 2003).

4.3.1.1 H-2K normal muscle cells
The 2'0MeAO HM19A(+35+65) (Table 3.2 and Figure 4.8), originally
described by Takeshima et al. (1995), was the first 2'0MeAO tested to provide a
necessary starting point for the project. Myotube transfections were performed by
complexing HM19A(+35+65), at a standard dose of 300nM, with Lipofectin at the
optimised ratio of 2: 1 Lipofectin:2'0MeAO (weight:weight) as described earlier. Total
RNA was extracted from pooled duplicate wells 24 hours post-transfection and purified
for analysis of the dystrophin gene transcripts. The RNA was then reverse transcribed
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into cDNA with subsequent amplifications between nested primers flanking exon 19.
Only two transcript fragments separated by gel fractionation were detected - the larger
759bp product corresponding to the full-length amplicon (includes exon 19) and the
shorter 671 bp product corresponding to the transcript species missing exon 19 (Figure
4.6).
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Figure 4.6

Exon 19 skipping induced by 1si, 2nd and 3rd generation 2'0MeAOs in H-2K normal mouse

mRNA. RT-PCR analysis of RNA harvested 24 hours after cultured myotubes were transfected with

2'0MeAOs at 300nM. The full-length product spanning exons 17 to 21 is 759 bases long and the shorter
product is missing 88 bases due to the precise removal of exon 19. The smeared larger bands above the
full-length products are due to heteroduplex formation, as it is not seen in the untreated lane where there
are no shorter products. Subsequent secondary PCRs were performed with a more internal reverse primer
which greatly reduced formation ofheteroduplexes.

To confirm the exact nature of the exomc arrangements ansmg from the
2'0MeAO-induced splicing modification, both products were isolated and directly
sequenced to confirm their predicted identities (Figure 4.7). It was concluded that
HM19A(+35+65) had indeed induced the precise removal of dystrophin exon 19 from
the normal H-2K mouse rnRNA.
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Exon 19
Exon 20

Exon 18
TT G C AA G

Figure 4. 7
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DNA sequence chromatogram of the PCR products across the junction of dystrophin exons

18 and 20, indicating precise removal of exon 19. The junction of exons 18 and 19 and exons 19 and 20
are shown for comparison.

We subsequently designed two shorter overlapping 2'0MeAOs within
HM19A(+35+65), HM19A(+35+54) and HM19A(+46+65), as the second generation of
2'0MeAOs to further define the crucial region(s) of this ESE (Table 3.2 and Figure
4.8). Separate 300nM dose transfections of H2K normal muscle cells were performed,
and a gel analysis of the subsequent RT-PCR fragments revealed that both
HM19A(+35+54) and HM19A(+46+65) were also able to induce precise and consistent
exon 19 skipping (Figure 4.6).
A third generation of 2'0MeAOs was designed to assess a likely minimum
threshold for 2'0MeAO length as well as to refine the putative ESE-like motif. These
two 2'0MeAOs, HM19A(+49+65) and HM19A(+52+65), are 17- and 14mers
respectively directed at sequences within the region previously targeted by
HM19A(+46+65) (Table 3.2 and Figure 4.8). This region was chosen based on a
marginally but consistently stronger product induced by HM19A(+46+65) as compared
to HM19A(+35+54), initiating speculation that the motif involved in exon 19
recognition and inclusion in the mature mRNA may reside in this region. Transfection
with HM19A(+49+65) and HM19A(+52+65) at a final concentration of 300nM was
sufficient for the 14mer to induce very similar levels of exon 19 skipping as the 17mer
(Figure 4.6). However, the induced products appeared less abundant when compared to
that induced by the parent 2'0MeAO, implying either a possible restriction for
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2'0MeAO length or that only part of the crucial region had been blocked from splicing
factors.
Subsequent experiments involved a senes of titrations of each 2'0MeAO to
determine the minimum effective dose required to cause the removal of exon 19 in the
normal H-2K mouse pre-mRNA. Exon 19 skipping was induced most effectively by
HM19A(+35+65) and HM19A(+46+65), with the induced transcript consistently
detectable after transfection at concentrations of 20nM. HM19A(+35+54) induced
consistent skipping at 30nM (and more sporadic skipping at 20nM), while neither the
17mer, HM19A(+49+65), or the 14mer, HM19A(+52+65), could induce consistent
exon 19 skipping when delivered at concentrations below 200nM (results not shown).
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d~~~Fon

;

lntron 19

Schematic representation of the annealing sites for 2'0MeAOs to dystrophin pre-mRNA

inside the 52bp deletion within exon 19. The putative ESE (shaded region in exon 19) was targeted by the
first, second, third and fourth generation 2'0MeAOs (sequences shown 3' - 5') The nucleotide sequence
of exon 19 within the ESE in mouse and human dystrophin genes was identical, allowing the application
of each 2'0MeAO across species (Errington et al., 2003).
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4.3 .1.2 H-2K mdx muscle cells

The next series of experiments was conducted in the transformed H-2K mdx
muscle cell line, as it was anticipated that the turnover rate of both natural and
2'0MeAO-induced transcripts would be similar and therefore provide a better estimate
of the relative degree to which the 2'0MeAOs affect splicing patterns. Separate
duplicate transfections were performed by complexing Lipofectin at 2: 1 with either the
first, second or third generation 2'0MeAOs, HM19A(+35+65), HM19A(+35+54),
HM19A(+46+65), HM19A(+49+65) and HM19A(+52+65) (Table 3.2) at a standard
dose of 300nM, as described earlier. Twenty-four hours after transfection, total RNA
was extracted and purified and RT-PCR of the relevant dystrophin transcripts
conducted. Agarose gel analysis of the amplified transcripts revealed that
2'0MeAO-induced exon 19 skipping appeared to be stronger in mdx cell cultures at the
300nM transfection concentration (Figure 4.9) than that detected in normal mouse cells.
Again, only two transcript fragments were observed, the full-length 759bp product and
the 671 bp exon 19 deleted product.
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Figure 4.9

Agarose gel image of exon 19 skipping induced by 1si, 2°d and 3rd generation 2'0MeAOs at

a final transfection concentration of 300nM. Skipped transcripts appeared to be more easily detected in
the mdx cell line.
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The two 2'0MeAOs HM19A(+l2+45J and HM19A(+46+S7) weie tested only

in the mdx cells (Table 3.2 and Figure 4.8). These represent the fourth and final
generation 'of 2'0MeAOs designed to assen the sensitivity of the two polypurine
stretches identified by Pramono ct al. (1996) as targets for 2'0McAO-induced cxon 19
skipping. HM19A(+32+4S) wa~ directed at a 14 base region commencing 2 bases
upsU'ellm from the S' end of HM19A(+JS+S4). We hypothesised thal lhc crucial region
lay panially in the overlap between HMl9A(+3S+S4) and HMJ9A(+46+6S), and !hat a
2'0MeAO directed to block the S' sequence targeted by HM19A(+JS+S4) would be ]es.~
likely to induce exon 19 skipping. Conversely, !he 12mer HM19A(+46+S7), lhe shoncst
2'0MeAO used in the study, was directed at !he overlap and was expected to induce
exon 19 skipping, assuming it could bind at sufficient strength to displace the
competing splicing factors. Transfections wilh lhesc 2'0MeAOs at a final concentration
of 300nM resulted in the precise and r~produciblc removal of exon 19 by
HM19A(+46+S7). HM19A(+32+4S) was unable to reliably induce exon 19 skipping
(Figure 4.10).

4.3.1.2.1 Titration of2'0MeAOs directed at the exon 19 ESE

In order to prove the hypothesis that H2K mdx cells were a better model for
dctennining efficiency of 2'0MeAO-induced skipping, t11c 20MeAOs were tested at a
range of concentrations from 600nM to SnM. Separate transfections with each
2'0MeAO resulted in marked increases in exon 19 skipping between the minimum
concentration required and IOOnM. However, 2'0McAO transfection concentrations of
600nM, the highest dose tested, generally resulted in only marginal increases in the
level of induced tnmscript compared to that induced by a 2'0MeAO nt JOOnM (Figure
n

4.10). Furthcnnore, the highest transfection concentration of 600nM was never able
10 cause 100% exon 19 skipping as detected by RT-PCR, presumably because some

full-length mRNA would be present prior to the transfcction. Moreover, an increase in
the concentration of the 2'0MeAO (with a concomitant rise in the amount of
Lipofectin), was associated with an increase In the degree of cell damage after
tralllifcctio,n.
A dosage effect was clearly evident with all 2'0MeAOs tested.
HMl9A(+3S+6S), HMl9A(+46+6S) and HM19A(+3S+S4) all induced precise and
reproducible CJ.on 19 skipping when delivered at concentrations as ]ow as SnM (Figure
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4.IOA-C), compared to the minhnum transfec1ion concentration of 20nM required for

the same effect in lhc nonnal H-2K cells. HMl9A(+49+65) and HMl9A(+52+65) were
again judged leS5 efficient lhan lhe first and second generation 2'0MeAOs bucd on
their ability lo induce skipping at 50nM (Figure 4. IOD,E). This, however, still
represented a four-fold decrease in the minimum concentration required to consistently
detect skipping induced in the nonnal cells, supporting the use of H-ZK md:c muscle
cells as the preferred model for n.~scssing 2'0MeAO-induccd exon skipping. Previoll!ily,
HM19A(+32+45) could not consistently induce exon 19 skipping at 300nM and
mmsfections with this 2'0MeAO at 600nM could only induce low levels of skipping

,,

(Figure 4.IOF). However, the shortest 2'0MeAO tested in this study, HMl9A(+46+57),
was able to induce the specific removal of exon 19 at IOOnM (Figure 4.100\
Experimental controls included trnnsfection with a random sequence 2'0MeAO
at 600nM, which had similar base composition to M19A(-20+o5) (Table 3.2), an
uncomplexed 2'0MeA0, HM19A(+35+65), also at 600nM, and Lipofectin alone at a
mock concentration of 600nM (-4J1g/S00µL). In all three cases, no skipping of exon 19
was ev,:r detected (Figure 4.IOA).
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Figure 4.10

Agarose gel images of titrated 2'0MeAOs directed at exon 19. A 2'0MeAO consisting ofa

random arrangement of a similar base composition to HM19A(-20+05), as well as Lipofectin only, were
used as controls in panel A.
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4.3.2 Exon 19 skipping in human muscle cells

4.3.2.1 Primary human muscle cells

At the time these experiments were conducted, the transfection reagent
Lipofectin was used at the optimised ratio of 2: 1 Lipofectin:2'0MeAO (weight:weight).
As ExGen 500 was evaluated only late in the project, a thorough series of transfections
testing the ability of this reagent to transport 2'0MeAOs directed at the exon 19 ESE or
splice sites was not performed. Although retrospective transfections in these cells did
indicate that ExGen 500 may deliver M23D(+12-08)-FITC to the nucleus slightly more
efficiently in the primary human cell line, the 2'0MeAO-induced exon 19 deleted
product at no stage appeared stronger than its counterpart induced by the same
2'0MeAOs complexed with Lipofectin (results not shown).
RT-PCR analysis of the RNA harvested from 2'0MeAO-transfected primary
human cells found that HM19A(+35+65), HM19A(+35+54) and HM19A(+46+65) were
each able to induce consistent and precise exon 19 skipping and that the shorter third
generation 2'0MeAOs, HM19A(+49+65) and HM19A(+52+65), while not as effective,
could still prevent the inclusion of exon 19 in the final transcript (Figure 4.11 ).
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Agarose gel image of exon 19 skipping induced by I •i, 2°d and 3rd generation 2'0MeAOs

when transfected into primary human cells at a final dose of 300nM.
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Titrations to determine a minimum concentration at which skipping could be
detected found that HM19A(+35+65), HM19A(+35+54) and HM19A(+46+65) could
each induce the consistent removal of exon 19 at a concentration of at least 200nM.
However, the shorter 2'0MeAOs, HM19A(+49+65) and HM19A(+52+65), required a
final transfection concentration of no less than 300nM for the same reproducible effect
(results not shown).
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DNA sequence chromatogram of the PCR products across the junction of human

dystrophin exons 18 and 20, indicating precise removal of exon 19.

4.3.2.2 HDMD muscle cells
Initial transfections in HDMD muscle cells were performed by complexing
Lipofectin with a 300nM dose of 2'0MeAO at the optimised ratio in mouse cells of 2:1
(weight:weight). The resulting induced transcripts were difficult to detect and were only
observed at low levels, possibly indicating that delivery of the 2'0MeAO to the nucleus
of these cells may be a limitation. Subsequent experiments also evaluated
Lipofectamine 2000 and ExGen 500 as potential delivery agents for the fluorescently
labelled 2'0MeAO, M23D(+ 12-08)-FITC. It was found that Lipofectin at 2:1
(carrier:2'0MeAO), Lipofectamine 2000 at 3:1 (carrier:2'0MeAO), and ExGen 500 at 4
equivalents were the optimal ratios for each carrier molecule to 2'0MeAO, with the
least degree of cytotoxicity or excess extracellular aggregates. Furthermore, in a directly
comparable experiment, 300nM of HM19A(+35+65) was transfected separately using
each of the delivery agents at their optimised ratio (or equivalents). We found that
Lipofectamine 2000 at a ratio of 3:1 (weight:weight) was the only reagent able to
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efficiently deliver the 2'0MeAO and result in a comparatively stronger exon 19 deleted
product detected by RT-PCR (Figure 4.13).
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A comparison of delivery reagents for the transfection of 300nM ofHM19A(+35+65) into

HDMD myoblasts. Lipofectamine 2000 was the most effective carrier while Lipofectin and ExGen 500
were presumably unable to consistently transport the HM19A(+35+65) to the cell nucleus.

Following these findings, each first, second and third generation 2'0MeAO
directed at the exon 19 ESE was transfected into the HDMD cells at a final
concentration of 300nM complexed with Lipofectamine 2000. Twenty-four hours
post-transfection, the RNA was harvested and assayed for the presence of the exon 19
deleted transcript. HM19A(+35+65), HM19A(+35+54) and HM19A(+46+65) were all
able to induce the precise and repeatable removal of exon 19. HM19A(+49+65) and
HM19A(+52+65), however, were found to be less efficient as judged by their extremely
limited ability to induce exon 19 skipping in these cells at a concentration of 300nM
(Figure 4.14).
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Agarose gel image of exon 19 skipping induced by 1'\ 2°d and 3rd generation 2'0MeAOs

when transfected into HDMD cells at a final concentration of 300nM. The skipped transcript was
consistently detected, but was weaker than that observed in the normal primary cell line.

4.4 Summary
Optimisation of transfection conditions for each cell type was performed,
resulting in the selection of Lipofectin at a ratio of 2: 1 (Lipofectin:2'0MeAO) for
transfection in H-2K mouse and primary human muscle cells. In HDMD cells, however,
Lipofectamine 2000 at a ratio of 3:1 (Lipofectamine 2000:2'0MeAO) was the only
reagent able to efficiently deliver the 2'0MeAO.
In normal H-2K mouse cells, exon 19 skipping was induced most effectively by
HM19A(+35+65) and HM19A(+46+65), as the induced transcript could still be
detected at a transfection concentration of 20nM. HM19A(+35+54) was also very
effective, inducing consistent exon 19 skipping at 30nM. The shorter 2'0MeAOs,
HM19A(+49+65) and HM19A(+52+65), were not as efficient, requiring concentrations
of at least 200nM to achieve consistent exon 19 removal.
The same hierarchy of 2'0MeAO effectiveness was observed in the H-2K
mdx muscle cells. However, the exon 19 skipped transcript could still be detected

when the 2'0MeAOs were at lower transfection concentrations. HM19A(+35+65),
HM19A(+46+65) and HM19A(+35+54) could each induce exon 19 skipping at 5nM,
and HM19A(+49+65) and HM19A(+52+65) induced detectable exon 19 skipped
transcripts at 50nM. In addition, it was demonstrated that the 14mer, HM19A(+32+45),
designed within HM19A(+35+54), was very ineffective at inducing exon 19 skipping,
even at a concentration of 600nM. However, a 12mer, HM19A(+46+57), was capable
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designed within HM19A(+3S+S4), was very ineffective at inducing cxon 19 skipping,
even at a concentration of 600nM. However, a 12mer, HMJ9A(+46+57), was capable
of inducing precise and consistent skipping of cxon 19 when at a transfection
concentrntion of SOnM.
In primary human cells, HM19A{+3S+6S), HM19A(+35+S4) and
HMl9A{+46+6S) could each induce comistent and precise removal of exon 19 al lower
concentrations than required to achieve the same result with HM19A(+49+6S) and
HMl9A(+S2+6S). Th_cse concentrations, however, were up to 40.fold greater than those
used in the mdx cells. Results for HDMD cells were similar, except that skipped
products were generally less abundant and HM19A(+49+6S) and HM19A(+52+6S)
could not induce a detectable eJton 19 skipped transcript at transfection concentrations
comparable to !hat used in the prinwy human cells.

4.5 Discussion
4.5.1 Trandectloa reagenUI and cell \Ines
Cationic lipids have been used to enhance cellular uptake and activity of
2'0MeAOs in cell culture. One such formulation, Lipofectin, has been used as a
transfection reagent for 2'0MeAOs in primary mdx, H·2K mdx and C2C12 mouse
myobJo.sts (Mann et al., 2001; Wilton ct al., 1999). Since it has been suggested that no
single cationic application is optimal for all uses (Bennett, 1998), a comparison of
Lipofectin with another reagent, Lipofectamine 2000, was undertaken to ensure optimal
1ransfection conditions for each of the four cell lines to be evaluated io the current
study. In addition, a 2001 study by van Deutekom and colleagues successfully
employed fuGen SOO as a transfection reagent in mause and human cells. Al this time,
evaluation of the 2'0MeAOs targeted to eJton 19 had been completed, so EJtGen SOO
was investigated retrospectively, with the analysis thought to be of interest for the
remaining e~periments and future studies,
In optimising 2'0MeAO transfection conditioru;, it was found that the different
transfcctinn reagents evaluated had varying degrees of efficiency in different muscle
cell lines. This is consistent with the observation that the ability of different cell types to
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take up oligonucleotide molecules or liposomes varies to a large degree (Galdcrisi,
Cascino & Giordano, 1999; Gao & Huang, 199S). This may be related to the size of the
panic\e to be internalised and differences in the levels of endocytic activity between the
different cell types (Gao & Huang, 199S). The particle sire of 2'0MeAO-liposome
complexes (lipoplexes) varies, and appears to be dependent on a combination of the
cationic liposome fonnulation used and the lino] concentration of the lipoplex (Gao &
Huang, 1995). The results presented in this thesis emphasise the necessity for
optimising 2'0MeAO delivery for each cell type.
In H-2K mouse myoblasts, Lipofectin at a ratio of 2:1 appeared to be an
effective uansfection reagent, as nuclear fluorcsce'lce was observed in approximately
100% of cells at 24 hours post-transfection, and cell death was not observed, consistent
with previous reports (Mann et al., 2001; Wilton et al., 1999). In contrast, H-2K cells
uansfected with Lipofectamine 2000 complexed with M23D(+l2·08)-FITC did not
exhibit the same degree of distinct nuclear localisation and displayed fluorescent
aggregates when higher ratios of Lipofectamine 2000 to 2'0MeAO were used.
Inlerestingly, these same aggregates were observed following transfection with high
doses of El.Gen 500. Cells transfected with this reagent showed predominant nuclear
localisation of the f1110rescent 2'0MeAO at 24 hours post-uansfection and there was no
toxic reaction at the optimal dose of 3.Seq, consistent with observations reported
previously (DunckJey et al., 1998; van Deutekom et al., 2001).
11 is unclear why cells uansfected with ExGcn SOO or Lipofectaminc 2000 at
doses required to achieve signifi~ant nuclear localisation were observed to have
fluorescent aggregates at 24 hours post-transfection. These cytoplasmic structures could
represent the internalised 2'0MeAO-liposome complexes (lipoplcxes) within
endosomes or lysosomes (Bennett, 1998). Their presence may be relateo to the amount
of time the lipoplexes spend in the endosome, detennined by the differing mechanisms
of action of the reagents. For eHrnple, the DOPE component ofLipofectin is thought to
function by reducing the aggregation of complexes and facilitnting the release of the
2'0MeAO from the cndosome 3fter internalisation (Zelphati & Swka, 1996). While
DOPE is also one of the constituent~ of Lipofectamine 2000, it represents a lower
proFurtion of the liposorne fonnulatlon compared to Lipofectin. As the efficiency of the
cytoplasmic release is detennined by the DOPE content of the liposomes (Gao &
Huang, 199S), it can be assumed that Lipofectin would be more efficient in releasing
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the 2'0MeAO. fa.Gen S00 has been suggested lo act by buffering the acidic endosomal
environment, thereby protecting the 2'0McAO until it is released into the cytoplasm by
subsequent endosomal swelling and rupture {Boussif et al., 1995; Kiebler, Leborgne,
Coeytaux, & Danos, 2001). It is therefore possible that the aggregates observed in cells
trllrlSfected with Lipofectamine 2000 or ExGen 500 simply represent a slower escape
from the endosome, delaying the passive diffusion of the 2'0MeAO to the nucleus.
Thus, improved nuclear localisation may have been observed 48 hours posttmnsfection, similar to that reported by Dunckley et al (1998).
While there were no differences in M23D(+l2-08)-FITC uptake for any of the
trnnsfection reagents between the H-2K nonnal and mdtcells, results did differ between
prilllllry human and HDMD cells. In the primary human cells, Lipofectin at a ratio of
2:1 was found to be the most effective reagent, although the fluorescence was observed
to be more diffuse throughout the cell (and less localised to the nuclei) compared !O that
observed io mouse cells. Lipofectamine 2000, at the ratio required to achieve o
comparable degree of nuclear localisation, again resulted in high levels of cell death.
ExGen SOO performed most effectively ot 3.5 eq, consistent with the findings of van
Deutekom et al. (2001) for human muscle cells. In contrast, HDMD cells required
higher doses of each delivery reagent to achieve efficient fluorescent 2'0MeAO
uansfection, with Lipofectamine 2000 proving to be the best carrier at o ratio of 3:J.
Interestingly, this ratio was associated with a much lower level of cell death than that
observed in H-2K mouse and primary hnman cells when transfected with the same
concentration of Lipofectmnine 2000, again highlighting the importance of optimising
tran~fcctioo conditions for each cell type.

4.5.2 Elon 19 skipping In H-2K n.irmal and mdr muscle cells
Our initial auempl.'i to induce dystrophin exon 19 skipping were undertaken
using the conditionally immortalised normal H-2K mouse myoblast cell line. However,
in unaffected cells, dystrophin mRNA missing exon 19 is out-of-frame and would be
subject to nonsense mediated tlecay (Maquat, 199S). Therefore, detection of the exon
19·deletcd message was anticipated to be more difficult relative to the more stable
wild-type rnRNA. Based on the results of these early investigations, it was hypothesised
that a better estimate of the extent nf skipped and full-length transcript could be
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achieved using the H-2K ,ndx cell line, where both natural and 2'0MeAO-intbced
dystrophin IJ'allsmpts should be metabolised at comparable rates.
As arnicipatcd. a higher abundance of e,;on 19 skipped transcripts was detected
in the 2'0MeAO-transfectr.d H-2K mdx muscle cells, as compared to those detected in
the

H-2K normal muscle ceJ\s thnt had been transfccted with the same ooncentration

of 2'0MeAO. For both cell Jines, lhe same transfection reagent was used and the
nuclear fluorescence observed was identical at each ratio and at eacli time point tested.
This would suggest that the difference in stability and metabolism of the endogenous
and 2'0MeAO-induced skipped transcripls is a more likely explanation than the
efficiency of the transfection process.
Although 2'0MeAO efficiency differed between H-2K normal and mdx muscle
cells, the pattern of efficiency of individual 2'0MeAOs was very simillll'. This study
investigated the effect of several 2'0MeAOs in both cell lines. The first generation
2'0MeAO evaluated, HMl9A(+35+65), originally designed by Tak:eshima et al. (1995),
was able to consistently induce the efficient and precise removal of exon 19. However,
a study by Pramono el al. (1996), reported that an antisense o\ig~cleotide
version of HM19A(+35+6S) was able to induce 100% e,;on 19 skipping 24 hours after
transfection in normal human lymphoblastoid cells. The present project was unable to
induce exon 19 removal from all transcripts in either mouse or human muscle ceUs. This
discrepancy may be due in part to the difference in levels of dystrophin expression in
each cell type. Human lymphoblastoid cells are known to pNducc very low levels of
dystrophin mRNA by illegitimate transcription (Chelly ct al., 1988), and we have
previously shown that a 2'0MeAO could induce 100% exon skipping in myoblast
cultures where there were also low levels of dystrophin e,;pres~ion (Wilton et al., 1999).
However, the same 2'0MeAO was less effective in H-2K muscle cells, where much
higher levels of dystrophin are synthesised (Mll!Ul et al., 2001).
Perhaps more significant is the difference in the chemistry of the !llltisense
agents utilised. DNA:RNA dup\e,;es are cleaved hy RNaseH (Furdon, Dominski &
Kole, 1989). Therefore, the selection of a DNA AO in the Pramono el al. (1996) study
could have biased their assay, as any full-length message may have been degraded
through RNaseH activity, leaving only the induced transcripts missing exon 19 to be
detected by RT-PCR. Subsequent studies from this same group using a dystrophic
primary human muscle cell line deleted for exon 20 did not report the same high level
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of induced in-frame transcript ming 2'0McAO chemisiry (Takcshima ct al., 2001).
Finally, nonnal dystrophin mRNA has an estimated half life of some 16 hours
(Tennyson ct al., 1995), so even if 2'0McAO-induced c11.on skipping was 100%
efficient soon after transfcction and nuclear uptake, some full-length mRNA would be
CJpccted to remain in the cytoplasm after 24 hours.

The main focus of this section of the project was to attempt to refine the ESE
motif within dystrophin uon 19. ESEs arc thought 10 play a crilical role in correct
splice site selection through cross-exon interactions between splicing factors bound to
the 3' 1111d 5' splice sites (Recd, 1996), perhaps promoting the use of nearby weak splice
sites (Coulter, Landree & Cooper, 1997; Tanaka ct al., 1994; Watakabc et al .. 1993).
Disruption of an ESE can lead to partial or complete exon skipping (Liu, Cartegni,
Zhang & Krainer, 2001a), either lhrough alterations in secondary structure (Cartcgni,
Chew & Kraincr, 2002: Watakabc ct al., 1993) or disruption of sequences crucial for
recognition by splicing facton; such as SR proteins. These proteins arc thought to recruit
components of the general splicing machinery (Black, 1995; Reed. 1996). It h!lS been
suggested that targeting e1tonic sequences with 2'0McAOs may re~ult in more efficient
and specific ell.on skipping than targeting splice sites, as there is less disruption to !he
splicing process: the uon is simply not marked for inclusion (van Dcutclmm & van
Onunen, 2003).
The hierarchy of 2'0McAO efficacy followed a similar pattern in each cell line.
However, the H-2K mdx myoblasts will be discussed in greater depth as this cell line
represented the best molecular model for 2'0McAO-induccd exon skipping. Exon 19
wns initially targeted for 2'0McAO-induced skipping by the first generation 3lmcr
HM19A(+35+6S). This 2'0MeA0, directed at a region containing two ESE-like
polypurinc stretches (GCAAGA and AGCAGA • Pramono ct al., 1996; Takcshima ct
al., 1995), could induce consistent nnd precise exon 19 skipping at very low
co,nccntrations (SnM). Subsequently. a second generation of two overlapping 20mers
was designed to the upstrenm and downstream portions of this region to dctennine
which (if either) was more significant to the splicing process. The downstream
HM19A(+46+6S) was consistently more efficient than the upstream HMI 9A(+3s+54).
based on the relative abundance of e1,on 19 skipped transcripts. Although secondary
structure h!lS been suggested as a limiting factor in hybridisation (Crooke, 1999; Dagle
& Weeks, 2001) and therefore 2'0McAO-induced c11.on skipping, !he 31merwas able to
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induce cxon skipping at lhe same level of efficiency as lhe downstream 20mer.
Therefore, it is doubtful !hat lhe difference between thc performance of the two scrond
generation 2'0MeAOs was due to accessibility to their respective targets. A second
consideration is lhat the annealing potentials of the two 20mcrs differed. As the
annealing lCmpcraturc (T.J increases with higher GIC content, it is possible that the
upstream 20mcr annealed less efficiently than il5 downstream counterpart, as the GIC
conlents were SO% and 65% respectively. Bolh 2'0MeAOs should still anneal
efficiently at 37°C, so it is likely that the motif crucial for splicing enhancement ofexon
19 resides in the downstream region targeted by HM19A(+46+65).
Consequently, lhe third generation of 2'0MeAOs was designed within the
downstream 20mer to further define the ESE motif. An additional aim was to assess a
likely minimum threshold for 2'0MeAO lenglh, as indicated by the ability of the
2'0MeAO to hybridise under cellular conditions and to Cllfl}' out lhe desired effect
(Dagle and Weeks, 2001). The 17mer, HM1.9A(+49+6S) induced exon 19 skipped
products of higher abundance than that induced by the 14mer, HM19A(+S2+6S),
however both were less efficient compared to the first and second generation
2'0MeAOs. Since lhe T,. of the 2'0MeAO:pre-mRNA complex decreases with a
concomilant dccrcasc in length, shorter 2'0McAOs may have lower affinity to the target
sequence at 37"C (Agrawal. 1992; Crooke, 1999), Thus the reduced length oflhe 17mcr
and 14mcr may have resulted in a diminished level of affinity to theil' target sequences,
particularly since the G/C contents of these two 2'0MeAOs (S9% and 57%
respcctivdy) were actually higher than that of the more efficient upstream 20mer.
Alternatively, the lower abundance of the exon 19-sklppcd transcripts may indicate that
the 17mer and 14mer were targeted too far downstream and were no bnger blocking the
ESE from splicing factors 115 effectively as the longer2'0MeAOs.
It is possible that the crucial region is at least partly within thc area overlapped
by the two 20mers but e,i:lCnds more into the downstream portion of the exon. This
could account for thc more efficient skipping induced by HM19A(+46+6S) compared to
the upstream 20mer, and lhe ability of the 17mer and 14mcr to induce precise skipping
of exon 19, albeit at low levels, despite the reduced length.
To test the hypolhesis Iha! the region crucial for exon inclusion lay within the
overlap of the two 20mers, a fourth generation consisting of two 2'0MeAOs were
designed and evaluated in H-2K mdx cells. Consistent with this hypothesis, a 14mer
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HMl9A(+32+4S), targeted to lhe 14 bases commencing two nucleotides upstream of
lhe overlap, was unable to induce reliable e:,;.on 19 skipping, even 111 a final transfection
of 600nM. The targeted region included lhe upstream purine-rich ESE-like motif
identified previously (Figure 4,8; Pramono et al., 1996; Takcshima et 111., 199S),
Howev~r, p]though ESEs commonly occur in purine-rich or A/C-rich regions (Coulter,
ct Iii., 1m: Tll!lllka et al., 1994), it has been noted lhat many natural sequences lhat are
ESE-like do not function as ESEs unless Ibey occur in an appropriate context (Liu et al.,
1998). It is unlikely that the inemciency of lhis 2'0MeAO could be due to secondary
strocture as lhe )!mer and upstream 20mer targeting lhe same

IU'CO

were efficient in

inducing ellon 19 skipping. The difference between these 2'0MeAOs was that the
regions targeted by HM19A(+35+6S) and HM19A(+35+54) also included the
downstream polypurine ESE-like motif, whereas HM19A{+32+45) did not (Figure 4.8;
Pr11mono et al., 1996; Takeshima et al., 1995). Decreased length, while a possible
factor, is also unlikely to ellplain the failure of HMl9A(+32+45) to induce efficient
exon skipping as the 14mcr, HM19A{+S2+65), directed 111 the downstream region, was
successful. Interestingly, the G/C content of the region targeted by HM19A(+32+45)
was 36%, the lowest of the 2'0MeAOs tested. A ~uction in 11MCaling temperature
resulting from the combination of decreased length and lower G/C content could
partially account for the inefficiency of this 2'0MeAO. A likely additional factor could
be that the sequence targeted, despite containing a region which resembled an ESE, was

not as important to e,:on inclusion as the region conlilining the downstream motif. In
addition, the 12mer HMl9A(+46+57), which was directed at the downstream motff,
was able to induce consistently precise skipping of exon 19, although Jess effectively
than the 14mer HMl9A(+S2+65) and 17mer HM19A(+49+65). This suggests that
although the shoner length of this 2'0MeAO may have reduced its annealing
temperature, a motif crucial for exon 19 inclusion was containl'-0 within the target
5equence. Whether the 2'0MeAO-induced skipping of e:,;.on 19 was effected by
lliterations in secondary structure or by disruption of sequences crucial for recognition
by splicing factors remains unclear.
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4.5.3 Exon I!' skipping in primary human and HDMD mlllll,!Je cells
The 31 base region of exon 19 contuining the putative ESEs wns homologoll!I in
mouse and human cells, allowing the 2'0MeAOs directed at this region to be tested on
both species. In primary human and. HD:MD cells, the hierarchy of 2'0MeAO efficacy
followed a similar pattem to that observed in the mouse cells, as discussed previously
(Section 4.5.2), Compared to the moll!le cells, however, the 2'0MeAOs were not as
efficient in human cells, requiring higher concentrations to achieve consistent exon 19
skipping. This was particularly evident in the HDMD cell line. The differences between
the level of 2'0MeAO-induced exon 19 skipped transcript& between the normal cell
lines and the cell lines with dystrophin gene mutations may be partly due to the

variation in turo over rates of natural and exon 19 skipped products (Maquat, 1995).
However, the differences in 2'0MeAO-induced skipping efficiency between primary
human and H-2K normal mouse cells (unaffected cell lines), or between HDMD and
H-2K mdx cells (affected cell lines), may not be attributable lo variations in transcript

turnover rates as the natural and skipped transcriptS should be metabolised at siuular
rates in each case.
The reason for the apparent disparity in the expected abundance of exon 19
skipped transcript detected Ul the human and mouse cells is unclear. It is possible that
there are differences in target site accessibility between species or that the ESEs in the
human exon 19 were not as significant to exon inclusion as those in the mouse exon 19.
It has been suggested that ESEs promote the use· of nearby weak splice sites (Coulter et
al., 1997; Tanaka et al., 1994; Watakabe el al., 1993). However, the strength of the exon

19 acceptor and donor splice sites in human (93% and 76% respectively) and mouse
(91% and 78% respectively), are very similar (Senapathy, Shapiro & Harris, J990),
which should indicate a similar reliance on ESEs or other enhancers. The difference in
ability to detect the induced transcript at lower transfection concentrations between
mouse and human cells is more likely to be due to differences in efficiency of
2'0MeAO delivery to the nucleus, consisteot with the results of the fluorescence studies
(Section 4.1.2).
It has been noted that primary cells are typically more sensitive to the effects of
antisense oligonucleotides than transformed cells (Baker et al., 2001). This may
partially account for the de.;reased efficiency of the 2'0MeAOs in HDMD cells
compared to the primary human cells. However, this did not appear to limit the
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perfonnance of 2'0MeAOs in the transformed H-2K cell lines, which supports the
efficiency of the transfcction process as the major limiting factor in the perfonnance of
the 2'0MeAOs in human cell lines, Although it is possible that further optimisation of
the lransfection process may have yielded more efficient 2'0MeAO-induced skipping of
exon 19, this study has demonstrated that the direction of 2'0MeAOs to ESEs is a
viable approach to the modification of splicing in human cells.

ChapLCr 5 - Results from targeting crnn 19: 2'0McAO,; direcl~d at Lh~ splice sites

Chapter 5 • Targeting exon 19: 2'0MeAOs directed at the
acceptor and donor splice sites
Previously, smdies involving the 2'0MeAO.induced removal of exon 23 in the
mdx mouse involved targeting the acceptor or donor splice sites (Dunckley et al., 1998;

Mann et al., 2001; Wilton et al., 1999). These splice sites were obvious targets as ESEs

are often ill- defined, but characterised by purine-rich regions within an exon. However,
it has been suggested that the targeted 2'0MeAO-induced removal of an exon may be
more specific if these exonic motifs are employed (van Deutekom et al., 2001). In the
previous chapter, it was shown that the ESE was intimately involved with the precise
definition of exon 19. Therefore, the next logical step was to evaluate the splice sites of
exon 19 as potenlial targets for the specific removal of this exon in mouse and human
dystrophin pre-mRNA.
Furthermore, the effect of targeting multiple sites with combinations of
2'0MeAOs was investigated to determine if the 2'0MeAO-induced removal of exon 19
could be enhanced while maintaining its specificity.
Finally, to ensure specificity of the antisense activity of the 2'0MeAOs, two
further assays were undertaken. First, mismatched 2'0MeAOs directed at the acceptor
and donor splice sites in mouse and hwnan cells Were assessed for their ability to induce

exon 19 skipping. Second, additional screens were perl'ormed to determine whether the
splicing patterns in other regioll!l of the dystrophin gene transcript were affected by the
2'0MeAOs directed atexon 19.

5,1 Quality assay of 2'0MeAOs directed at the exon 19 splice sites
All but one 2'0MeAO of the five designed to target the splice sites of exon 19 in
either mouse or human cell lines were part of the third generation of 2'0MeAO design
synthesised by Geneworks. Ml9D(+o2-l8), was designed to be a refined version of
Ml9D(+oS-20) (a third generation 2'0MeAO synthesised 'in-house'). However, to
maintain consistency, all 2'0MeAOs targeting splice sites were subject to the same
quality check. As described earlier, -200ng of each 2'0MeAO was complexed with
formarnide loading buffer and electrophoresed through a denatwing po!yacrylamide gel

(figure S.l). In most cases the 2'0MeAO integrity was confirmed to be relative1y high
with a predominant single band indicating the full length 2'0MeAO. Furthennore, the
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quality of Ml 9D(+02-18) validated the acceptable standard of manufacture of the
'in-house' synthesised 2'0MeAOs compared to those commercially available, although
the yield was lower than expected and subsequently corrected prior to evaluation in cell
culture.
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Figure 5.1 Each 2'0MeAO targeting the splice sites for both mouse and human dystrophin exon 19 was

run on a denaturing polyacrylamide gel to assess the standard of synthesis. As apparent yields varied,
2'0MeAO concentrations were adjusted and evaluated by spectrophotometry prior to cell transfection.

5.2

Induction of exon 19 skipping across species using 2'0MeAOs

directed at the splice sites

As exon 19 removal had only been attempted by directing 2'0MeAOs at the
ESEs, it was necessary to evaluate the splice sites as possible targets for exon skipping.
Earlier investigations by our group involved the 2'0MeAO-induced removal of exon 23
by targeting the donor splice site (Mann et al., 2001; Wilton et al., 1999). Attempts to
repeat the work reported by another group that induced the non-specific removal of
exons 22-30 by directing 2'0MeAOs at the acceptor site (Dunckley et al., 1998),
however, were not successful (Mann et al., 2001; Wilton et al., 1999). In this study we
designed 2'0MeAOs to target either the acceptor or donor splice sites and wished to
compare these regions to the ESE targeted earlier. The choice to direct the 2'0MeAOs
at mostly intronic sequence was based on the early findings of our group which found
the more exonic sequences in the donor splice site region to be less effective at inducing
exon 23 skipping (Mann et al., 2001; Mann et al., 2002; Wilton et al., 1999) (Figure
5.2).
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Figure 5.2 Schematic representation of the placement of 2'0MeAOs targeting the mouse and human
splice sites of dystrophin exon 19. The position of mismatches between species sequence and species
specific 2'0MeAOs are indicated by" • "(Errington et al., 2003).

5.2.1 Exon 19 skipping in mouse muscle cells

All H-2K mouse myotube transfections were performed by complexing
Lipofectin at the ratio of2:1 Lipofectin:2'0MeAO (weight:weight) with each 2'0MeAO
at a standard dose of 300nM. Total RNA was extracted from pooled duplicate wells 24
hours post-transfection and purified for analysis of the dystrophin gene transcripts by
RT-PCR.

5.2.1.1 H-2Knormal muscle cells

Initial experiments assessed only one 25mer 2'0MeAO directed at each splice
site M19A(-20+05) or M19D(+05-20) (Table 3.2 and Figure 5.2). In the H-2K normal
cells, the donor site appeared to be the more amenable target, as M19D(+05-20) would
induce a consistently stronger exon 19 skipped transcript compared to M19A(-20+05)
(Figure 5.3). In fact, analysis of the minimum effective dose for both 2'0MeAOs
revealed that transfection of M19D(+05-20) at a final concentration of lOOnM could
still induce exon 19 skipping, whereas M19A(-20+05) could not consistently remove
exon 19 when the transfection concentration was below 300nM (results not shown). It
should also be noted that at no time did transfections with M19A(-20+05) or
M19D(+05-20) induce the removal of any other exons, nor did their presence initiate
any aberrant splicing at cryptic splice sites. Exon 19 removal was always found to be
precise, with exon 18 joined exactly to exon 20 (Figure 4. 7).
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5.2.1.2 H-2K mdx muscle cells

Based on the results from the H-2K normal muscle cell transfections with
M19A(-20+05) and M19D(+05-20), it was anticipated that the exon 19 skipped
transcript would be easier to detect in mdx muscle cells due to nonsense mediated
decay of both wild-type and 2'0MeAO-induced messages at similar rates. Initial
experiments in the H-2K mdx cells demonstrated more abundant exon 19 deleted
transcript fragments following transfection with the splice site-directed 2'0MeAOs
M19A(-20+05) and M19D(+05-20) at 300nM (Figure 5.3). The natural (full length)
H-2K mdx transcripts appeared to be less abundant when compared to the normal intact

transcript. As some degree of full length H-2K mdx transcript would be expected to be
present before the 2'0MeAO was added to the cells, these results suggest that the
2'0MeAO-induced skipping of exon 19 in the H-2K mdx cells was very efficient,
particularly when the donor site was targeted.
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Figure 5.3 Comparison of exon 19 skipping induced by 2'0MeAOs directed at the acceptor or donor
splice site in H-2K normal and mdx mouse mRNA. RT-PCR analysis of RNA harvested 24 hours after
cultured myotubes were transfected with 2'0MeAOs at 300nM. Shortened transcripts appeared to be
moderately more abundant in the mdx cell line. The full-length product spanning exons 17 to 21 is 761
bases long and the shorter product is missing 88 bases due to the precise removal of exon 19.
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A titration of M19A{-20+o5) and Ml9D{+05-20) demonstrated that both
2'0MeAOs were consistently able to induce the shortened transcript when transfected at
a dose as low as lOnM, although the abundance of the induced transcript was slightly
higher in cells transfected with the donor site-directed 2'0MeAO. This was despite the
apparent lower quality of Ml9D(+o5-20) compared with M19A{-20+05) (Figure 5.1),
demonstrating that the shorter bands, which still contain the same sequence as the fuil
length 2'0MeAO, do not compromise the ability of the 2'0MeAO to induce efficient
exon skipping. Interestingly, the lowest effective concentration for either splice
site-directed 2'0MeAO w~ only SnM more than that required by the best 2'0MeAOs
directed at the ESE. This effect was not seen in normal mouse cells which further
validates the use of mdx muscle cells to assess 2'0MeAO effectiveness In vitro.
As the sequence targeted by M19D(+o5-20) appeared to be the most sensitive to

2'0MeAO-induced CJton skipping, Ml9D{+o2-l8) was designed to determine if the
original target region could be further refined. This 2'0MeAO was directed at the same
exon:intron coordinates which had proved efficient for 2'0MeAO-induced skipping of
exon 23 (Mann et al., 2002). It was thought that targeting these coordinates in exon 19
could help to determine whether this region was as efficient a target in other exons.
Titrations ofM19D{+02-l8) demoostrated that the smaller 2'0MeAO, while targeting n
highly sensitive region, could not consisteotly induce the same level of skipping as the
parent 2'0MeAO when at a final transfcction concentration of IOnM (Figure 5.4). This
may indicate that the sequences not obstructed were important for exon boundary
definition by splicing factors, or that the longer 2'0MeAO could anneal at a higher
efficiency and displace splicing factors more effectively. Interestingly, the opposite
effect was reported when optimising 2'0MeAOs directed at the donor splice site of
exon 23 (Mann et al., 2002). Efficieot exon 23 skipping was induced using a 25mer but
the motif targeted was refined by directing a smaller 2~mer within the snme region,
suggesting that there may be specific motifs recognised by the spliceosome for
individual exons or that there were differences in secondary structure which affected the
ability of the 2'0MeAOs to anneal to the target sites.

·):.- •.,
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Figure 5.4 Titration of 2'0MeAOs directed at the acceptor or donor splice site of exon 19 skipping in
H-2K mdx mouse mRNA. The smaller Ml9D(+02-l8) directed at the donor splice site was less effective

than its parent but was still consistent and completely specific.
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5.2.2 Exon 19 skipping in human muscle cells

5.2.2.1 Primary normal human muscle cells

Delivery of the 2'0MeAOs in the primary human muscle cells may again have
been an issue as neither H19D(+10-15) nor H19A(-20+10) (Figure 5.2) were deemed
very effective at inducing exon 19 removal from the final transcript. Transfection with
H19D(+10-15) at a 300nM dose was sufficient to produce the skipped product
(Figure 5.5), however, 200nM was the threshold at which skipping was consistent.
H19A(-20+10) was only able to induce reliable exon exclusion at 600nM, but was able
on occasion to induce exon 19 skipping at 300nM (Figure 5.5), suggesting that the
human acceptor splice site was the least amenable target for human exon 19 removal,
similar to that of the mouse.
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Figure 5.5 Exon 19 skipping induced by 2'0MeAOs directed at the acceptor or donor splice site in
primary human muscle mRNA. RT-PCR analysis of RNA harvested 24 hours after cultured myotubes
were transfected with 2'0MeAOs at 300nM. The full-length product spanning exons 17 to 21 is 668 bases
long and the shorter product is missing 88 bases due to the precise removal of exon 19.

5.2.2.2 HDMD muscle cells

HDMD myoblasts were transfected with either H19A(-20+10) or H19D(+10-15)
at 300nM complexed with Lipofectamine 2000 at a 3: 1 ratio. RT-PCR analysis of the
transcripts showed a similar pattern to that seen in the primary human cells. While the
exon 19 skipped transcripts were of much lower abundance in the less reliable HDMD
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cells, the donor site usually appeared to be the more amenable of the two targets to
antisense modification (Figure 5.6).
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Figure 5.6 Agarose gel image of exon 19 skipping in HDMD muscle cells. Each splice site-directed
2'0MeAO was transfected into the cells at a final concentration of 300nM. The skipped transcript was
consistently detected but also weaker than that observed in the unaffected primary cell line.

The shorter transcript fragment was isolated from the gel by the bandstab procedure
(Wilton et al., 1997b) and analysed by direct sequencing. The identity of the 668bp
product was confirmed to be exon 18 joined precisely to exon 20, again verifying the
specific action of each splice site-directed 2'0MeAO to induce precise exon 19 skipping
in HDMD myoblast mRNA (Figure 4.12).
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5.3 Targeting multiple sites
When targeting either the ESE or splice sites of dystrophin exon 19, the
2'0MeAO-induced skipping was observed to be very effective in some cells. We
therefore tested if directing 2'0MeAOs at both sites in combination would enhance the
action of the 2'0MeAOs compared to targeting a single site.
HM19A(+35+65), M19A(-20+05) and M19D(+05-20) were transfected into
mdx

myotubes individually and at the concentration equating to the threshold of

detection of the induced transcript by our standard RT-PCR assay. Each 2'0MeAO was
added to target the three splicing motifs according to the 4 possible combinations;
acceptor and donor splice sites, acceptor splice site / ESE, ESE / donor splice site and
acceptor splice site / ESE / donor splice site. In these combinations, the final
concentration was the sum of the concentrations used for each individual 2'0MeAO.
Twenty-four hours post-transfection, RNA was extracted and analysed by
RT-PCR. When transfected singly, the shortened product was barely visible on the gel
relative to the natural product. However when added to the cells together, each
combination appeared to have a synergistic effect. Furthermore, targeting all three sites
in concert seemed to elicit a degree of skipping greater than the sum of all three

2'0MeAOs singly (Figure 5.7). This may indicate that adding low doses of 2'0MeAOs
that block each motif, rather than high doses of a 2'0MeAO which targets a single
splicing motif, may be preferable.
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Figure 5.7

Exon 19 skipping induced by targeting multiple sites with 2'0MeAOs. Singly

HM19A(+35+65) was transfected at 2nM, M19A(-20+05) at lOnM and M19D(+05-20) at lOnM. Alone,
each could barely induce exon 19 skipping but in combination the level of skipped product increased.
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SA Mismatched 2'0MeAOs
As one of the essential antisense controls, it WIIS necessary to investigate
potential nonspecific effects of2'0MeAO mismatches on the ability to remove er.on 19
from the mature transcript Unlike the exonic region bounded by HM19A(+35+65),

target sequence homology between the human and mouse genes was not conserved at
the acceptor and donor splice sites. This allowed some mismatched controls (Stein &
Krieg, 1994) when the 2'0MeAOs H19A(-2o+10) and Hl9D(+10-15) were tnmsfected
into mouse cells and Ml9A(-2o+<JS) and Ml9D(+OS-20) were transfected into the
human cells (Figure 5.2).
5.4.1 Human-specific 2'0MeAOs directed at mouse pre-mRNA
Hl9A(-20+10), the 2'0MeAO directed at the human intron 18 acceptor splice
site, extended 5 nucleotides further into the exon than M19A(-2o+-05)."H19A(-20+10)
differed from the mouse sequence by 3 nucleotides, one at the 3' end and the other two
at the penultimate and antepenultimate bases of the 5' end, thereby providing perfect
sequence homology between bases -19 and +07. The 2'0MeAO H19D(+10-15), which
is directed at the human intron 19 donor splice site, has 5 mismatches but is identical to
the mouse sequence from bases i-04 to --09 (Figure 5.2).
5.4.1.1 H-2KnormaJ muscle cells
Based on the previous experiments performed in these cells using perfectly
matched 2'0MeAOs, induction of mouse dystrophin e:rnn 19 skipping by human
specific 2'0MeAOs directed at the splice sites was predicted to be difficult to detect. As
shown earlier, persistence of the modified transcript is fleeting relative to the natural
mei;sage, due to the instability of the exon 19 skipped transcript through nonsense
mediated decay. Furthermore, the number of mismatches with the target sequence WIIS
expected to significantly decrease the 2'0MeAO's annealing potential. Consistent
with this ei1pectation, H19D(+I0-15) was not able to induce the removal of exon 19,
despite the donor site appearing to be the more 111Denable of the two splice sites to
2'0MeAO manipulation with the mouse-specific 2'0MeAO (Section S.2.1.1., Figure
5.8). However, exon 19 skipping was consistently detected in cells transfected with
Hl9A(-2o+10) at a final concentration of 600nM, and sporadically at a final
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concentration of 300nM. This could be due to the longer region (26 bases) of perfect
homology between this 2'0MeAO and its target region.
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Figure 5.8 Hum.an specific 2'0MeAOs directed at normal H-2K mouse pre-mRNA. Both 2'0MeAOs
were transfected separately at 600nM and 300nM and RNA extracted 24 hours later. RT-PCR analysis
across the region targeted by H19A(-20+ 10) could detect only a low level of exon 19 skipping.
H 19D(+ 10-15) was unable to induce the removal of exon 19 on every attempt.

5.4.1.2 H-2K mdx muscle cells
As observed earlier in the transfected mdx cultures, a higher level of the
dystrophin mRNA transcript missing exon 19 was detected relative to the full length
transcript. Despite the mismatches in the 2'0MeAO sequence, H19A(-20+10) was
occasionally able to induce exon 19 skipping in mdx cultures at a transfection
concentration of 50nM, but only consistently when delivered at lOOnM (Figure 5.12).
While H 19D(+ 10-15) could induce the sporadic and very weak excision of exon 19 at
several of the concentrations tested, it could not consistently induce skipping even at a
final transfection concentration of 600nM (Figure 5 .9).
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Figure 5.9 Agarose gel image of mismatched human 2'0MeAOs transfected into mdx mouse cells. As

observed in the normal cells, the acceptor site directed 2'0MeAO, HI 9A(-20+ I 0) was better able to
induce exon 19 skipping than H l 9D( + I 0-15), which targeted the donor splice site.

5.4.2 Mouse-specific 2'0MeAOs directed at human pre-mRNA

Two mouse-specific 2'0MeAOs, M19A(-20+10) and M19D(+05-20), were
tested in both primary human and HDMD cells. M19A(-20+05) was directed at the
mouse intron 18 acceptor splice site, extended 5 nucleotides less into exon 19 than did
H19A(-20+10) and differed from the human sequence by only the last 3' nucleotide,
thus providing 96% perfect sequence homology. M19D(+05-20) was the same length as
its human-specific homologue but extended 5 nucleotides further into intron 19 and had
7 mismatches.

5.4.2.1 Primary human muscle cells

Transfection of the primary human myoblasts with the mouse-specific
2'0MeAOs did not yield any unexpected results. Ml 9A(-20+05) induced a consistent,
low level of exon 19 skipped transcript of similar abundance to that induced by the
human-specific 2'0MeAO, H19A(-20+10), when delivered at a final concentration of
600nM. However, H19A(-20+10) was still able to induce sporadic exon 19 skipping
when transfected at 300nM, whereas the mismatched 2'0MeAO did not. It is difficult to
say at this point if it was the additional 6 homologous bases or the single nucleotide
mismatch in M19A(-20+05) that would explain the marginal difference in efficacy. No
skipping, specific or aberrant, was detected in the RNA from primary human cells
transfected with the seven base mismatched M19D(+05-20) even at a final
concentration of 600nM.
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Figure 5.10 Mouse-specific 2'0MeAOs transfected into primary human myoblasts. RT-PCR analysis

of the RNA extracted from human muscle cultures after separate 600nM transfections with either
M19A(-20+05) or M19D(+05-20). Only the 2'0MeAO directed at the acceptor site, M19A(-20+05),
could induce a detectable exon 19 skipped transcript.

5.4.2.2 HDMD muscle cells

Previous experiments in these cells with human-specific 2'0MeAOs directed at
the splice sites showed a similar but weaker pattern to that observed in the primary cell
line. This was also the case when the HDMD cells were transfected with the
mismatched 2'0MeAOs. The exon 19 skipped product induced by M19A(-20+05) at
600nM was less abundant and less reproducible than that seen in the unaffected primary
cell line, and M19D(+05-20) was never able to induce a detectable exon 19 skipped
transcript.
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5.5

Specificity of 2'0 MeAO action throughout the dystrophin

transcript
Additional tests to assess the disruption of splicing patterns in other regions of
the dystrophin transcript were undertaken using total RNA from 2'0MeAO treated mdx
cells which had previously shown exon 19 skipping. These regions included exons 1 to
10, 20 to 26 and 70 to 79. No other splicing patterns were consistently generated, other
than the removal of exon 19 (Figure 5.11 ).
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Figure 5.11 2'0MeAOs targeted to exon 19 do not alter dystrophin processing in other regions of the
gene transcript. Each lane represents RNA preparations pooled from 4 separate transfection experiments
in which the RNA had been extracted from either untreated or 2'0MeAO treated cultures shown to have
skipped exon 19. Apart from occasional sporadic alternatively processed transcripts (eg shorter product
in the untreated sample, exons 1-10), no consistent rearrangements in dystrophin processing were
detected. (Errington et al, 2003).
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5.6 Summary
Exon 19 skipping induced by splice site-dirccted 2'0MeAOs was precise and
very efficient. Transfection studies in H-2Knormal muscle cells revealed that the donor

site appeared to be a more wnenahle target for 2'0MeAO-induced skipping of exon 19.
In H-2K mdx cells, both Ml9A(-20+05) and Ml9D(+o5-20) were effective at
concentrations as low as lOnM. An attempt to refine the highly efficient Ml9D(+05-20)
by designing a smaller 2'0MeAO within the same region was not successful,

11!1

Ml9D(+02-18) proved to be less effective.
In primary human muscle cells transfection with the 2'0MeAO targeting the
donor site, Hl9D(+10-l5), required a minimum concentration of 200nM to induce
consistent exon 19 skipping. The 2'0MeAO targeting the acceptor site, Hl9A(-20+10),
was even less effective, requiring a concentration of 600nM to achieve the same effect.
A similar pattern was seen in HDMD myoblas15, with the donor site appearing to be a
better target than the acceptor for 2'0MeAO-induced skipping of exon 19.
Targeting multiple splicing motifs in H-2K mdx myotubes revealed that
targeting two motifs was more effective than just one, and that targeting the donor,
acceptor and ESE appeared to hPve a greater effect than the sum of that induced by all
three 2'0MeAOs individually.
Transfection of the H-2K normal and mdx muscle cells with the human-specific
2'0MeAO directed at the acceptor splice site was able to induce exon 19 skipping,
despite the three mismatched bases. Conversely, rhis effect could not be induced by
transfection of the mouse cells with the mismatched donor site-directed 2'0MeAO. The
same outcomes were observed with mismatched 2'0MeAO transfections in the human
"1IB.

Finally, a screen of several regions of the dystrophin gene transcript including
the 3' and 5' ends was underlllken. No other splicing patterns were consistently
generated, other than the specific removal of exon 19.
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5,7 Discussion
The acceptor and donor splice sites flanking exon 19 were evaluated 11.'1 potential
target.II for 2'0MeAO induced skipping of that exon. The efficient 2'0McAO-induced
skipping of dystrophin exon 23 by targeting the donor splice site has been reported
(Mann ct al., 2001; Mano ct al., 2002). Attempts lo remove that exon with 2'0McAOs
directed at the acceptor site have been unsuccessful, possibly due to secondary
structures in this region restricting accessibility of the 2'0MeAO to that tnrget.
Furthermore, additional skipping of adjacent exons was observed when the exon 23
donor splice site was blocked (Mann et al., 2001; Mann et al., 2002; Wilton et al.,
1999). It has been suggested that targeting inte~lli exonic motifs may result in more
specific exon skipping (van Deutekom et al., 2001). By targeting 2'0McAOs to the
splice sites of exon 19, it was possible to compare the efficiency and specificity of
skipping induced to that induced by targeting the ESEs.
5.7.1 Exon 19 skipping in H·2K mouse muscle cells

In H-2K normal and mdx alls the 2'0McAO Ml9D(+05-20), directed at the

donor splice site of exon 19, appeared to consistently induce more exon 19 skipped
transcript than M19A(-20+0S), which was directed at the acceptor splice site. It is
Important to note that the skipping observed with either 2'0MeAO was reliable and
precise. Compared to theH-2K normals, skipping was consistently stronger in the mdx

cells, again most likely due to the relative rates of tum over of the natural and exon 19
skipped products In the two cell lines (Maqirat, 1995).
In an attempt to refine the donor splice site motif, the 20mer Ml9D(+02-l8) was

designed within M19D(+0S-20). An 2'0MeAO, M23D(+02-18), directed to the
corresponding bases of exon 23, had improved the efficiency of skipping compared to a
2Smer targeting the same region (Mann et al., 2002). However, this effect was not
observed when exon 19 was targeted, as the shortened product was considerably less
abundant than that induced by M19D(+OS-20). The T,. of a duplex decreases as its
length decreases (Agwwal, 1992; Crooke, 1999). This may account for the lower
activity of the shorter M19D(+-02-18) relative to the parent 25mer, through a reduction
in affinity to the tafget sequence or less effective competition with splicing factors.

However, this does not account for the difference in the level of activity between
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Ml9D(+02-18) and M23D(+02-18). It is possible that the five bases no longer
obstructed by M19D(+02-18) were important for exon 19 donor splice site fwiction, or
perhaps that secondary structures played a comparatively more significant role in
accessibility of the exon 23 donor splice site. Interestingly, the G/C content of the
sequence targeted by M23D(.+02-18) was 60%, twice that ofMl9D(+02-18) at 30%. As
the annealing temperature increases with G/C content, this may also have contributed to
the higher efficiency of the exon 23-directed 20mer.

!!.7.2 Exon l'hklpping In human muscle cells
In the primary human cells, neither 2'0MeAO targeting the spl!ce sites of exon
19 induced very efficient skipping. The donor site-directed H19D(+I0-15) did induce
precise removal of exon 19 but at higher concentrations than required in mouse cells. A
similar pattern was observed in HDMD musc_le cells, in that the exon 19 skipped
ttanscript induced by the 2'0MeAO targeted to the donor site was of greater abundance
than Iha! induced by the 2'0MeAO targeted to the acceptor site. In both cases, although
the skipping of exon 19 was precise and specific, it was significantly weaker than that
observed in either the primary human cells or the mouse cells. Compared to the primary
cells, the rela.tive rates of transcript turnover should result in the exon 19 skipped
transcript being easier to detect in the HDMD cells. All this was not reflected in the
results, it appears that transfection efficiency may have been a limitation in these cells.
Thei.e are several possible explanations for the differences in efficiency of exon
19 skipping observed in the human and mouse cells. It could be that the splice sites are

less significant lo exon 19 inclusion in humans, pelhaps relying more on the activity of
ESEs or other splicing enhancers. However, the similarity of exon 19 splice site
strengths between human and mouse (Senapathy et al., 1990), and the results of
2'0MeAOs targeting ESEs in eJton 19, suggest that this is unlikely (Section 4.5.2).
Another possible reason is that secondary structures in these regions may differ between
the species, which could influence accessibility to the splice sites (Crooke, 1999; Dagle
& Weeks, 2001). Additionally, it is not known whether there are differences in the

general splicing machinery between mouse and man which may have an effect on
competition for the targeted site. However, as transfection of the human cells was
observed lo be less efficient than that of the mouse cells (Section 4.1.2), limitation in
delivery of the 2'0MeAO is again the most likely reason for the difference in abundance
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of induced transcripts detected in the two species. While it has been demonstrated that
the targeting of splice sites with 2'0MeAOs is a feasible approach to the specific
modification of splicing in human cells, further optimisation of transfection conditions,
including the evaluation of additional reagents, may result in improved efficiency of
exon skipping.
5.7.3 Targeting multiple sites
Targeting either the ESE or the splice sites of dystrophin eii:on 19 resulted in
similarly effective 2'0MeAO-induced skipping in H-2K mdx cells. However, a study
targeting the same motifs of eii:on 23 demonstrated significantly disparate results, as
neither the acceptor splice site nor an ESE-like motif proved to be amenable to
2'0MeAO-induced exon skipping (Mann et al., 2001; pers. comm, C. M1mn).
Furth,)nllore, a study by Ito and colleagues (2001) investigated the eii:tent to which
in1emal exon sequences in three dystrophin exons influence splicing and how they
compare to the 3' conselll!us splice sites of these exons. The significance of each of
these motifs to splicing varied between exons,. and there appeared to be no obvious
relationship between splice site strength and the presence of ESEs (Ito et al., 2001).
Based on the results of these studies, it is highly likely that more thwi one motif may
need to be targ~ted to achieve efficient exon skipping if there is not a predominwit
strong or controlling site. wid it may be difficult to predict which motif to target based
only on the strength of the corn;ensus splice site sequences. It has been reported that
targeting a combination of splicing motifs, such as both splices sites, can improve the
efficiency of skipping (De Angelis et al., 2002).
This approach was tested in H-2K mdx mouse muscle cells, as the results of the
previous chapter suggested that this cell line may represent a better molecular model for
determining the efficacy of 2'0MeAO-induced skipping in the dystrophin gene than the

other models evaluated. The 31mer HM19A(+35+65), and the two splice site-directed
25mers, Ml9A(-20+0S) and Ml9D{+o5-20), were transfected into H-2Kmdx myoblasts
in each of the four possible combinations. Each combination of two 2'0MeAOs induced

an exon 19 skipped transcript of higher abundance than that induced by individual
2'0MeAOs, consistent with the findings of De Ange!is et al. (2002). Of these
combinations, that of the two 2'0MeAOs directed to the splice sites appeared to induce
the most effective removal of eii:on 19. However, the combination of all three
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2'0MeAOs resulted in a significant increase in the abund.wce of the CJ:on 19 skipped
product compared to the paired combinations, and at a fmal concentration of only
22nM, The abundance of this shorter product was similar to that induced by each of the
three individual 2'0MeAOs at final concentrations of SOnM. This suggests that adding
low doses of 2'0MeAOs to block each motif rather than high doses of a single
2'0MeAO may be preferable, particularly 1 ince it may result in a lower level of cell
damage associated with the transfection reagent used. This approach may be
particularly useful when excluding CJ:OllS which prove resistant to 2'0MeAOs targeting
a single motif.
5.7.4 Effects of mismatched 2'0MeAOs In mouse and human ~lb

Mismatched AOs represent a useful control for the demonstration of target
hybridisation specificity through changes in both composition and secondary structure
(Stein & Krieg, 1994). Homology between the human and mouse sequence at the
acceptor and donor splice sites is not maintained, thereby allowing mismatched
2'0MeAOs to be evaluated between species. Two human-specific splice site-directed
2'0MeAOs were transfected into mouse cells. Although the three mismatches within
HI9A(-20+10) appeared to reduce its binding affinity (as indicated by the increasOO
2'0MeAO concentration required to induce consistent skipping of e;,;.on 19), the 26
consecutive homologous bases were adequate to induce consistent skipping at a final
concentration of 600nM. As there were three mismatched bases at the ends of
H19A(-20+10) (Figure 5.2), they would not have destabilised the duplCJ: to the same
degree as would be CJ[pected to result from the presence of internal mis!lllltches (Woolf,

Melton & Jennings, 1992).
The fact that a 26 base sequence successfully hybridised to the mouse
pre-mRNA despite three flanking mismatches is not a partk:ular concern, as a specified
sequence 26 nucleotides in length is unlikely to occur more than once in the human
genome (Agrawal, 1992; Branch, 1996). However, as the lc:011;th of a 2'0MeAO
increases, there is a seemingly paradoxical decrease in specificity. This is because
longer 2'0MeAOs contain many nested internal sequences of sufficient length to
hybridise to non-targeted pre-mRNA sequences (Stein, 2001; Woolf et al., 1992). It has
been demonstrated in Xenopus oocytes that sequences as short as 10 bases can cause
antisense effects (Woolf et al., 1992), and even the I2mer evaluated in this study,
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HM19A(+46+57),

//

WB..'l

able to induce comistent exon 19 skipping, In addition,

H19D(+IO-IS), with five mismatches to the analogous mouse sequence and only 13
bases of straight homology, was able lo induce exon 19 skipping, albeit sporadic and
wellk, at 600nM, This was despite having mismatches more intemal lo the 2'0MeAO
compared lo Hl9A(-2o+IO), The fact that the donor site appeav; to be more amenable
to 2'0MeAO activity may have contributed to the level of skipping induced by the

mismatched 2'0MeAO. It has been estimated statistically that a specific 13 base
sequence may occur over 40 times in the human genome (Bra,,1ch, 1996). Based on
these results, it is theoretically possible that the 30mer Hl9A(-2o+IO) could hybridise
with a number of unintended sites, although the s~ondacy structures of these regiom
would be expected to differ from that of the intended target. It has been demonstrated
that the structure of mRNA has a significant effect on antisense activity (Vickers, Wyatt
& Freier, 2000), and that variations in accessibility will result in some mRNA

sequences being more susceptible lo non-specific hybridisation than others (Branch,
1996), which may be the case for the donor site of exon 19. It is unknown how many
flanking mismatches would be required to sufficiently alter secondacy conformation of
the 2'0MeAO or to reduce binding affinity such that non-specific hybridisation would
be avoided,
A similar pattern was seen in the human cells transf~ted with two mousespecific 2'0MeAOs. Ml9A(-20+-0S), with only one mismatch and 24 bases of straight
homology, consistently induced exon 19 skipping at 600nM in human cells. Not
unexpectedly, this mismatched 2'0MeAO proved almost as efficient as the human
specific 2'0MeAO, H19A(-2o+I0). It is difficult to discern whether the marginal
decrease in efficacy observed with the mismatched 2'0MeAO would be due to the
single mismatch or the decreased length of the 2'0MeAO, at 25 rather than JO bases.
Ml9D(-+OS-20), with 7 mismatches and 13 bases of straight homology, did not induce
exon 19 skipping in human cells, even at a final concentration of 600nM. This
2'0MeAO had the same number of internal cons~utive homologous bases but two
more mismatches with the human sequence compared to Hl9D(+10-15) when directed
against mouse cells. It is possible that the lack of 2'0MeAO activity in the human cells
could be due to the secondacy structure alterations induced by the additional two
mismatches; however, as tmnsfection conditions appeared to be a limiting factor in
these cells, it was expected that any skipping induced would be weaker in comparison to
that observed in the H-2K mdx cells. Determining the relative contribution of these
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factors would require further evaluation of the effects of number and position of
mismatches in 2'0MeAOs of various ler.glhs.
The mismatched 2'0MeAOs were demonstrated to have a reduced annealing
potential, reflecting their weakened biological function, and supporting the conclusion
that their effect is mediated by a true antisense mechanism (Stein & Krieg, 1994).
Additionally, these data demonstrate that the high 2'0MeAO concentrations (:!lµM),
often used in other studies, may have the potential for the non-specific removal of
untargeted exons in other genes that contain splicing motifs homologous to small
slretches within the 2'0MeAO. The fact that some skipping was induced, despite the
presence of mismatched bases, is a safety concern for non-specific effects. These results
highlight the importance of optimising 2'0MeAOs so that lower concentrations can be
used, thus reducing the likelihood of non-specific effects.
S.7.5 Spedftdty or 2'0MeAO action throughout tbe dystrophln lransl:rlpl
To evaluate the spedficity of antisense effects to the targeted region of the
dystrophingenc, RT-PCR was perfonned across exons 1-10, 20-26 and 70-79 on pooled
RNA samples extracted from 2'0MeAO-treated and untreated cultures. Four
2'0MeAOs were selected for evaluation: HMl9A(+35+6S), HM19A(+46+6S),
HMl9A(+S2+65) and Ml9D(+o5-20). For each of the 2'0MeAOs, it was demonstrated
that exon 19 skipping was absolutely specific to the target sequence, at least in the
target gene el8Jilined here. There was no loss of adjacent exons, and splicing patterns
elsewhere in the dysttophin gene transcript did not appear to be altered by the lrelltmenl
Although this does not proolude the possibility of non-specific activity elsewhere in the
genome, these results are encouraging. AJJ the 3lmer, HM19A(+35+65), and the 2Smer,

Ml9D(+o5-20), are significantly longer than ·the 16 to 20 bases recommended to
minimise non-specific effects (Stein, 2001), there is the concern that these longer
2'0MeAOs will contain multiple short sequences capable of non-specific hybridisation
(Stein, 2001; Woolf et al., 1992). However, this effect was not observed in the regions
of the dystrophingene included in this assay. The 14mer, HM19A(+52+6S), Wll!I shorter
than the recommended length, as a specified sequence of 14 nucleotides would be
expected to occur more than once in the human genome (Agrawal, 1992; Branch, 1996).
Although it is possible that this 2'0MeAO would be capable of annealing to sites other

than the intended target, this was not observed in other regions of the dr,;trophin gene.
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Although thia 115say screened only certain regiODS of the dyslIOphin mRNA, the

·:; t\ .-· . . -·positive results indicate the reduced likelihood that these 2tOMeAOs would induce
;_;): }),.\·.\. 11.~~specific effects, and strengthen the observailon that targeting the dysttophin exon

·i:'.~t>.Y:d,,'.19~pli~sitcs pn>duces lhe same high degree ofspecifidty as targeting the ESE.
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Chapter 6 - Results from targeting exon 46
Van Deutekom and colleagues reported the 2'0MeAO-mediated removal of
dystrophin exon 46 from the gene transcript in both mouse and human myotubes (van
Deutekom et al., 2001). They proposed that 2'0MeAO-induced skipping of this exon
would restore the reading frame in -7% of patients with DMD. Furthermore, their work
demonstrated that at least 75% of 2'0MeAO-transfected DMD patient myotubes were
expressing correctly localised dystrophin as a result of the removal of exon 46. The
study by van Deutekom et al. (2001) directed a series of overlapping 2'0MeAOs at
polypurine-rich exonic regions, but omitted targeting the splice sites. We considered it
would also be important to assess exon 46 splice sites as possible targets for 2'0MeAOs
to compare the efficiency of re-directing splicing.

6.1 Quality assay of 2'0MeAOs directed at exon 46
Prior to myotube transfection, all exon 46 directed 2'0MeAOs were subject to
quality control assessment. As described earlier, approximately 200ng of each
2'0MeAOs was electrophoresed through a denaturing polyacrylamide gel (Figure 6.1 ).
Only 'in-house', Expedite 8909 (Applied Biosystems) synthesised 2'0MeAOs were
used in this part of the study and all were found to be of a sufficiently high quality to
proceed to cell transfections.
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Figure 6.1 Each 2'0MeAO targeting exon 46 was run on a denaturing polyacrylamide gel to assess the

standard of synthesis. As apparent yields varied, 2'0MeAO concentrations were adjusted prior to
transfection.
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ti.2 Transfection or primary human cells with 2'0MeAOs directed at

exon 46
Initial experhnents attempted to reproduce the results of van Deutekom et al.
(2001) and, as such, all procedures outllned in that study were adhered to. The
2'0MeAO hAON 8 (nomenclature used by van Deutekom et al.) was, however,
renamed H46A(+11S+l34) (Figure 6.2 and Table 3.2) according to our nomenclature
system (Mann el al., 2001), and selected as the first 2'0MeAO to be evaluated. Exon 46
skipping was reported to be most efficient when targeting this region in both nomial
and dystropbic human cells. In addition, we designed another 20mer 2'0MeAO,
H46D( +-02-18), to anneal to the donor splice site of exon 46 to allow comparison of the
motifs as 2'0McAO-induccd exon skipping targets. A 1:1 mixture of the two
2'0McAOs was included in the assay to assess any combined effect, and an exon 19
2'0McAO, HMl9A(+35+6S), was included as an experimental positive control.
Primary normal human ocils were seeded onto collagen coated plates and
allowed to differentiate into myotubes over 12 days in a low-serum (5% horse seJUlll)
medium. Transfections were conducted in the absence of serum for 3 hours after
complexing 2'0McAOs at a fmal concentration of lOOOnM with ExGen 500 at 3.Seq.
At 24 hours post-transfcction, total RNA was extracted from the myorube cultures and
purified. RT-PCR was perfonncd on IOOOng of RNA using human dystrophin specific

primers, cncomp11S11ing exons 17 to 21 and exons 44 to 47, to screen for the skipping of
cxons 19 and 46 respectively. After a secondary round of PCR amplification, the
fragments were separated on a 2% agarose gel and viewed by UV b'anSillumination.
Under these conditiom, we contd not detect the removal of exon 46 from the mature
transcript (da!a not shown), However, the transfection positive control,
HMI9A(+3S+65), was able to induoc exon 19 skipping at a level achieved in previous
experiments (refer to Figure 4.11).
A further series of experiments were performed in which various experimental

parameters were addressed sequentially. Firstly, the substrate collagen was substituted
for matrigcl, a well established ocll attachment substralC. Also, the time for myorube
differentiation was varied between 4 and the reported 12 days. In addition, Lipofeetin
and Llpofcctaminc 2000 were tested as 2'0MeAO delivery reagents and the 2'0McAO

final transfection concentrations were also varied to maximise ocll survival.
Furthermore, RT·PCR conditions were adjusted, where various amounts of RNA were
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used as template to minimise possible carry-over of Inhibitory contaminants from the
, RNA extraction procedure. The standard Titan one tube RT-PCR reaction kit was also

used to compme reverse transcription capabilitiC!l, Under no circumstances wu exon 46
skipping detected, whcrcu the positive control HM19A(+3S+6S), delivered at a final
concentration of 300nM with any transfection reagent, was consistently able to induce
exon 19 skipping.

6.3 Attempting exon 46 removal wi~ 5eCOnd gelieradoll 2•0MeA~
li.J.1 RNA binding assay (RDA)

Based on the failure of the initial ·experiments to induce exon 46 skipping, an
assay to assess DNA AO (dooxy-AO) binding to its target RNA was designed. Briefly,
a 413 base T7 transcribed RNA fragment (li:agmcnt 1). containing the desired target
sequence.was placed into a hybridisation reaction with a deoxy·AO (sec Section 3.6) for
30 minutes at 37°C and separated on an 8% polyacrylamidc gel for 3 hours.
Hybridisation of the deoxy-AO to the target RNA sequence was assessed by
visualisation of the SYBR gold stained complexes by UV transillumination. The
efficient annealing of the deoxy-AO to the RNA fragment should induce a
confonnatiooal change, resulting in altered migration of the complex through the
,polyacrylamidc gel, relative to the unbound RNA. The resultant separation of the two
,species was visualised u two bands, where the duplex band was 'shifted' from the
unbound RNA band. To dctcmrlne the most amenable targets by this assay, a titration of
'each dcoxy-AO against a constant SOng of RNA was performed, The deox:y-AO that
. was still able to induce a bandshift which scored uating of at least 2, (figure 3.2) when
added at Sog per reaction, was deemed suitable for synthesis u a 2'0MeAO.
A total of 14 deoxy-AOs were tested in this fashion: five targeting regions
within cxon 46, four targeting the acceptor site and five targeting the donor site. Of the
cxonic deoxy·AOs, three were directed at regions targeted by van Deutekom ct al.
(2001) and two were dircctcd at other motifs (Figure 6.2), Results of the RDA for all 14
deoxy-AOs msummartsed in Table 6,1,
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Intron 45

Exon 46

Intron 46

,. cttctttctccagGCTAGAAGJ,..I\CAA.AAGAAT.?\TCTTGTCAGAATTTCAAAGAGATTTAAATGMTTTGTTrTATGGTTGGAGGMGCAGATMCAT'!'GCTAGTATCCCACTTGAACCTGGAi\JJIGAGC.i\GCAACTA.~A.GW.?\GCT'!'GAGCAAGTCAAGgtaattttattttctcaa l'

---d!i46A{ - :N7)----

---d~~6A {-: 1-09) ------d.'i46A {- 09· ~) -- --

---dll 6A (- 2H7) ----

---dH46A (-63+82 ) - ---

---dil4 6J (+02- !8 ) ----

---dH46A !-83•i03)----

--dH4 6A (-115- :34 ) ---

-·-df'.4 6J I •04-16) ----

---dH4 6D (• 06-14 )----

---d~46A {- 07• :3)------dH~6 (•08-' ~)----

Figure 6.2 Schematic illustration of annealing sites for deoxy-AOs to a section of the 413 base human dystrophin RNA fragment including exon 46. The cxonic sequence is in
upper case and the intronic sequence am in lower case (sequences arc given 5' - 3'). The annealing sites arc indicated by the broken lines nanking the dcoxy-AO. The deoxy-AO ,
dH46A(+63+82), dH46A(+I I l+l 25) and dH46A(+ 115+ 134) arc DNA versions of the 2'0McAOs described by van Dcutckom, ct al. (2001 ).
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6.3.1.1

Deoxv-AOs directed at !he exon 46 ESE
Of the five dcoxy-AOs directed at motifs within exon 46, three were selected

from the 2'0MeAO versions used by van Deutekom et al. (2001), We designed
dH46A(i63+82), dH46A(+ll1+I25) and dH46A(+ll5+134) based upon the levels of
efficacy reported for the 2'0MeAO homologues by van Deutekom and colleagues using
two different tests, the 'gel mobility shift assay' and myotube transfection. This group
reported that each of the 2'0MeAOs displayed a high affinity for radiolabelled exon 46

targets when evaluated using the gel mobility shift usay; an RNA:2'0MeAO binding
afrmity test similar to our RNA binding assay. However, the reported protocol (van
Deutekom et al., 2001) involved radiolabelling of the RNA fragment before the addition
of the 2'0MeAO. The second assay was lhe standard transfection of human myotubes
with the 2'0MeAOs at a final dose of IOOOnM. In their study, H46A(+63+82) and
H46A(+115+134) were reported to induce exon 46 skipping with the skipping
efficiency induced by H46A(+ll5+134) being reproducibly highest. H46A(+ll 1+125),
however, did not induce exon 46 skipping despite its apparent high affmity for the
radiolabelled RNA in the gel mobility shift assay. In our study, an additional two
deoxy-AOs, dH46A(+28+47) and dH46A(+B3+103), were designed to target exonic
regions which had not been previously evaluated.
Two different lllllOunts of each of the five deoxy-AOs, 200ng and Sng, were
added to 50ng of the 413bp human dysttophin mRNA fragment spanning exon 46. At
200ng, dH46A(+63+82), dH46A(+B3+103) and dH46A(+lll+125) all induced
bandshifts with ratings of approximately 4. At the same concentration, dH46A(+28+47)
was able to induce a bandshift with a rating of only 2. Surprisingly, dH46A(+ll5+134),
the reportedly most efficient 2'0MeAO (van Deutekom et al., 2001) was apparently
unable to bind to its RNA target, although it is possible that it did anneal but did not
result in a conformational change such that a bandshift was induced. Furthermore,
H46A(+ll5+134), the 2'0MeAO used in the initial cell transfection uperiments, was
retrospectively tested in the Sllllle manner. This 2'0MeAO also did not appear to anneal
to the target, based on the lack of bandsbift, possibly indicating a limitation in the
predictive ability of the assay.
At Sng, dH46A(+63+82), dH46A(+83+103) and dH46A(+lll+l25) each
demonstrated a high affinity for the RNA target with bandshift ratings of 3, 2, and 2
respectively. dH46A(+28+47), however, did not achieve a bandshift at this lower
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concentration (Table 6.1), Based on these results, dH46A(+63+82) was selected for
synthesis as a 2'0MeAO for subsequent tr11D11fection into the nonnal primary human
muscle cells.

6.3.t.2 Peoxy-AOs directed at the exon 46 ~Hee sites
Annealing experiments with the deoxy-AOs directed at the exon 46 splice sites
indicated that the acceptor site for this CJ:On may be the more amenable of the two for
2'0MeAO binding. A bandshift rating of 2 Was induced by dH46A(-I3+o7) ll!ld
dH46A(-07+ 13) while dH46A(-Ut-09), dH46A(-09+11) coold only achieve a bandshift
· rating of 1 (Table 6.1). Based on the fact that dH46A(-07+13) was the only deoxy-AO
to induce a blllW!lhift with a rating of 4 at 200ng, it was selected for synthesis as a
2'0MeAO for subsequent evaluation in cell culture.
The donor splice site was deemed a poor target for 2'0MeAO-induced exon
removal as only two deoxy-AOs were able to induce a bandshift. When 5ng of these
deoxy-AOs, dH46D(i-06-14) and dH46D(+08-l2), were added to the lal'get, each was
only able to induce a bandshift which rated less than 1 (Table 6.1).
6.3.1.3 ESE- and donor- directed deoxy-AOs targetinK a shorter RNA fragment
A second smaller RNA fragment (fragment 2) was designed to determine if the
length of the RNA fragment was a factor in allowing access to lhe target sequence by
the less effective deoxy-AOs. This could partly account for the difference in RNA
binding ability observed between the deoxy-2'0MeAO, H46A(+ll5+134), evaluated in
this study and the 2'0MeAO tested by van Deutekomet,al. (2001). Fragment 2 was 286
bases long and did not include the 127 bases of 5' sequence in fragment 1. Due to the
promising results obtained with the deoxy-AOs directed at the acceptor site, we decided
to truncate the 5' end entirely, rather than remove sequence from both ends.
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6.3.1.3.1 Deoxy-AOs directed at the ESE
Although Sng of dH46A( +63+82) was able to induce a similar level of bandshift
when annealed to fragment 2 as compared to that induced when annealed to fragment 1,
a dramatic increase in deoxy-AO-induced handshift was observed for
dH46A(+115+134). Where previously no shifl could be detected when 200ng was
added to fragment l, Sng of dH46A(+115+134) added to fragment 2 induced a
band~hift with a rating of 3. However, as already shown, this result did not correlate
with the initial transfection experiments, emphasising the possibility that the modified
secondary or tertiary structures formed in this system may not provide a realistic
indication or !he situation in cells. This is not surprising as this In vitro binding assay
Jacks the muscle specific nuclear proteins present in vivo, and the target RNA transcript
is not being continually tmnscribed as would be found In vivo. No significant difference
was induced by Sng of dH46A(+BJ+IOJ) using fragment 2 as wget, where a bandshift
rating of 2 was achieved compared to the same rating with fragment 1. Hybridisation of
200ng or the deoxy-AO dH46A(+28+47) to the wget sequence could induce a
bandshift which rated 2 but Sng produced no detectable shift, indicating that access to
this region may not be possible in the system due to secondary or tertiary
confonnations.
Ci.3.1.3.2 Deoxy-AOs directed at the donor splice Site
The donor splice site on fragment 2 also appeared to be a poor target.
H46D(+02-l8), (a 2'0MeAO), dH46D(+04-I6) and dH46D(+08-l4) each failed to anneal
lo their respective targets, even when added at 200ng. However, while a bandshift was •

evident when either dH46D(+06-I4) or dH46D(+08-l2) were added to fragment 2 at
200ng each, both appeared to induce bandshlfts which rated less than 1 when added at Sng.
This degree ofbandshift still falls well below the bandshift rating of 2 arbitrarily selected
for a deoxy-AO to progress to subsequent evaluation in cell cultum.
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Table 6.1

Estimated amounts of RNA fragment bound and induced to 'shift' due to a

conformational change, given as a rating, where O represents no bandshift and 4 represents a
complete bandshift (Figure 3.2).

Bandshift rating after exposure to varied
amounts of deoxy-AO(ng)
deoxy-AO tested

Fragment 1 (413nt)

Fragment 2 (286nt)

200ng

5ng

200ng

5ng

dH46A(-13+07)

3

2

-

dH46A(-11 +09)

3

1

-

-

dH46A(-09+ 11)

3

1

-

dH46A(-07+13)

4

2

-

-

dH46A(+28+47)

2

0

2

0

dH46A(+63+82)

4

3

4

3

dH46A(+83+103)

3

2

4

2

dH46A(+ll 1+125)

4

2

4

2

dH46A(+ 115+134)

0

0

4

3

dH46D(+02-18)

0

0

0

0

dH46D(+04-16)

0

0

0

0

dH46D( +06-14)

3

1

0

0

dH46D(+08-12)

3

1

0

0

dH46D(+08-14)

0

0

0

0

6.3.2 Exon 46 skipping in primary human muscle cells

Primary normal human cells were seeded on to matrigel coated plates and
allowed to differentiate into myotubes over 4 days in a low-serum (5% horse serum)
medium. A parallel series of myotube transfections were conducted in the absence of
serum for 3 hours, after complexing the second generation 2'0MeAOs at a final
concentration of lOOOnM with ExGen 500 at 3.5eq or with Lipofectin at 2:1
(weight:weight). At 24 hours post-transfection, total RNA was extracted from the
myotube cultures. Reverse transcription was performed on 1000, 200, 50 and 5ng of
RNA followed by 30 cycles of amplification across dystrophin exons 19 or 46 using
human specific primers. After a secondary round of PCR amplification of 25 cycles, the
cDNA transcript fragments were electrophoresed through a 2% agarose gel and viewed
by UV transillumination. Dystrophin exon 46 skipping was induced at marginally lower
levels compared to that reported by others (Aartsma-Rus et al., 2002; van Deutekom et
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al., 2001). However, the very weak and inconsistent exon 46-deleted transcript
fragments were detected in the mRNA ofmyotubes transfected with H46A(-07+13) and
H46A(+63+82) and complexed with Lipofectin but not ExGen 500 (Figure 6.3).
Furthermore, RT-PCR using 50 and 5ng of RNA template provided the only detectable
dystrophin exon 46-skipped transcript fragments observable as a 478bp product, 148bp
shorter than the 620bp full length transcript fragment generated across exons 44 and 47.
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Figure 6.3 Agarose gel image demonstrating a very weak 478bp product corresponding to dystrophin
exon 46 skipping. Only H46A(-07+ 13) and H46A(+63+82) were able to induce the removal, albeit
inconsistent, of exon 46 at a final transfection concentration of 1OOOnM and complexed with Lipofectin at
2:1. The positive control, HM19A(+46+65), was able to induce exon 19 skipping when delivered
complexed with either Lipofectin at 2: 1 or ExGen 500 at 3 .5 equivalents.

Confirmation of the identity of both amplicons was established after isolation
and direct sequencing of each product (Figure 6.4). H46A(+115+134) was unable to
induce exon 46 removal that could be detected by our assay. Furthermore, such was the
inconsistency of exon 46 removal that subsequent experiments involving transfection of
2'0MeAO combinations such as H46A(-07+13) with H46A(+63+82) or H46A(-07+13)
with H46A(+115+134) were unable to reproduce the removal of exon 46. However,
HM19A(+46+65), a second generation 2'0MeAO targeting exon 19, was able to induce
the consistent removal of exon 19 under every condition tested (Figure 6.3) indicating
that there should be no limitation in delivery of the 2'0MeAO to the cell nucleus.
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Figure 6.4 DNA sequence chromatogram of the PCR products spanning the junction of dystrophin exons
45 and 47, indicating precise removal of exon 46. The junction of exons 45 and 46 and exons 46 and 47
are shown for comparison.

6.4 Summary
Skipping of exon 46 in primary normal human cells proved difficult. The RBA
was limited in its ability to identify amenable sites for 2'0MeAO annealing and activity.
Very weak and inconsistent exon 46 skipping was seen in normal primary human
myotubes transfected with H46A(-07+13) and H46A(+63+82). No skipping was
observed following transfection with H46A(+ll5+134), and combinations of these
three 2'0MeAOs were ineffective in increasing the level of exon 46 skipping. The
transfection process was excluded as a limiting factor, as an exon 19 positive control
2'0MeAO was successful in inducing exon 19 skipping under the same conditions.
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6.S Discussion
2'0MeAO-induced exon 46 skipping had been reported by van Deutekom et al.
(2001), and was attempted in this study using the 2'0MeAO reported as being the most
efficient. In addition to this 2'0MeAO which targeted a putative ESE, a new 2'0MeAO
directed at the donor splice site was evaluated to provide a comparison of the two
motifs, Despite following the same protocol utilised by van Deutekom et al. (2001),
exon 46 skipping was not induced with either 2'0MeAO. The same group repeated this
experiment in a later study, using an identical protocol, with less efficient skipping of
exon46 reported (Aartsma-Rus et al., 2002). In the current study, an 2'0MeAO directed
at the =n 19 ESE was included as a positive control, and was able to induce exon 19
skipping, which suggested that the limitation was not in the transfection process.
Attempts to identify a limitation in the protocol by modifying each varinble, from type
of cell attachment substrate to the amount of RNA template in RT-PCR, were
unsuccessful.
At this point an assay was implemented to test the potential of a 2'0MeAO to
anneal to its target sequence. This was to facilitate the screening of a huger nwnber of

potential 2'0MeAOs using PCR grade DNA homologues (deoxy-AOs) against RNA
fragments. Such screening is desirable because the testing of multiple oligonucleotides
(20 - 50) in cells is usually required for the dillcovery of just a few active antisense
sequences (Lebedeva & Stein, 2001; Matveeva et al., 1998). Deoxy-AOs are less
expensive to synthesise because they do not require the chemical modifications
necessary lo protect 2'0MeAOs from nuclease degradation in the cellular environment.
A 11iinilar assay was employed by van Deutekom et al. (2001) to detect bound
and unbound RNA. In their study, the shift induced by the deoxy-AOs that had bound to
a radiolabelled RNA fragment was detected, whereas in this report the gel was simply
stained with SYBR gold. Fourteen deoxy-AOs were tested by this method, three of
which, H46A(+63+82), and H46A(+lll+l25) and H46A(+ll5+134), were the
2'0MeAOs reported as showing a high affmity for the radiolabelled exon 46 RNA
fragment in the study by van Deutekom and colleagues. The other 11 deoxy-AOs were
spread across two more regiOD!I within exon 46 and the acceptor and donor splice sites.
Furthermore, the annealing potential of these deoxy-AOs was evaluated using
two different length RNA fragments to assess deoxy-AO access to different length
RNA. The two fragments used, at 413 and 286 bases long, were both longer than the
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164 base fragment used by van Deutekom et al. (2001). As the confonnation of the
fragments could be different, it was necessary to detemune if the length of the RNA
fragment was a factor in allowing access to the target sequence and hence the difference
obSm'ed between the deoxy-AOs lrialed in this study and those used by van Deutekom
and colleagues. Significant differences were found between the two fragments for
several of the deoxy-2'0MeAOs (Table 6.1), confirming that fragment length can affect
the ability nf a deoxy-AO to anneal, presumably through alterations in secondary
structure. It was considered likely that the shorter fragment would less accurately reflect
In vivo conditions, and

it is probable that even the longer fragment would be insufficient

to mimic secondary structures existing in full-length RNA. A further consideration is
that synthetic assays lack certain significant features of the cellular environment, such
as hnRNPs or other splicing factors (Matveeva et al,, 1998; Moore, Query & Sharp,
1993), which could affect binding of the 2'0MeAO through competition for the target
site.
Of the 14 deoxy-AOs directed against splicing motifs in the long RNA fmgment,
the two which demonstrated the strongest affinity to their targets, dH46A( +63+82) and
dH46A(-Ut07), were then synthesised as 2'0MeAOs for subsequent evaluation in cell
culture. Interestingly, 200ng of dH46A(+l1S+l34) apparently failed to induce a
detectable bandshift in every trial, despite being the DNA homologue nfthe 2'0MeAO
which induced the strongest exon 46 skipping in the study by van Deutekom et al.
(2001). However, when tested against the second smaller RNA fragment, as little as Sng
of dH46A(+l1S+l34) was able to induce a bancfahift, This highlights the potential
effect of fragment length on the ability of a deoxy-AO to anneal to its target, and
therefore the importance of fragment length on the validity of the RBA as a predictor of
2'0MeAO activity.
Another interesting finding was that the two donor site-directed deoxy-AOs,
dH46D(+06-l4) and dH46D(+o8-l2), appeared to a1U1eal to their targets while
dH46D(+o2-I8) and dH46D(+o4-16) did not, despite targeting regiowi only two or four
bases further into the intron. In additioo, dH46D(+08-14) also did not appear to induce a
bandshift, despite incorporating the sequences targeted by the two deoxy-AOs,
dH46D(+o6-l4) and dH46D(+o8-l2), which had successfully induced bandshifts,
While secondary structure of the fragment may have played a role, particularly with the
downstream deoxy-AOs, it is also possible that the apparently W1Successful deoxy-AOs
did anneal to their targets but that this hybridisation did not result in a confonnational

113

Clmpter 6 -Results from tllrgeting e~on46

chang11 sufficient to induce a bandshift. For this reason, RNase H digestion assays may
be a useful adjunct to the RBA in predicting the ability of a 2'0MeAO to anneal to its

target, in that this method does not rely on conformational change to detect binding of
the deoxy-AO (Matveeva et al., 1998).
In evaluating the three selected 2'0MeAOs in cell culture (the two chosen as a

result of the RBA as well as the original H46A(+ll5+134) previously tested), a variety
of transfection protocols were employed. Under previously reported conditions (Ell.Gen
500 as the transfection agent, allowing cells to differentiate for 12 days and using
IOOOng of RNA as template in RT-PCR) (van Deutekom et al., 2001), none of the
2'0MeAOs tested induced exon 46 skipping. However, using the protocol which had
been successful for exon 19 skipping in both hwnan and mouse cells (Lipofectin as the

transfection agent, allowing cells to differentiate for four days and using SOng or Sng of
RNA as template in RT-PCR) resulted in the induction of exon 46 skipping by
H46A(-07+13) and H46A(+63+82) when delivered at a final transfection concentration
of IOOOnM. These results demonstrate that binding to a target sequence, as indicated by
a bandshift, does not necessarily guarantee antisense activity in cellular conditions. This
was also seen in the study by van Deutekom et al. (2001), as only four of the five
2'0MeAOs which induced a shift in the gel mobility assay induced skipping of e;,i:on46,
It is possible that U!ling the in vitro methods currently available, exon skipping can only
be reliably predicted by biological assays, rather than in a synthetic environment using
fragments of RNA.
In the current study, skipping of exon 46 was eventually achieved by targeting

either the acceptor splice site or an internal exonic sequence, although this was n
different site to the putative ESE targeted by van Deutekom et al. (2001). A study which
examined the nucleotide sequences of dystrophin exons 43, 46 and 53 for splicing
enhancer activity was unable to identify any sequences in e;,i:on 46 which enhanced
splicing when inserted into Drosophila doublese;,i: pre-mRNA (Ito et al., 2001). This
Wll!I

despite some of these sequences being purine-rich, leading the authors to conclude

that exon 46 Jacb II significant splicing enhancer sequence. It was suggested that the
strength of the 5' and 3' splice sites (which had splice site scores of 97.3% and 85.6%
respectively) may have been adequate to promote correct splicing, or that the flanking
introns may contain splicing enhancers (Ito et al., 2001). It is also possible that the
skipping of exon 46 in the study by van Deutekom et al. (2001) was achieved through
disturbance of the RNA secondary structure indu<;ed by the binding of the 2'0MeAO,
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rather than the target sequence being an actual ESE (van Deutekom & van Ommen,
2003). Whatever the mechanism, the reasons for the difference in results reported by
van Deutekom and colleagues and !hose obtained in lhe current study are not clear.
One difference between the protocols employed in lhe two studies may partially
explain the discrepancy in results. The 2'0MeAOs used in the study by van Deutekom
ct al. (2001), were all 5'-fluorescein (FAM)-labelled and originated from a different

source to those used in this report A study by Mann et al. (2001) reported that a 20tner
2'0MeAO with a 5'-fluorescein tag (FITC) was highly efficient in removing exon 23 as
compared to the unlabelled 2'0MeAO of lhe same sequence. In addition, a 25mer
2'0MeAO (unlabelled) directed at the same region, but extending five bases funher
into intron 23, was found to induce efficient skipping. It was suggested that the
5' fluorescent tag extended the displacement properties of the 2'0MeAO further into

("'··;;!-·,

·.;t'·' ;e-

intron 23 than the wllabe\led 20mer, possibly obstructing sequences important for
splicing. This was confirmed by the efficient skipping induced by 2'0MeAOs which
were subsequently designed to extend further into this intronic region (Mann et al.,
2002). It is therefore conceivable that the FAM label may have had a similar effect on

the exon skipping reported by van Deutekom et al. (2001). The extended length of
H46A(+ll5+134) in the van Deutekom study compared to the unlabelled 2'0MeAO
used in this study may have resulted in the blocking of sequences upstream of the
targeted region. It is possible that these sequences are involved in the efficient
recognition of exon 46. In addition, 2'0MeAOs are eventually degraded by nucleases,
predominantly by a 3' to 5' exonuclease activity, regardless of 2'0Me modifications
(Agrawal 1999). It is possible that the 2'0MeAOs employed by van Deutekom and
colle11gues (2001) were able to persist longer in the cellular environment because of
some level of protection conferred by the fluorescent moiety, thereby facilitaling
nuclear uptake of the 2'0MeAO. Furthermore, it has been reported that
oligodeoxynucleotides carrying a fluorescent tag were observed to have comparatively
greater stability inside cells than their untagged counteiparts (Politz, Taneja & Singer,
1995). It is likely that similar differences exist between tagged and untagged
2'0MeAOs.
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Chapter 7 - Results from targeting exons 19-25
The focus of this project was to evaluate several pre-mRNA motifs as potential
sites for blocke.de by 2'0MeAOs, to induce lhe specific removal of lhe targeted exon.
The final aspects oflhe project sought to apply the knowledge gllined regarding target
selection, to assess the possibility of multiple exon removal u is seen in protein studies
on naturally occurring revertant fibres. These rare dystrophin-posi1ive fibers occur
singly, or in clusters, and may represent up to 10% of the total muscle fibre population
(Sherratt et al., 1993). Furthermore, their vecy existence coupled with a reported
increase in number with age (Hoffman et al., 1990) suggests there may be some
selective advantage at play, perhaps indicating an attempt to compensate for nonsense
or fnuneshift mutations in the dystrophin gene. We therefore hypothesised that utilising
the 2'0MeAO-induced removal of a specific block of cxons to mimic an intrinsic
biological phenomenon may produce a more natural or functional revcrtant dystrophin
and !hereby provide a more effective therapy in the long tenn. The minimum number of
naturally skipped exOil.'I has boon reported 8!I being as low as five (Wilton et al., 1999).
This group has detected several of lhcse rare revertant transcripts, one of which was
missing dystrophin cxons 21 to 2S, and more significant to this project, one which was
missing uons 19 to 2S (Wilton et al., 1999). We therefore attempted to induce multiple
exon skipping

8!I

observed in revertant transcripts in H-2K mdx mouse muscle cells.

We anticipated that initial experiments would detennine the best target for the
2'0MeAO-induced removal of each exon individually, and subsequent experiments
would then apply the best 2'0MeAOs in combination to induce multiple exon skipping.

7.1 RNA binding &S.98Y
The RNA binding assay was used to evaluate the splice sites of each exon

8!I

potential targets for its 2'0MeAO-induced removal. Pre-mRNA fragments of between
329 and 390 bases were transcribed, comprising regioDll of lhe acceptor and donor
splice sites and the flanking intronic sequences of each exon to be evaluated.
Each fragment was synthesised using DNA isolated from H-2K mdx mouse
muscle cells as template in lhc in vitro T1 transcription reaction (Section 3.6.3), After
quantifying lhc purified RNA fragments by spectrophotometry, SOng was placed into
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incliv,idna1 hybridisation reactions with each of the relevant deoxy-AOs to assess their
ability to anneal to their specific target and induce a bandshlft.
Initial experiments were performed by adding 200ng of each deoxy-AO to the
hybridisation reactions. Following the preliminary evaluation, the amount of each
deo:ty-AO was titrated against SOng of RNA to determine which target might be most
amenable to dcoxy-AO hybridisation. Assessment of lhe degree of bandshift was made
subjectively, based on the difference between the RNA alone control (bandshift rating
of 0) and complete bandshift (bandshift rating of 4 ).
For case of presentation, findings from the RBA with deoxy-AOs directed to
pre-mRNA fragments comprising e:tons 21, 22 or 25 will be reported first, as the results
were similar. Exons 20 and 24, which required the evaluation of additional target sites
to achieve e:ton skipping, will be described in lhe subsequent sections.

E:ton 23 skipping in the H-2K mdx mouse has previously been reported (Mann
et al., 2002; Mann et al., 2002; Wilton ct al., I997a). Therefore, RNA binding studies
were not performed as the motif targeted by the previously described M23A(+02-I8)
(Maon et al., 2002) has been shown to be highly effective al inducing the removal of
. exon23.
7 ,1,1 Target selection tor exons 21, ll and 25

RNA fragments of 383, 340 and 380 bases representing exons 21, 22 and 25
respeclively were synthesised in a cell-free assay to assess four deoxy-AOs designed lo
target the donor splice site of each exon. For each exon, all four deo:ty-AOs tested were
able lo induce a bandshift rating of 4 at 200ng. The deo:ty-AOs were titrated to
determine the lowest effective dose. The results of the binding assay for all twelve
dco:ty-AOs are sununarlsed in Table 7.1.
Even when added at Sng, all four deo:ty-AOs targeting exon 21 achieved a
bandshift rating of at least 2, demonstrating the possible high amenability of the donor
site for2'0MeAQ.induced exon skipping. As a lower dooe of2.Sng of dM21D(+04-16)

was still sufficient to induce a strong bandshift, scoring a rating of 3, it was selected for
testing in cell culture.
Following titration of the dcoxy-2'0MeAOs targeting exon 22, dM22D(+04-l6)
appeared to bind most efficiently as O.Sng was still sufficient to induce a complete
bandshift. One nanogram of either dM22D(+08-12) or dM22D(+o6-14) was enough
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to induce a bandshift which scored a rating of 2, whereas the same dose of
dM22D(+02-18) resulted in a bandshift rating of only 1. Of the deoxy-AOs screened,
dM22D(+04-16) was selected to be synthesised as an 2'0MeAO for trial in cell cultures
due to its apparent high annealing potential and dM22D( +08-12), four bases further into
the exon, was evaluated as a comparison.
Subsequent titrations of the amount of deoxy-AO available to anneal to the exon
25 pre-mRNA fragment found that both dM25D(+08-12) and dM25D(+06-14) were
able to induce moderate bandshifts (rating of 2) when as little as 2.5ng was added.
Moving the deoxy-AOs just 2 or 4 bases more into the intron markedly decreased the
proportion of induced shift relative to that induced by dM25D(+08-12) and
dM25D(+06-14), indicating a potential reduction in the opportunity for dM25D(+04-16)
or dM25D(+02-18) to anneal to the RNA.

Table 7.1

Estimated amounts of RNA fragment bound and induced to 'shift' due to a

conformational change, given as a rating, where 4 represents a complete bandshift.

Bandshift rating determined after
exposure to varied

II

I

I

lng

0.5ng

0

0

4

2

0

-

4

3

3

1

-

dM21D(+02-18)

4

4

2

0

-

dM22D(+08-12)

4

4

4

2

1

dM22D( +06-14)

4

4

4

2

1

dM22D(+04-16)

4

4

4

4

4

dM22D(+02-18)

4

4

3

1

1

dM25D(+08-12)

4

3

2

1

-

dM25D(+06-14)

4

3

2

1

dM25D(+04-16)

4

2

1

0

dM25D(+02-18)

4

2

0

0

-

deoxy-AO tested

200ng

5ng

dM21D(+08-12)

4

2

dM2 lD(+06-14)

4

dM21 D( +o4-16)

2.5ng
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7.1,l Target selectiOD for exon 20
The length of exon 20 (242bp), was such that it was considered nece~ to
lrallSCribc two RNA fragments to evaluate the splice sites as potential targets for ils
2'0MeAO-induccd removal. These two fragments were 329 bases and 353 bases in
length, comprising e:ii:on 20 and the acceptor or donor flanking intronic sequences
respectively.
Four 2'0MeAOs had been designed to target the acceptor splice site
and four were directed at the donor splice site of exon 20. The eight
dcoxy-AOs, dM20A(·l8+02), dM20A(-I6+-04), dM20A(-14+o6), dM20A(-12+08),
dM20D(+08·12), dM20D(+o6-l4), dM20D(+04-l6) and dM20D(+02-l8) were then
assessed for their ability to anneal to their specific target and induce a baruhhift.
As can be seen in Table 7.1, dM20D(+04-l6) and dM20D(+08-l2) were able to
induce the greatest degree of bandshift when delivered at Sng. As such, these
deoxy-AOs were selected for synthesis as 2'0MeAOs and tested in cell culture.
However, subsequent difficulties in inducing exon 20 skipping with these 2'0MeAOs
led to the evaluation of an additional four longer deoxy-AOs. dM20A(-1S+IO) and
dM20A(-10+1S) were directed at the acceptor site, and dM20D(+I0-15) and
dM20D(+I0-20) t:irgeted the donor site. Although these dcoxy-AOs were designed to
anneal to a larger region of each splice site, none were able to increase the degree of
bandshift induced in the RNA binding studies and so they were not considered for
synthesis as 2'0MeAOs. It is not known whether the inllbility of the longer dcoxy-AOs
lo anneal to the target was related to secondary structure complicalions from either the
dcoxy-AO or the synthcslsed RNA fragment. Results of the binding assay for all 12
dcoxy-AOs are summarised in Table 7.2,
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Table 7.2

Estimated amounts of RNA fragment bound and induced to 'shift' due to a

conformational change, given as a rating, where 4 represents a complete bandshift.

Bandshift rating after exposure to
varied amounts of deoxy-AO(ng)

200ng

5ng

Ing

d.M20A(-18+02)

0

0

0

d.M20A(-16+04)

2

0

0

d.M20A{- l 4+06)

2

0

0

d.M20A(-12+08)

2

0

0

dM20A{- l 5+ 10)

4

1

0

d.M20A(-10+15)

4

0

0

d.M20D{+08-12)

4

2

1

d.M20D(+06-14)

4

0

0

d.M20D(+04-16)

4

2

0

d.M20D(+02-18)

4

1

0

d.M20D( + 10-15)

4

0

0

d.M20D( + 10-20)

4

0

0

deoxy-AO tested

11

7.1.3 Target selection for exon 24

To assess possible targets for inducing exon 24 skipping, a 390 base pre-mRNA
fragment comprising exon 24 and flanking intronic sequences was synthesised. Eight
deoxy-AOs were designed, four to target the acceptor splice site, dM24A(-18+02),
dM24A(-16+04), dM24A(-14+06) and dM24A(-12+08) and four directed against the
donor

splice

site,

dM24D(+08-12),

dM24D(+06-14),

dM24D(+04-16)

and

dM24D(+02-18). All eight deoxy-AOs were able to induce a complete bandshift.
However, the acceptor site appeared to be slightly less accessible than the donor site to
deoxy-AO hybridisation, as only one deoxy-AO, dM24A(-12+08), was able to induce a
bandshift which scored a rating of 4 when added at 5ng. It was difficult to discern the
degree of shift induced, possibly indicating that when bound, the donor site directed
deoxy-AOs did not induce a substantial change in the conformation of the RNA
fragment. Nevertheless, dM24D(+08-12) and dM24D(+06-14) did appear to bind most
RNA when only 5ng of each was present.
An additional four deoxy-AOs, dM24A(-15+10) and dM24A(-10+ 15), which

were directed at the acceptor site, and dM24D(+ 10-20) and dM24D( + 15-10) which
120

Chapter 7 - Results from targeting exons 19-25

targeted the donor site, were designed to anneal to a larger region of each splice site.
For three of the second generation deoxy-AOs, dM24A(-10+15), dM24D(+10-20) and
dM24D(+15-10), 5ng was capable of inducing bandshifts which rated as 4.
dM24A(-15+10) was the only second generation deoxy-AO not able to anneal to its
target even when added at 200ng. The results are summarised in Table 7.3.
Table 7.3 The amounts of RNA fragment bound and induced to 'shift' have been estimated as a
rating, where 4 represents a complete bandshift.

;r
i

Bandshift rating after exposure
to varied amounts of deoxy-AO(ng)
200ng

5ng

dM24A(- l 8+02)

0

0

dM24A(-l 6+04)

2

0

dM24A(-14+06)

2

0

dM24A(-12+08)

2

0

dM24A(-15+ 10)

0

0

dM24A(- l O+ 15)

4

4

dM24D(+08-12)

4

2

dM24D( +06-14)

4

3

dM24D(+04-16)

4

1

dM24D(+02-18)

4

1

dM24D(+l0-20)

4

4

dM24D(+10-15)

4

4

deoxy-AO tested

11
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7.2 Quality assay of 2'0MeAOs directed at exons 20 - 25
Prior to myotube transfection, all 2'0MeAOs were subject to the standard
quality control assessment. As described earlier, -200ng of each 2'0MeAO was
electrophoresed through a denaturing polyacrylamide gel (Figure 7.1). Only 'in-house'
2'0MeAOs were used in this part of the study and all were of an acceptable standard
to proceed to cell transfections. In cases where synthesis was not of high quality,
eg. M21D(+4-16) and M25D(+6-14), 2'0MeAO concentrations were adjusted and
re-evaluated by spectrophotometry prior to cell transfection. Shorter products, while not
ideal, still contain some sequence of the full length 2'0MeAO. It should also be noted
that the presence of these shorter products does not necessarily compromise the ability
of an 2'0MeAO to induce efficient and precise exon skipping (Figures 5.1, 5.6 and
5.15).
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Figure 7.1 Each 2'0MeAO directed at exons 20 to 25 were run on a denaturing polyacrylamide gel.
Despite the presence of additional bands, all 2'0MeAOs were judged to be of a sufficiently high standard
to proceed to cell transfection studies. Furthermore, 2'0MeAOs of questionable concentration were
re-evaluated by spectrophotometry prior to their use in cell culture.
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7.3 2'0MeAO-induced Exon Skipping
Oeoxy-AOs that were able to induce a bandshiftrating of at least 2 when present
at a maximum of 5ng per reaction were re-synthesised as 2'0MeAOs for further
evaluation in cell Clllture.
A titration of the transfection concentration of each 2'0MeAO was perfonned.
Total RNA was extracted 24 hours post-transfection and analysed for the presence of
exon skipping. Subsequently, any 2'0MeAO-induced products were isolated by
bandstab (Wilton et al., 1997b) and subjected to a further 35 cycles of PCR before being
purified and directly sequenced. Analysis of the sequences was pelformed to verify the
specific removal of an eimn from the mature transcript and to characterise any
additional products.

If it was found that the first generation of 2'0MeAOs produced were unable to
induce exon skipping at an acceptable transfection dose (300nM or less), a second
generation of 2'0MeAOs were designed. This Occurred with exons 20 and 24, which
will be described in sections 7.3.5 and 7.3.6 respectively. In keeping with the format of
the previous section of this chapter, the results for exons 21, 22, 23 and 25 will be
reported first.
7.3.1 Exon 21
Of the four deoxy-AOs assayed for exon 21, dM21D(+o4-16) was selected for
synthesis as a 2'0MeAO and transfected into cells. Following RNA exti:action, RT-PCR
analysis of the transcripts revealed an unmodified product correspooding to 890bp and a
smaller, out-of-frame exon 21-deleted product of 709bp (Figure 7.2). M2ID(+04-16)
was able to induce the precise and reproducible exon 21-skipped transcript when
delivered at a final concentration of 300nM.

.,<
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Figure 7.2

Products generated from the nested RT-PCR analysis of H-2K mdx mRNA following

myotube transfection with a titrated 2'0MeAO, M2 ID( +04-16), targeting the donor splice site of exon 21 .
A dose-dependent effect of 2'0MeAO concentration on the abundance of the 709bp transcript fragment

was observed, corresponding to the exon 21 skipped product

Isolation of the shorter transcript fragment by bandstab and direct sequencing
confirmed the identity of the 709bp product as exon 20 joined precisely to exon 22,
verifying the specific action of M21D(+04-16) to induce exon 21 removal (Figure 7.3).
Exon 21
Exon 20
, G

TT AAAAA TTT G

Exon 22
T AA G
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TT

T
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C

Figure 7.3 DNA sequence chromatogram across the junction of dystrophin exons 20 and 22, indicating
the precise removal of exon 21.
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7.3.2 Exon 22

The RBA for exon 22 resulted in the selection of two deoxy-AOs for synthesis
as 2'0MeAOs, dM22D(+04-l6) and dM22D(+08-l2). Following cell transfection, total
RNA was extracted and analysed for the presence of the out-of-frame exon 22-skipped
transcript fragment. M22D(+08-l2) and M22D(+04-l6) were each able to consistently
induce a shorter product corresponding to 627bp, indicating the removal of exon 22, at a
final transfection dose of 1OnM (Figure 7.4 ). Subsequent isolation and sequence
analysis of the 2'0MeAO-induced product verified that exon 21 was spliced exactly to
exon 23, confirming the complete removal of exon 22 from the mature transcript
(Figure 7 .5).
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Figure 7.4 Agarose gel image of titrated 2'0MeAOs targeting the donor splice site of exon 22 in mdx
cells.
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Figure 7.5 DNA sequence chromatogram of the dystrophin gene transcript across exons 21 and 23. The
precise excision of exon 22 from H-2K mdx dystrophin rn.RNA, induced by the donor splice site directed
2'0MeAOs, M22D(+04-16) and M22D(+08-12), is shown.
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7.3.3 Exon 23

To confirm the findings of Mann et al. (2002), titrated amounts of the 2'0MeAO
M23A(+02-18) were transfected into H-2K mdx muscle cells. Total RNA was then
extracted 24 hours post-transfection, purified and quantified for subsequent analysis by
RT-PCR. Consistent with the previously reported results (Mann et al. , 2002),
transfection doses from 600nM down to 50nM were able to induce two additional
transcripts, one in which exon 23 alone was skipped, and a less abundant product
missing both exons 22 and 23 (Figure 7.6).
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Figure 7.6 A titration of the exon 23 donor site-directed M23D(+02-18), demonstrating the two induced

transcript fragments . A dose-dependent effect on the abundance of both the exon 22 skipped product and
the product resulting from the co-skipping of exons 22 and 23 was clearly evident.

Direct sequencing of the transcript fragments corresponding to 688bp and 542bp
confirmed the effect of M23A(+02-18) as inducing both exon 23 skipping alone and
co-skipping of exons 22 and 23 respectively (Figure 7. 7A and B).

126

Chapter 7 - Results from targeting exons 19-25

Exon 23

A
Exon 22
T

C

G

G

G A

Exon 24
A

A

TT

A

C

A

G A

A

T

C A

C

T A

A

A

A

A

C

Exons 22 and 23

B

Exon 24

Exon 21
AAA

A

G

A

G

C T

A

C A

G

A

C AAAA

T

C A

C A T

AAAAA

CC T

Figure 7.7 DNA sequence chromatograms of the dystrophin gene transcript across exons 22 and 24

and exons 21 and 24. Chromatogram (A) verifies the precise skipping of exon 23 and (B) confirms the
co-skipping of exons 22 and 23 .
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7.3.4 Exon 25
Based on the RNA binding study, M25D(+06-14) was selected for testing in cell
culture. Transfection and subsequent RT-PCR analysis of the amplified transcript
fragments revealed a full-length product corresponding to 824bp and a smaller exon 25
deleted product of 668bp. Consistent exon 25 skipping was detected when the
transfection concentration was 1OOnM, with the sporadic appearance of the induced
transcript when delivered at a final concentration of 50nM (Figure 7.8). Sequence
analysis of the shorter transcript fragment confirmed that exon 24 was precisely spliced
to exon 26 (Figure 7.9).

M250(+06-14)

900

600

Figure 7.8 Titration of the splice site-directed 2'0MeAO M25D(+06-l4) from 600nM to 50nM. A single

amplicon of 668bp corresponding to exon 25 skipping was consistently detected when the transfection
concentration was at least 1OOnM.
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Figure 7.9 DNA sequence chromatogram of the dystrophin gene transcript across exons 24 and 26.

The precise excision of exon 25 from H-2K mdx mouse muscle mRNA, induced by the donor splice
site-directed M25D(+06-14 ), is shown.
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7.3.5 Exon 20

For exon 20, the results of the RBA suggested that the acceptor site was
generally less amenable than the donor site to deoxy-AO hybridisation. Therefore
dM20D(+04-16) and dM20D(+08-12) were synthesised as 2'0MeAOs and evaluated in
cell culture. Despite the indication by the bandshift assay that M20D(+08-12) might
bind more efficiently (Table 7.2), it failed to induce exon 20 skipping even at lOOOnM.
Only M20D(+04-16) was able to consistently induce a detectable, albeit extremely
weak, exon 20 skipped transcript provided the transfection concentration was at least
600nM (Figure 7.10).

M20D(+04-16)

900
600

Figure 7.10

Exon 20 skipping induced by M20D(+04-l6) in H-2K mdx mouse mRNA. RT-PCR

analysis of RNA harvested 24 hours after cultured myotubes were transfected with M20D(+04-l6) at
concentrations ranging from 600nM down to 50nM. The full-length product spanning exons 18 to 23 is
890bp long. The shorter transcript fragment corresponds to a product of 648bp (indicated by arrow)
missing exon 20.

The faint 648bp amplicon was isolated by bandstab and directly sequenced.
M20D(+04-16) was confirmed to have induced the precise removal of exon 20 from the
mature message (Figure 7 .11 ).
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DNA sequence chromatogram demonstrating the precise excision of exon 20.

M20D(+04-16) was never associated with the removal of other exons or the initiation of splicing from
sites other than the consensus splice site sequences flanking exon 20.

Due to the relatively high cell transfection concentration of 2'0MeAO required
for exon 20 removal, four longer deoxy-2'0MeAOs were assessed using the RNA
binding assay. However, none were able to appreciably increase the degree of bandshift
induced and therefore theywere not considered for synthesis as 2'0MeAOs.
In an attempt to enhance the skipping of exon 20, putative exonic splicing
silencers were added to the 2'0MeAOs. These elements, which may act to repress or
inhibit the inclusion of exons, can be purine or pyrimidine rich and are thought to bind
many of the proteins involved in the splicing process (Fairbrother & Chasin, 2000).
Three more 2'0MeAOs were designed by modifying the marginally effective
M20D(+04-16) at the 3' or 5' ends to include a purine or pyrimidine rich silencing
element (Table 3.2). M20D(+04-16)-Pu and M20D(+04-16)-Py were synthesised with
one of either of the silencing motifs (abbreviated from purine and pyrimidine to Pu and
Py respectively) included at the 3' end of the molecule. We hypothesised that this
modification may have the potential to further enhance 2'0MeAO stability by shielding
the 2'0MeAO from exonuclease degradation which is initiated predominately
from the 3' end (Agrawal & Ahktar, 1995). For comparison, the third 2'0MeAO,
Pu-M20D(+04-16), was synthesised with a purine-rich motif at the 5' end. The addition
of these silencing elements also provided an opportunity to assess whether these
modifications would play a part in reducing accessibility to the donor site by competing
splicing factors.
Regardless of the motif or its position, transfection of the H-2K mdx cells with
these modified 2'0MeAOs did not increase the level of exon 20 skipping over that
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observed when the original 2'0MeAO, M20D(+04-16), was delivered at 600nM.
Curiously, this extremely low level of transcript missing exon 20 was sometimes
detected when the transfection concentration was 50nM, a six-fold decrease from that
observed previously (Figure 7.12).
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Figure 7.12 A titration in H-2K mdx cells of the original 2'0MeAO M20D(+04-l6) coupled with one of

two putative human splicing silencers (Fairbrother & Chasin, 2000). Similar levels of a product of low
abundance corresponding to the exon 20 skipped transcript (indicated by arrows) were consistently
detected at transfection concentrations from 600nM down to 50nM.

Due to the fact that neither splice site appeared to be a very effective target for
exon 20 skipping (the acceptor splice site rated poorly in the RNA binding assay
although its effectiveness as a target for 2'0MeAO-induced exon skipping in cell
culture was not assessed), the possibility of targeting exon splicing enhancers (ESEs)
was explored. No specific regions within exon 20 have been reported to play a role in its
recognition or inclusion, as was the case for exon 19. Therefore, a computer program,
RESCUE-ESE, was employed to predict the likely positions of ESEs by the statistical
analysis of exon-intron and splice site composition within the given sequences
(Fairbrother et al., 2002). Numerous positions were highlighted as sequences likely to
possess ESE activity (Figure 7.13).
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Based on the predictions made by the RESCUE-ESE program, two 25mer
2'0MeAOs, M20A(+23+47) and M20A(+140+164), were designed to anneal to regions
appearing to occupy the greatest concentration of 'ESE-like' motifs. Subsequently, the
2'0MeAOs were transfected separately into H-2K mdx muscle cells at final
concentrations of 600nM and lOOnM and the mature message analysed by RT-PCR.
,m;-,;r,.,. tar....uGT 1·~C!W(;l,,IO IG~cx;-GGICACU.ct.:tl lro::"'"A
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Figure 7.13 The entire exon 20 sequence (242 bases) was submitted for analysis by the ESE prediction
program. This is the standard output received upon analysis of the sequence given. Predicted ESE sites
were numerous and overlapping.

In addition to the expected full length product, two transcript species were
consistently detected in the RNA exposed to M20A(+23+47), a product of low
abundance corresponding to exon 20 skipping and a much stronger novel product
- 130bp shorter than the full length transcript fragment. M20A(+140+164) was able to
induce two products of very low abundance: one corresponding to exon 20 skipping and
a novel product of -570bp (indicated by arrow) in both 600nM and 1OOnM samples
(Figure 7.14).
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900
600

Figure 7.14 An agarose gel image of the amplified fragments of both the natural and modified transcripts

resulting from transfection with M20A(+23+47) or M20A(+140+164). Both 2'0MeAOs were able to
induce a very weak 648bp product corresponding to exon 20 skipping, and each also consistently induced
non-specific skipping. M20A(+23+47) activated a cryptic splice site 135 bases downstream from the
consensus acceptor splice site of exon 20, resulting in a novel product (755bp) of high abundance.
M20A(+ 140+ 164) induced a weak product of 560bp corresponding to the co-skipping of exons 19 and 20
(indicated by arrow).

Each product was isolated by the bandstab method (Wilton et al., 1997b) and
directly sequenced. M20A(+23+4 7) and M20A(+ 140+ 164) were confirmed to have
induced the precise and repeatable skipping of exon 20 from the final message (Figure
7.11). In addition, the novel product induced by M20A(+23+47) was identified as
resulting from the activation of a cryptic acceptor splice site 135 bases downstream
from the normal acceptor site of exon 20 (Figure 7.15). As a consequence, the first 134
bases of exon 20 were removed when intron 19 was spliced out. The novel product
induced by M20A(+ 140+ 164) was confirmed to have resulted from the removal of both
exons 19 and 20 (Figure 7.16). This non-specific activity further supports the notion
that blocking pre-mRNA sequences containing ESE-like motifs from splicing factors
has the potential to interfere with correct exon definition.
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Figure 7.15 DNA sequence chromatogram of the dystrophin gene transcript across exons 19 and
20. Blocking the site recognised by M20A(+23+47) has activated a cryptic acceptor splice site which was
135 bases downstream of the consensus acceptor splice site.
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Figure 7.16 DNA sequence chromatogram of the dystrophin gene transcript from exons 18 to 21. The
precise excision of exons 19 and 20 from H-2K mdx mouse muscle mRNA, induced by the donor splice
site directed M20A(+ 140+ 164), is demonstrated.

In another attempt to induce exon 20 skipping, cell transfections with
combinations

of

2'0MeAOs

involving

M20D(+04-16)-Pu,

M20A(+23+47),

M20A(+140+164) and the successful exon 19 2'0MeAO, HM19A(+35+65), were
performed. HM19A(+35+65) was transfected at lOOnM, M20D(+04-16)-Pu and
M20A(+ 140+ 164) were transfected at 600nM, and M20A(+23+4 7) was transfected at
1OOnM, the lowest concentration that was still able to induce the strong novel
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product reported above. RT-PCR analysis of the RNA that had been targeted by
M20D(+04-16)-Pu in combination with either of the ESE-directed 2'0MeAOs showed a
small increase in the level of precise exon 20 skipping compared to that induced by
M20D(+04-16)-Pu alone. Furthermore, activation of the cryptic splice site was
abolished as no combinations induced the partial removal of exon 20. The combination
of M20D(+04-16)-Pu and M20A(+ 140+ 164) also induced the product corresponding to
a low level of exons 19 and 20 skipping, slightly stronger than that observed when
M20A(+l40+164) was transfected alone. The combination of the two 2'0MeAOs
directed at the ESE, M20A(+23+47) and M20A(+l40+164), produced much more
abundant exon 20 skipped and exons 19 and 20 co-skipped transcripts (Figure 7.1 7).
However, the combination of all four 2'0MeAOs was not able to increase the level of
co-skipping of exons 19 and 20, despite the fact that one of the additional 2'0MeAOs
was specifically targeted to exon 19.
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Figure 7.17 Agarose gel image of the RT-PCR products induced by three combinations of2'0MeAOs
directed at various exon 20 motifs. Alone, each was able to modify the splicing pattern to either remove
exon 20 entirely at a low level, or imprecisely through cryptic splice site activation. The combination of
M20D(+04-l6)-Pu and M20A(+ 140+ 164) was able to induce the removal of both exons 19 and 20.
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7.3.6 Exon 24
From the results of the initial RBA. it was decided to synthesise
dM24D(+08·l2) and dM24D(+o6-l4) as 2'0MeA0s. However, neither 2'0MeAO was
able to induce a detectable exon 24 skipped transcript, even when the transfection
concentration was as high as IOOOnM, Therefore, in an attempt to COllll out exon 24,
combinations of 2'0MeAOs targeting exons 23, 24 and 25 were also transfccted into
H-2K mdx cells. A high degree of cell death was observed post-trarufection due to the

concomitant increase in Lipofoctin concentrations. Moreover, RT·PCR analysis of the
RNA extracted did not detect the removal of eimn 24 from the mature transcript,
although transcripts with either exon 23 or 25 skipped were detected (results not
shown).

7.3.6.l 2'0McAOs directed at 5Plice sites
Based on the results of the RNA binding assay of the additional four
deoxy-2'0MeAOs directed against the splice sites of exon 24, M24A(-IO+l5) and
M24D(+l0-l5) were selected to be tested in cell culture. Both 2'0MeAOs were
transfected into cells and RT-PCR analysis perfonned on the extracted RNA.
M24A(·l0+15) and M24D(+I0-15) were each able to induce consistent and specific
exon 24 skipping but at very low levels. However, a dose-dependent effect was not
evident, as the same level of induced transcript was observed at concentrations tested
down to 50nM, possibly indicating that a maximum level of competition with splicing
factors may have been 11ehieved under these conditions (results not shown).
The 685bp amp\icons were rcamplified by the bandstab procedure (Wilton et al.,
1997) and directly sequenced. Both M24A(·lo+l5) and M24D(+J0-15) were confumed
to have induced the precise removal of exon 24 from the final message (Figure 7.18).
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DNA sequence chromatogram of exon 24 skipping in H-2K mdx mRNA. Both

M24A(-10+15) and M24D(+l0-l5) were able to induce the precise removal of the target exon, where
exon 23 was spliced exactly to exon 25 .

7.3.6.2 2'0MeAOs directed at ESEs

As with exon 20, the splice sites for exon 24 were not amenable as targets for
2'0MeAO-induced skipping. This discovery was not surprising for the acceptor splice
site, considering the splice site score was relatively high (95.3%). However, the donor
splice site score of 72.8% could indicate a sub-optimal motif and hence the potential to
overwhelm splicing factors and induce exon 24 removal by targeting the donor site. As
this was not the case, and as with exon 20, no specific regions within exon 24 have been
identified in the literature as playing a role in its definition, the computer program
RESCUE-ESE was again employed to predict the likely positions of ESEs within exon
24.
Based on the predictions made by RESCUE-ESE, two 25mer 2'0MeAOs,
M24A(+ 16+40) and M24A( + 78+ 102), were designed to anneal to regions likely to
include the greatest concentration of 'ESE-like' motifs. Both 2'0MeAOs were
subsequently transfected separately into H-2K mdx muscle cells at final concentrations
of 600nM and lOOnM and the mature message analysed by RT-PCR.
An exon 24 skipped product, of similar abundance to that induced by
M24A(-10+15), was detected in the cells transfected with M24A(+16+40). Similar to
earlier experiments with the splice site-directed 2'0MeAOs, no difference was observed
between the 600nM and 1OOnM transfection concentrations tested (Figure 7 .19). The
2'0MeAO-induced product was isolated for characterisation to ensure that the action of
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M24A( + 16+40) was specific. Sequencing of the product revealed that exon 23 had been
joined precisely to exon 25 (Figure 7.18). However, a shorter novel product of 539bp
corresponding to the co-skipping of exon 22 and 24 was seen on occasion (Figure 7.20)
This could indicate the potential for low level non-specific activity by this 2'0MeAO, or
that the splicing of these two exons may be linked as seen with 2'0MeAO-induced
co-skipping of exons 22 and 23 when exon 23 is targeted. The shorter novel product
was sequenced, confirming the precise excision of exons 22 and 24 (Figure 7.21).
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Figure 7.19 RT-PCR analysis showing the natural transcript fragments and the modified transcript
fragments resulting from transfection with M24A(+ 16+40). The same level of induced transcript
(indicated by arrow) was detected at both transfection concentrations. M24A(+78+102) consistently
failed to induce exon 24 removal.

In another attempt to induce more pronounced exon 24 skipping, cell
transfections with combinations of 2'0MeAOs targeting exon 24, M24D(+ 10-15),
M24A(+16+40) and M24A(+78+102), were performed. Each 2'0MeAO was
transfected at a final concentration of 300nM to minimise the degree of cell death
associated with the high dose of Lipofectin. The 2'0MeAOs were then added to target
the four possible combinations of the three splicing motifs. In these combinations, the
final concentration was the sum of the concentrations used for each individual
2'0MeAO. RT-PCR analysis of the RNA from cells that had been targeted by each of
the three paired combinations of 2'0MeAOs revealed specific exon 24 skipping. The
combination ofM24A(+ 16+40) with either M24D(+10-15) or M24A(+78+102) resulted
in a skipped product of much higher abundance than that produced following
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transfection with any single 2'0MeAO. The combination of M24D(+ 10-15) and
M24A(+78+102) had the same effect but to a lesser degree, inducing a transcript
marginally greater in abundance than when the 2'0MeAOs were transfected
individually (Figure 7 .20).

900
600

Figure 7.20 Agarose gel image of the RT-PCR products induced by the four combinations of2'0MeAOs
directed at various exon 24 motifs. In individual transfections, only M24A(+78+ 102) was unable to
modify the splicing pattern to remove exon 24 although the skipping induced by M24A(+ 10-15) was
highly inefficient. M24A( + 16+40) also induced a novel 539bp product corresponding to the co-skipping
of exons 22 and 24. All of the combinations resulted in specific skipping of exon 24.
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Figure 7.21 DNA sequence chromatogram of precise co-skipping of exons 22 and 24 in H-2K mdx
mRNA sporadically induced by transfection with M24A(+ 16+40).
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13.1 Muldple HOO sldpplng
The focus of this section was 10 determine appropriate targets for lhe
2'0MeAO-induced removal of each exon. The ultimate goal was to apply these
2'0McAOs in combination to H·2K mdx muscle cells and to induce the skipping of
multiple exons such as that seem in revertant fibres. While the majority of revertant
fibres skip in excess of 20 exons, designing 2'0MeAOs to 1arget such II number of
exons was beyond the scope of this project. Instead, experiments were performed in
which each of the 2'0MeAOs identified earlier were combined in an attempt to force
the splicing machinery to remove exons 19 to 25 inclusive from the final transcript. This
particular arrangement, while rare, has been detected in naturally occurring revertant
fibres in H·2K mdx a11d CS7 normal mice (Wilton, et al. 1997). In mdx mice, the
removal of exons 19 to 25 would not only bypass the nonsense mutation in exon 23, but
also maintain the reading frame. This shorter mRNA transcript would therefore be
capable of being translated into a shorter but presumably functional dystrophin protein.
The same combination of2'0MeAOs could be applied to any mutation OCC\lffillg within
the targeted exons, resulting in restoration of the reading frame. Therefore, efficient
removal of exons 19 to 2S in combination could have broad application lo DMD
patients exhibiting a ra11ge of mutations within this region.
Two experiments were undertaken, trllllsfection with the 2'0MeAOs at the
minimum transfection concentration found lo induce the removal of the targeted
exon, 811d transfection with all 20MeAOs at 50nM. Nine 20MeAOs in Iola! were
selected for the transfection, M19A(+46+6S), M20A(+23+47), M20A(l40+164),
M21D(+o4-16), M22D(+o4-16), M23D(+02-l8), M24A(+l6+40), M24A(+78+102)
811d M2SD(+o6-l4). Not surprisingly, cell death was very high in the first condition
where the total 2'0MeAO transfection concentration was 17SOnM. The total
transfection concentration in the second condition was nilly 4SOnM 811d as such only a
moderate degree of cell death was observed. Twenty.four bJurs posMnmsfection, RNA
was extracted from the duplicate wells for both conditions and analysed by RT-PCR.
While a full length product of 1363bp (gC11erated across exons 18 and 26) was not
observed, a novel transcript fragment (223bp) corresponding to the skipping of exons 19
to 25 was detected in bolh conditions (Figure 7.22).
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Additional tests were performed to screen for any non-specific activity of the
combined 2'0MeAOs in other regions of the dystrophin transcript. Using the RNA
extracted from the mdx cells which had been transfected with the two concentrations of
combined 2'0MeAOs, regions across exons 1 to 10 and 70 to 79 were amplified. No
alterations in the normal splicing patterns were detected other than the specific
2'0MeAO-induced removal of exons 19 to 25 (Figure 7.22).

1-10

18-26

69-79

1400

200

Figure 7.22 An agarose gel image showing the two 223bp products corresponding to exons 19 to 25
skipping detected in H-2K mdx mRNA. The combined 2'0MeAOs were transfected at the minimum
effective concentration (CM) required to induce the removal of the target exon (where the minimum dose
was never below 50nM) or at 50nM each (C50). 2'0MeAOs designed to skip exons 19 to 25 do not alter
dystrophin processing in other regions of the gene transcript.

The 223bp amplicon was isolated by the bandstab method, then purified and
directly sequenced. Transfection with all nine 2'0MeAOs directed at different motifs
within seven exons and flanking introns was successful in inducing the precise removal
of exons 19 to 25, such that exon 18 was spliced exactly to exon 26 (Figure 7.23).
2'0MeAO-induced skipping of multiple exons has not been reported previously in the
literature.
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Figure 7.23 DNA sequence chromatogram of the dystrophin gene transcript from exons 18 to 26. The
precise excision of exons 19 to 25 from the mature transcript, induced by the combination of 2'0MeAOs
directed at each of the seven exons, is demonstrated.

7.4 Summary
This section of the project investigated the possibility of multiple exon removal
which occurs naturally in revertant dystrophin-positive fibres. Initial experiments
sought to determine the best target for the 2'0MeAO-induced removal of each exon
individually. This proved to be a relatively simple process for certain exons and
somewhat more challenging for others.
The donor splice sites of exons 21 , 22 and 25 proved amenable to
2'0MeAO-induced exon skipping. In each case, 2'0MeAOs directed at the donor splice
sites were able to induce consistent and precise removal of the target exon at
an acceptable transfection concentration. Highly effective skipping of exon 23 and
co-skipping of exons 22 and 23 was induced by targeting the donor splice site,
concurring with the previously reported findings of Mann et al.. (2001 ).
Inducing the removal of exon 20 proved more difficult. Of the two 2'0MeAOs
targeting the donor splice site of exon 20, only M20D(+04-16) consistently induced
skipping of exon 20, and this was at a very low level even at a concentration of 600nM.
Modifying this 2'0MeAO with human exonic splicing silencers did not increase the
level of skipping. Transfection of the cells with M20A(+23+47), designed to an
ESE-like motif within exon 20, resulted in poor skipping of exon 20 as well as a novel
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product arising Crom lhe activation of II cryptic splice site, A second ESE-directed
2'0MeAO, M20A(+140+164), induced both precise cxon 20 skipping and the
co-skipping of exons 19 and 20. Combinations of M20D(~·16)·Pu with either of lhe
ESE-directed 2'0MeAOs resulted in a small increa.'<l in lhe lcvd of preciw: non 20
skipping. More efficient skipping of cxon 20 was induced by the combination, of lhe
two ESE-directed 2'0MeAOs and all four 2'0McAOi., but ,.ith roncomilant
co-skipping of exons 19 and 20. In bolh cases, activation of the cryJWic ,pl ice i.itei; was
abolished.
Similarly, all 2'0MeAOs targeting lhe splice 1itn of uon ?.& were either
ineffective or highly inefficient at inducing i;kipping. In addition, comhin.ationi of lhese
2'0MeAOs and 2'0MeAOs iargedng exom 2) and 25

\ICfl:

unable to induce lhe

removal of exon 24. Low levels of cxon 24 ,kipped ln!UCripl ,.·ere induced by targeting
an ESE-like motif wilh M24A(+l6+40), along with lbc: ,ror.lic induction of nons 22

and 24 co-skipping. However, transfection wilh a rombin•tion of M2.& I( +16+40) and
eilher M24D{+IO-IS) or M24A(+78+102) increaM:d lhe abundance of the uon 2.&
skipped product compared to lhat produced from 1r1ni.fcction \l'ith any ,ingle
2'0MeAO, wilhout any non-specific activity.
lmtemiining lhe targets amenable to 2'0MeAO-indllCCd

fCr.>(IU,I

of individual

exons culminated in lhe ttansfcction of H-2K mdx cells with c:ich of !he cffccti,·e
2'0MeAOs in combination. The ultimate goal of ~kipping non, 19 to 2S .... a, achie,·cd,
using a total of nine 2'0MeAOs. Using lhis combination re.~ultcd in ,kipping "hich wu
far more efficient lhllll lhat achieved by individual 2'0MeAOs, 11s no foll•kngth
transcript remained. In addition, other regiom of lhc gene tran~ipt were Krecncd,
confuming !hat allllrations in lhe splicing process were localised to the 1arge1 arc;i.
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7.5 Discussion
7.5,1 Exons21,22and15

Selection of 2'0MeAOs and transfection of exons 21, 22 and 25 will be
discussed togelher as each yielded similar results. First, RNA binding assays were to
used to select which dcoxy-AOs were to be synlhcsiscd as 2'0McAOs. The limitlltions
of the RBA in predicting !he ability of a 2'0McAO to re-direct splicing have been
discussed in the previous chapter. For each CJ:On, four deoxy-AOs were designed to
targCI the donor splice site and assessed for their ability 10 anneal to their specific target.
It was decided to test the donor splice site first, based on. studies directed at this region
of exon 23 (Mann et al., 2001; Wilton ct al., 1999) as well as lhe results obtained for
cxon 19 in the current study (Errington ct al., 2003). The observation !hat 2'0MeAOs
directed at donor splice sites tend to have greater influence on splicilig has also been
made by anolher group (Sierakowska et al., 1996). In the current study, very low doses
of each donor site-directed dcoxy-AOs tested induced a bandshift sufficient to justify
lhe synlhesis of 2'0McAO homologues. Consequently, other splicing motifs in lhcse
exons were not assessed as potential targets for 2'0McAO induced exon skipping.
For exon 21, the 2'0MeAO M21D(+04-16) was found to Ulduce precise and
reproducible skippilig at a final concentration of 300nM. While !his concentradon is
considered to be relatively high by our grDllp, it is still comparatively low considering
the transfection concentrations reported in olher studies (Dunckley et al., 1998; van
Dcutekom et al., 2001). The splice site score for !he donor site of exon 21 is 87%
(Senupalhy et al., 1990), which may indicate a relatively high level of competition with
splicing factors. The final concentration required to induce reliable exon 21 skippilig
falls within acceptable limits. However, further testilig of lhe ncceptor site, which has a
score of 76% (indicating a lower competilion with splicing factors), or of regions
predicted to contain ESE-like motifs, may detennine the location of targets more
amenable to 2'0MeAO-induced skipping. It is interesting to note that while lhe RBA
was generally correct in predicting the ability of the 2'0McAO to anneal to the target, it
did not reflect the concentration required to induce exon skipping and lhus docs not
predict the efficacy of an 2'0MeAO targeted to a particular region.
Two deoxy-AOs directed at the dooor site of e1on 22 were selected for synthesis
as 2'0MeAOs. Despite a moderate difference in apparent binding efficiencies, both
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M22D(+-08-12) and M22D(+04-16) appeared equally effective at inducing specific and
efficient skipping of exon 22. For this exon, perfonnance of the 2'0MeAOs in cell
culture correlated well with the results of the RNA binding assay as both 2'0MeAOs
were able to induce specific and efficient skipping of exon 22 at a final tran.d"ection
dose of IOoM. These results were not unexpected because the splice site score for the
donor site, at 79% (Senapathy et al., 1990), indicates a relatively low level of
competition with splicing factors. In addition, removal of exon 23 is almost always
associated with concomitant removal of exon 22, indicating that the latter e,ton may be
panicuhuly susceptible to 2'0MeAO-induced skipping and that there may be a
relationship between the splicing of the two exons (Mann ct al., 2002). However, it was
Interesting to note that targeting exon 22 did not result in the co-skipping of exons 22
and 23 In the current study, possibly reflecting a non-sequential order of exon splicing,
as bu been observed in other genes (Kessler et al., 1993).
Finally, the donor splice site of exon 2S was evaluated with the 2'0MeAO
M2SD(+o6-I4), which Induced consistent exon 25 skipping at a transfcction dose of
IOOnM. The donor splice site score, at 84%, wu less than that of exon 21, and the lower
concentration of 2'0MeAO required to induce skipping of exon 2S may again reflect a
comparatively lower level of competition with splicing factors. Again, further testing of
the acceptor splice site or regions predicted to contain ESE-like motifs may be desirable
to determine the location of targets more amenable to 2'0MeAO-induced skipping of
this exon.
It is interesting that similar sequences targ~1ed by the donor site directed
deoxy-AOs appeared to induce similar degrees of bandshift between exons (Table 7.1).
This reflects the relatively high degree of conservation of the donor splice sites, which
would result in similar: secondary structures in these regions between exons. However, it
is important to note that the RBA only reflects the ability of a dcoxy-AO to anneal to an
RNA fragmenL The secondary structure of the pre-mRNA flanking the fragment may
be significantly different, and each splicing motif may contribute to the splic~ process
in varying degrees (Ito ctal., 2001).
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7.5.2 Exon 20

Based on the results or the RBA, the acceptor site appeared to be less accessible
than the donor site to deo;,r;y-AO hybridisation. Despite the indication by the bandshift
assay that M20D(+o8-l2) might bind more efficiently, only M20D(+-04-16) was able to
consistently Induce a detectable, albeit e1trcmely weak, c1on 20 skipped transcript
provided the tnmsfection conccmlration was at least 600nM. As both 2'0MeAOs more
than cover the consensus splice site, this may reflect a difference between the stmctures
of the RNA fragmenl used in the bandshift 1USay and full-length cellular RNA such that
the downstream region is actual!)' more accessible. A funher possibility is that the
intronic region targeted by M20D(+o4·16) may contain motifs more crucial to e1on
inclusion.
Toe calculated splice site score of 95% indicates that the donor site of e1on 20
might be highly efficient and therefore difficult to obstroct. This, however, docs not
appear to be constant for all splice sites. For e1ample, a strong positive correlation
between splice site score and efficiency of 2'0MeAO induced aon skipping has been
observed in other aons. Dystrophin e;,r;on 23 skipping was reponed 10 be very efficient
when targeting the donor splice site (M81Ul et al., 2001), which has score of 93.5%. In
addition, e1on 19 skipping was efficiently induced by targeting the acceptor splice site,
which has a score of 91 %. It is possible that as splice site scores increase, there is a
point al which competition with splicing factors prevents access of the 2'0MeAO to the
target site, such that skipping of an apparently highly efficient splice site, for example,
the donor splice site of exon 20, becomes very inefficient.
Due to the high transfection concentrations required for exon 20 removal,
further 2'0MeAOs wen: designed in an attempt to improve efficiency. Human silencing
.,,motifs thought to repress the inclusion of e;,r;ons (Fairbrother & Chasin, 2000), were
attached to the 3' or S' ends of the weakly effective M20D(+-04-16). The attachment of
these motifs to the 3' end was also Ltiought to have potential in improving the stability of
the 2'0Mt:AO by protecting it from exonuclcase degradation, which occurs from the
3' end {Agrawal & Ahk.tar, 1995). However, the three 2'0MeAOs designed with these
modifications failed to increase the level of exon 20 skipping over that observed with
the parent 2'0MeAO. One possible explanation is that these silencers were derived from

human DNA sequence, and that mouse silencing motifs differ in base composition.
Additionally, it is possible that the high level of competition with splicing factors
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prevented the modified 2'0MeAO from hybridising wilh !he donor splice site, in tum
preventing !he silencing motif from exerting any effect.
As ncilher !he donor or aoceptor splice sites appeared to be very amenable to
2'0McAO-induced exon 20 skipping, tprgeting exon splicing enhancers (ESEs) was
el\plored. It is important to note !hat the acceptor site was not evaluated in cell culture.
The splice site score of 85% indicates that it may have been a moderately efficient
splice site, but the RBA results suggested that accessibility to the site would have been
limited, thus excluding it as a target for lhis study.
The RESCUE-ESE program (Fairbrother et al.. 2002) was utilised to design
M20A(+23+47) and M20A(+I40+164), which were directed at regions that seemed to
contain the greatest concentration of 'ESE-like' motifs. Two transcript species were
consistently detected in lhe RNA exposed to M20A(+23+47), a very weak product
corresponding to el\on 20 uipping and a much stronger novel product 135 bases shorter
lhan the full length transcript fragmenL This suggests thal the spliccosome selected a
cryptic splice site when a motif (at least) partially responsible for el\on inclusion was
obscured by M20A(+23+47), The remarkable similarity of the splice site scores of the
consensus and cryptic splice sites, at 85% and 84% respectively, highlights lhe
importance of nearby motifs wilhin the el\on (or intron) which either enhance the
selection of the correct splice site or suppress the selection of the cryptic splice site
(Blencowe, 2000; Reed, 1996). It is possible that M20A(+23+47) blocked one of these
motifs, removing its effect from the bal11nce of factors determining splice site selection.
A similar effect has been observed in studies which lllrgeted a putative ESE in
dystrophin el\on Si (Aartsma-Rus et al. 2002, 2003). As well as specific skipping of the
el\on, a Ullll5Cript corresponding to partial skipping of exon 51 was induced as a result
of the activation of a cryptic splice site. Several studies have also reported the activation
of cryptic splice sites because of disruptions of a donor or acceptor consensus splice site
(Fernande.r.-Cadcnas et al., 2003; Fletcher et al., 2001: Tuffery-Giraud, Chlllllbert,
Demai\le & Claustres, 1999). It thus appears that alterations in either el\onic sequences
er spli~ sites can result in non-specific splicing. II has been suggested lhat targeting
CI\On•internal sequences with 2'0MeAOs might reduce the risk of non-specific splicing
aberrations through alteration of secondary structure such that the el\on is no longer
marked for inclusion (van Deutekom & van Ommen, 2003). However, the results of the
current study demonstrate that binding of an 2'0MeAO to exonic sequences will not
necessarily result in specific slr.ipping, as targeting certain regions may promote the
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selection of a cryplk splice site. Previously, we assumed that this could be
circumvented by applying another 2'0MeAO to lhe cryptic splice site. It now appears
that cryptic splice sites can be bypassed by selecting another motif in the pre-mRNA.
In addition, the second of the ESE-directed 2'0MeA0s, M20A(+J40+164), also
induced the complete removal of both exons 19 and 20. Co-skipping of exons was also
reported following targeting of dystrophin exons 2 and 29 with ESE-directed
2'0MeAOs (Aartsma-Rus et al., 2002). It is interesting that in some cases the same coskipped products were seen in the untreated RNA at weaker levels, suggesting that lhe
2'0MeAOs may be streogthening a naturally occurring alternative splicing process.
Efficient and precise skipping of exon 20 was finally ioduced following
transfcction of cells with combinations of the 2'0MeAOs M20D(+04-l6)-Pu,
M20A(+23+47) and M2DA(+l4o+l64). However, exon 20 removal was specific only in
the combinution of M20D(+o4-l6)-Pu and M20A(+23+47), as the othrr combinations
induced concomitant exon 20 and the co-skipping of ellon 19 and 20 skipping. This
co-skipping was similar to that reported by Mann et al. (2001) for 2'0MeAOs directed
at the ellon 23 donor splice site. The authors suggested that co-skipping may be due to
the intimate relationship between the splicing of intrans 22 and 23 rather than a
non-specific effect of the 2'0MeAO, particularly as there is no sequence homology
between the two exons. As the spliciog of downstream intrans has been shown to
inOuence the processing of intrans upstream (Watakabe et al., 1993), it is possible lhat a
similar intimate relationship ellists between ellons 19 and 20. M20D(t-04-16), when
transfected as au individual 2'0MeA0, was never associated with the removal of other
ellons or the initiatioo of splicing from sites other than the consensus splice site
sCqucnces flanking ellon 20. Thus the rcsull5 of these combined transfoctions suggest
that it was the targeting of the c:imnic sequences which contributed to the non·specific
effcclS. It is also interesting that the donor splice-site directed 2'0MeAO and the
ESE-directed M20A(+J40+164) both had the effecl of preventing the activation of the
cryptic splice site when combined with M20A(+23+47), and that the combination of
these 2'0MeAOs resulted in a higher level of specific ellon 20 skipping than
M20D(+o4-l6)-Pu alone. This may indicate that both the donor splice site and ESE
motifs were significant for correct recognition of the exor 20 boundaries.
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7.5.3 Exon 24

Two of the donor site deoxy-2'0MeAOs, dM24D(,j{)8-12) and dM24D(+-06-14),
identified by RBA as targeting the most accessible regions, were synthesised as
2'0MeAOs and lrllllsfected into cells. However, even transfection at IOOOnM of either
2'0MeAO was unable to induce detectable exon 24 skipping. The acceptor splice site
was not assessed in cell culture at this point due the pwr accessibility of the region as
indicated by the RBA.
Combinations of2'0MeAOs directed at exons 23, 24 and 2S were then tested in
an attempt to COillt out the recalcitrant exon. It was thought that if the splicing of these
exons was in some way linked or coordinated, removal of the flanking exons might
encourage skipping of the central exon. Such intimate relationships have been
demonstrated between exons 22 and 23 (Mllllll ct al .. 2001) and between exons 19 and
20 in the current study, in that it was difficult to induce skipping of the downstream
exon without co-skipping of the upstream exon. Interestingly, lhe same effect was not
seen for skipping of exon 19 or 22, perhaps reflecting the order in which these exons are
removed from the pre-mRNA. It has been demonstrated that while splicing occurs in a
general S' to 3' direction, the order of splicing is not necessarily sequential (Kessler et
al .. 1993). It is possible that exon 20 is spliced before 19, so that if exon 20 is skipped,
cenain signals contributing to the inclusion of exon 19 are lost. However, attempts to
induce the skipping of exon 24 thmugh this mechanism were not successful, perhaps
indicating that a similar link in processing does not exist between exon 24 and its
nanking exons.
As these attempts were unsuccessful, longer dcoxy-AOs were tested by RBA,
resulting in the synthesis of M24A(-lo+l5) and M24D(+l0-J5). Despite the seemingly
high binding efficiency of these deox'y-AOs, it would appear that the target sites
selected were not scn$itive to 2'0MeA0 activity, as only an extremely weak exon 24
skipped product was detected. The donor splice site score for exon 24 is only 68%
(Senapathy et al., 1990), indicating a very low level of efficiency, and therefore
obsuucting this site may not have been sufficient to prevent inclusion of the exon in the
mature transcript. Conversely, !he acceptor splice site score is 100%, which indicates an
extremely efficient site. It is likely that targeting the acceptor site WIIS unsuccessful due
to the vecy high level of competition with splicing factors inferred by this degree of
efficiency.
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It would seem logical that a strong acceptor splice site would not be as
dependent on internal exon sequences for recognition. However, it bas been
demonstrated that there is no correlation between the predicted strength of the acceptor
splice site and the presence of enhancer sequences (Ito ct al.. 2001). The significance of
putative enhancer sequences in e1ton 24 was evaluated using two 2'0MeAOs designed
to sites predicted to contain ESEs by the RESCUE-ESE program (Fairbrother ct al.,
2002). Individual transfections with M24A(+i6+40) and M24A(+78+102) did not
appreciably increase the degree of e1ton 24 skipping. Combinations of these 2'0McAOs
and ,the weakly effective M24D{+IO-IS) were then 1estcd, based on the observation that
muif.iple enhanc~r elements can synergistically increase the efficiency of splicing
{Gravely ct al., 1998). Positive results have been observed in similar experiments for
cxon 19 in the current study, and in a study which simultaneously targeted the splice
sites of exon SI (De Angelis ct al., 2002). Consistent with these findings, the
combination ofM24A{+l6+40) with either M24A(+78+102) or M24D(+IC·.1S) or both
resul!ed in a precise and much more abundant exon 24-skipped prodllct. This lends
further support to the observation that some e1tons may require the obstmction of
more than one splicing motif to augment their efficient removal from the final
transcript, similar to the results from the 2'0MeAO targeting of exon 20. furthermore,
non-specific exon removal was again observed following transfection with an
ESE-directed 2'0MeAO. In this case, the skipping of e1ton 24 induced by
M24A{+l6+40) wllS associated with the co-skipping of cxon 22. This, in addition to the
results of targeting the ESE of exon 20 and the results reported by Aar:stma-RtL~
and colleagues (2002), highlights the potential of e1ton-intemal 2'0MeAOs to induce
non-specific effects.

ISO

Chap1er 7 - Results from 1arge1ing c~o11~ 19-25

7.!A Multiple e1on skipping
To assess the possibility of skipping multiple adjacent exons, such as is seen in
naturally occurring revertant fibres, the most effective 2'0MeAOs for inducing skipping
of eJtons 19 to 25, nine in total, were co-transfected into H-ZK mdx cells. Two
2'0MeAOs were targeted against both exons 20 and 24 to improve the skipping
efficiency of these two recalcitrant eJtons. Despite the inevitable cell death associated
with high transfection concentrations in the two conditions, efficient and specific
skipping of eJtons 19 to 25 was induced. This would result in an in-frame transcript,
resembling a rare, previously characterised, naturally occurring revertant transcript
(Lu et al., 2000; Wilton et al., 1997), and thus in a shortened but presumably functional
dystrophin. The use of 2'0MeAOs to deliberately induce the skipping of multiple exons
and produce an in-frame transcript has not been previously reported. It is not known
whether the induced skipping was due only to the fact that a crucial splicing motif for
each ei1on was blocked, or if it was in combination with a low level naturally occurring
process (such as alternative splicing) favouring the formation of a revertant fibre.
Findings which appear to support the latter mechanism were reported by
Aarstma-Rus and colleagues (2002). In this study, alternative products, corresponding
to the skipping of between two and six eJtons, were observed in untreated primary
human muscle cells. Similarly, a subsequent study reported the identification of shorter
fragments corresponding to spontaneous skipping of a single exon from the untreated
cells of three different DMD patients (AW'Stma-Rus et al., 2003). In all but om: case, the
resulting transcript would be in-frame, perhaps indicating tha1 these transcripts were
responsible for populations of revenant fibres. These observations are not surprising
considering that revertant fibres are estimated to be present in the muscle of up to SO%
of DMD patients (Klein ct al., 1992; Uchino et al., !995). The ESE-directed 2'0MeAOs
targeting these cells appeared to enhance this naturally occurring alternative splicing
process, such that the skipped product (revertant-like transcript) was much more
abundant. This occurred whether or not the exon targeted by the 2'0MeAO was the
same exon naturally skipped in the untreated ceUs. These results are encouraging,
particularly since the majority of enhanced alternative transcripts were in-frame.
One concern with IIDY gene therapy approach is that the introduction of a gene
product previously absent in a tissue may result in an immune response to that product.
The lack of at least a few eJtons in revcrtant dystrophins suggests that restoration of
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full-length dystrophin (ie. with chimc:raplasts), or the introduction of full-length
dystrophin by a vector, could be hampered by immunogcnic responses (Lu et al., 2000).
Many dystrophic individuals will not hnve been exposed to dystrophin previously and
may perceive it as a neoantigen (Ferrer et al., 2000). The extent of this irnmunogenicity
is unclear. Immune responses were not observed following the transfer of full-length or
minidystrophin constructs in mdx mice by one group (Ferrer et al., 2000), but have been
observed following the introduction of full length dystrophin by gene transfer into mdx
mice in another study (Ohtsuk& et al., 1998).
An approach which increases the frequency of revertant-like fibres may avoid

the possibility of triggering an immune response. It has been suggested that a panel of
functional transgenes could be designed, based on commonly encountered revertant
isoforms (Lu et al., 2000). In order to avoid an immune response, it is likely that this
process would have to be applied on an individual basis, as the e1ton skipping required
to mimic a naturally occurring revertant transcript would vary between patients. This
may not always equate to the minimwn number of e1tons required to restore the reading

rmm,.
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Chapter 8 . Conclusions and Future Direcdons
8.1 Overview
Antisense oligonucleotides were initially investigated as sequence-specific
downregu[ators or gene e1tpression (Weiss, Davidkova & Zhou, 1999). In subsequent
studies, chcmiclllly modified versions of these molecules have demonstrated the ability
to restore the expression of genes inactivated by aberrant splicing (ie. cryptic splice site
activation) mutations (Dominski & Kole, 1993; Sieralcowska et al., 1996). More
relevant to potential DMD therapies, 2'0MeAO-induced modulation of pre-mRNA
splicing has been applied to the dystrophin gene to either restore the reading frame in
the case of frame-shifting deletions (Aartsma-Rus et al., 2002, 2003; De Angelis et al.,
2002; vnn Deutekom et al., 2001). or to iarget the disease-causing exons for removal
from the final message (Mann et al., 2002; Wilton et al.. 1999). In this manner, the
induced transcript could be translated into a shorter, but presumably semi-functional,
dystrophin.
At the commencement of this project, previous studies had targeted either the
splice sites or an ESE but none had compared these regions within the same exon or
across species. Therefore, the principal aim of this study was to identify the region(s) of
the dysirophin pre-mRNA mos! amenable to specific and efficient 2'0MeAO-induced
exon skipping. An additional aim was to apply the knowledge gained to induce multiple
exon skipping to mimic a naturally occurring revertant transcript. We repon varying
efficiency of2'0McAO-induced removal of single and multiple exons of thedystrophin
gene by targeting a variety of splicing motifs.

8.2 Target selection
,.-

'

..

It has been suggested that targeting ESEs 'lllay _result in more specific exon
skipping than targeting splice sites (van Deutekom et al., 2001). ln the current study, the
ESEs of several e1tons were targeted, with mixed results. Toe results of targeting exon
19 appeared to agree with this suggestion, as efficient and specific skipping was
induced by 2'0MeAOs directed at ESEs. Conversely, targeting the ESEs of exons 20
and 24 resulted in non-specific antisense activity, such as the activation of a cryptic
splice sites and the non-specific removal of an additional exon. Non-specific skipping
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and splicing aberrations induced by tllfgeting inll'a-exonic sequences have since been
reported in other studies (Aartsma-Rus et al., 2002, 2003). These effects may be related
to the 2'0MeAO target, or could be attributable lo the order of splicing of these cxons,

such that if one exon is skipped, important signals contributing to the inclusion of the
preceding exon are removed. A similllf intimate relationship has been suggested to exist
between exons 22 and 23 (Mann et al .. 2001), Furthennore, even though targeting the
ESE of exon 19 resulted in highly efficient skipping, this was not applicable to all exons
investigated in this study. Targeting the ESE of exon 46 resulted in very inefficient
skipping, and two ESE-directed 2'0MeAOs were required to induce the skipping of
both exons 20 and 24. This also reflects the increased degree of difficulty in inducing
!he skipping of some exons compared to olhers,
In contrast to some of the results from exon skipping induced by ESE-directed
2'0McAOs, highly specific and efficient skipping has been observed when targeting
splice sites. The level of skipping induced by targeting !he donor splice site of exon 19
was only marginally Jess efficient !ban !hat induced by targeting the ESE. The donor
splice sites of exons 21, 22 and 25 also proved amenable to 2'0MeAO-induccd exon
skipping, with vnrying degrees of efficiency from moderate to very high. In contrast,
targeting of the donor splice sites of exons 20 and 24 resulted in only very inefficient
skipping, and no detectable skipping of cxon 46 wns observed when a 2'0MeA0 was
directed to !his motif. Specificity of exon removal, however, was constant between
exons, ns targeting of the donor splice site was never associated with aberrant splicing
of the exons evaluated in this study. The acceptor splice site was also targeted in exon
19, resulting in skipping which was only marginally less efficient than that induced by
targeting !he donor splice site. However, targeting the acceptor splice sites of exons 24
and 46 resulted in very inefficient skipping. The acceptor splice site was not assessed in
the other exons as RNA binding assays predicted these sites to be relatively
inaccessible. Since there was not always a correlation between strong binding and
efficient exon skipping, future studies could re-examine these acalptor splice sites as
potential targets. Although not observed in this study, targeting of the acceptor splice
site has been reported to induce the co-skipping of exons (Mann et al., 2001). Thus the
specificity of exon removal does not appear to be a function of target acquisition but
rather rcfl~ the exon properties and position in the gene transcript relative to adjacent
exons.
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:·_, ·,_-:'-:;·~·e::.:n~rcued efficiency of exons 19, 20 and 24 skipping induced by
0

comb inalions of2'.0MeAOs suggests that wgeting a combination of splicing motifs can
improve the efficiency of skipping. Similar results were reported in a study which
simultaneously targeted the splice sites or exon 51 (De Angelis et al., 2002). It is also
likely that multiple eoharu:er elements can additively increase the efficiency of splicing
(Gravely, Hertel & Maniatis, 1998). Furthcnnore, the necessity of targeting more than
one site to achieve efficient skipping of exom 20 and 24 lends further support to the
observation that some exons may require the obstruction of more than one splicing
motif to augment their efficient removal from the fmal transcripL This agrees with the
suggestion that the significance of various splicing motifs and enhancers to exon
inclusion varies between cxons (Ito et al., 2001).

ii

8.3 Future directions
The final aspects of this project sought to apply the knowledge gained regarding
target selection to assess the possibility of multiple exon removal. Due to time
constrainsts the evaluation or possible targets was not exhaustive, and further testing of
the acceptor splice site or regions predicted to contain ESE-like motifs may determine
the IOClltion of targets more ameDllble to 2'0MeAO-induced skipping. Nevertheless, the
ultimate goal of skipping exons 19 to 25 was achieved, thus demonstrating the
feasibility of this approach in modulating splicing patterns to mimic a naturally
occurring revertant transcript. These results are very encouraging, particularly as the
initial attempt was successful and the mulliple exon removal appcarc:d to be very
efficient in that there were no other products of intermediate splicing. In addition, this
approach has the potential to avoid triggering an immune respome such as that seen
following the introduction of full-length dystrophin into previously dystrophin-dcficient
tissues (Lu et al., 2000; Ohtsuka et al., 1998). In a therapeutic setting, each mutalion
would have to be evaluated on an individual basis, as the cxon removal required to
mimic a naturally occurring revertant transcript would vary between patients. Exon
mapping has demonstrated that the most common revertant fibres arise from the
skipping of 10 or more exons (Lu et al., 2000); thus the minimum number of skipped
exons required to mimic an already occurring revcrtant fibre in a given cell population
may not always be the same as the minimum number of cxons required to restore the
reading frame. Further In vitro studies will be required 10 evaluate the skipping of other
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combirn1tions of exons to achieve a variety of revertant-type transcripts, as the exons
skipped in lhe current study would only be applicable lo patients wilh mutations in
eltons 19 • 25. This would result in the development of a range of 2'0McAOs which
could be administered in various combinations ('cocktails') to treat many different
mutations. In vivo studies will also need to be undertaken to verify lhat the shortened
dysiror.hin is functional and non-immunogenic.
One limitation of this approach is lhat while ll'allSfection with lhe combination
of 2'0MeAOs resulted in very efficient and specific skipping, ii was also associated
with a moderately high level of cell death. Further studies could assess the possibility of
achieving the same multiple cxon skipping using only selected 2'0McAOs, particularly
since the splicing of some cxons appeared 10 be linked. This would reduce lhe total
concentration required for transfection. One promising study has recently reported the
development of two 2'0MeAOs which can skip multiple exons. In lhis novel approach,
the lwo 2'0McAOs, joined by a ten base uracil linker. arc directed simultaneously at
splicing motifs within lhe first and last cxons of the multiple e11.on segment to be
removed (Aarstma-Rus et al .. 2004). Such an approach would minimise the number of
2'0MeAOs required and thus reduce the 1oxicity associated with the delivery of
multiple 2'0MeAOs. Further studies will be required to determine the maximum
number of exons which can be skipped using this technique.
The current study employed 2'0MeAOs, which arc modified for increased
slability and resistance 10 nuclease degradation (Altmann et al., 1998; Lavrovsky et al ..
1997: Dias & Stein, 2002; Seeberger & Caruthers. 1998). One concern. however, is Iha!
the phosphorothioate backbone modification may incite tolic or nonspecific effects in

vivo {Agrawal, 1999). Further modifications of antisense oligonucleotides may yield
improvements in ~equence-specificity, nuclease resistance and cellular uptake (van
Deutekom & van Ommen, 2003). The development of several relatively new and
promising chemical modifications, including locked nucleic acids, peptide nucleic acids
{Sazani ct al., 2002) and morpholino antisense oligonucleotides (Gebski, Mann,
fletcher & Wilton, 2003; Sazani ct al., 2002) is ongoing.
Even when antiscnsc oligonucleotide chemistries. pre-mRNA target selection
and transfcction conditions have been optimised. delivery of !he therapeutic molccule(s)
10 all dystrophin deficient tissues will remain a major challenge to !his form of genelic
therapy. Skeletal muscle is !he most obvious target, but as most DMD patients die as a
result of cardiac or respirlltory complications, and some suffer from a degree of mental
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impaimlem (Emery, 2002), it is crucial that the other affected tissues arc also treated
lntraperitoncal injection of morpholino oligonucleotides and PNAs has demonstrated
uplakc and activity in muscle and heart tissue (Sazani et al., 2002). However, because
the blood-brain barrier prevents access of oligonuc!eotides lo the cortex (Sazani et al,
2002), delivery to the brain will be particularly challenging. Persistence of the
therapeutic molecule Is also an issue, as it is not known how long a revenant-type
dystrophin will persist or whether ii will accumulate over time, and therefore Jmw often
repetitive administration will be tt:quired. Although repeated intramuscular injections of
2'0McAOs into mdx mice can result in the persistent production of the dystrophin
protein and an improvement in muscle function (Lu et al., 2003), a less invasive and
impractical method capable of delivery to all affected tissues will be tt:quired. As Jong
as a suitable means for the administration of antisense oligonucleotides.can be
developed, reading frame correction by these molecules represents a promising
therapeutic approach for many DMD patients.

8.4 Summary
The complexity of thC dystrophin gene and its protein have been a major
·, challenge to those seeking to find a successful therapy for DMD. Reports of the
suctessful reading-frame restoration in the primary cells of DMD patients are starting to
'·· e11:~rge (Aarstma-Rus et al., 2002, 2003: De Angeli,; et al., 2002), increasing optimism
for an antisense oligonucleotide therapy based on re-directing gene transcript
processing. However, lack of efficiency and delivery represent major obstacles to be

"

overcome before clinical success is attained. In addition, this approach could onJy
benefil those patients whose panicular dystrophin gene mutalion can be by-passed with
specific t.lon skipping combinations which do not involve essential functional domains.
The focus of the present study was to determine the best targets for the 2'0MeAOinduced removal of certain individual exons. The results presented suggest that the
sensitivity of either acceptor, donor or ESE splicing motifs to modulation by
2'0MeAOs is unique lo the exon selected for removal :md less dependent on the
targeted sites. Therefore, there docs not appear to be one s~ific splicing motif that can
be universally targeted. Each mutation may have to be ueated individually, assessing
the best motifs on an exon to t.lon basis.
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